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High grade serous epithelial ovarian cancer (HGS-EOC) is the most lethal gynaecological 
disease, usually diagnosed at advanced stages. Although most HGS-EOC patients are initially 
sensitive to therapy, about 20% of them does not respond to front-line platinum (Pt)-based 
chemotherapy, relapsing within 6 months from treatment. No molecular biomarkers are as yet 
available in the clinical practice to discriminate, at the time of diagnosis, the patients who will 
respond or not to first-line Pt treatment. The identification of a molecular signature associated 
with intrinsic Pt resistance would allow to select patients who will not respond to Pt compound, 
thus avoiding ineffective treatment and related toxicities. 
In this thesis, defects in transcriptional regulation mechanisms associated to intrinsic Pt 
resistance were investigated using two different omic approaches – microarray and RNA 
sequencing. Moreover, considering the correlation between defects in DNA repair Homologous 
Recombination and Pt sensitivity, we have started to develop an academic assay which exploits 
high-throughput DNA sequencing to evaluate Homologous Recombination Deficiency (HRD).  
Results obtained from three independent HGS-EOC cohorts (n=1080) indicate that the 
combined expression profile of three genes – PRKG1, SDF2L1 and PPP1R12A – could 
represent an independent prognostic biomarker for Pt response and survival. In addition, 25 
transcripts, 16 of which are unknown or partially known variants, have been identified that are 
differentially expressed between Pt-sensitive and Pt-resistant patients. These results, once 
validated, integrated and associated with the HRD status, could identify a molecular signature 
applicable in the clinical setting to enable stratification of patients at time of diagnosis, allowing 







A Roberto, Anita e Michele, 
le mie rocce. 
 
Alla vita 
“La vita non è uno scherzo. 
Prendila sul serio 
come fa lo scoiattolo, ad esempio, 
senza aspettarti nulla 
dal di fuori o nell’al di là. 
Non avrai altro da fare che vivere. 
La vita non é uno scherzo. 
Prendila sul serio 
ma sul serio a tal punto 
che messo contro un muro, ad esempio, le mani legate, 
o dentro un laboratorio 
col camice bianco e grandi occhiali, 
tu muoia affinché vivano gli uomini 
gli uomini di cui non conoscerai la faccia, 
e morrai sapendo 
che nulla è più bello, più vero della vita. 
Prendila sul serio 
ma sul serio a tal punto 
che a settant’anni, ad esempio, pianterai degli ulivi 
non perché restino ai tuoi figli 
ma perché non crederai alla morte 
pur temendola, 













“Living is no laughing matter: 
you must live with great seriousness 
like a squirrel, for example— 
I mean without looking for something beyond and above living, 
I mean living must be your whole occupation. 
 
Living is no laughing matter: 
you must take it seriously, 
so much so and to such a degree 
that, for example, your hands tied behind your back, 
your back to the wall, 
or else in a laboratory 
in your white coat and safety glasses, 
you can die for people— 
even for people whose faces you’ve never seen, 
even though you know living 
is the most real, the most beautiful thing. 
 
I mean, you must take living so seriously 
that even at seventy, for example, you’ll plant olive trees— 
and not for your children, either, 
but because although you fear death you don’t believe it, 












Preface and declaration 
The work described herein was performed at the Istituto di Ricerche Farmacologiche 
“Mario Negri”- IRCCS in Milan, Italy from 2015 to 2020. 
The work was performed under the supervision of Dr. Sergio Marchini (director of the 
study), Dr. Luisa Diomede (third party monitor) and Prof. Robert Brown (external 
supervisor). 
 
This thesis has not been submitted in whole or in part for a degree or diploma or other 
qualifications to any other university. 
The experimental work described here was performed by myself, but I declare that, 
although I have followed the various steps of analyses, the statistic and bioinformatic 
analyses presented in this work of thesis have been performed by the team of Prof. Chiara 














Table of contents 
Abstract           2 
Acknowledgments          3 
Preface and declaration         5 
List of tables           10 
List of figures          12 
Publications by the candidate        14 
List of abbreviations          17 
 
1. Introduction          20 
    1.1 Malignant Epithelial Ovarian Cancer      21 
          1.1.1 Epidemiology and risk factor       21 
          1.1.2 Classification         23 
    1.2 High-Grade Serous Epithelial Ovarian Cancer: clinical and 
          molecular features         27 
    1.3 Clinical management of High-Grade Serous Epithelial Ovarian Cancer  31 
         1.3.1 Diagnosis         31 
         1.3.2 Surgery          32 
         1.3.3 Chemotherapy         32 
                  1.3.3.1 First-line chemotherapy      32 
                  1.3.3.2 Treatments at recurrence disease     35 
    1.4 The issue of drug resistance in High-Grade Serous Epithelial 
          Ovarian Cancer                    38 
         1.4.1 Mechanism of action of platinum compounds    41 
         1.4.2 Mechanisms of resistance to platinum compounds    44 
                 1.4.2.1 Mechanisms of pre-target resistance     45 
                 1.4.2.2 Mechanisms of on-target resistance     47 
7 
 
                 1.4.2.3 Mechanisms of post-target resistance     55 
         1.4.3 Transcriptional signatures associated to platinum response   56 
2. Aims           60 
3. Materials and Methods         64 
    3.1 Tissue sample collections        65 
    3.2 Nucleic acid extraction        67 
         3.2.1 RNA extraction         67 
         3.2.2 DNA extraction from snap-frozen tumour tissue biopsies   68 
         3.2.3 DNA extraction from blood samples      69 
    3.3 Pathway analysis         69 
         3.3.1 Gene and microRNA expression profile     69 
         3.3.2 Microarray data processing       73 
                 3.3.2.1 Filtering steps        73 
                 3.3.2.2 RUV normalization       74 
                 3.3.2.3 Network analysis micrographite     74 
                 3.3.2.4 Network analysis: meta-pathway extension    75 
         3.3.3 Gene retrotranscription and qRT-PCR validation    76 
         3.3.4 Statistical analysis        80 
    3.4 Genomic instability analysis        81 
         3.4.1 Next generation sequencing of tumour and genomic DNA   81 
         3.4.2 DNA sequencing data analysis      85 
                 3.4.2.1 Quality control and alignment to the genome   85 
                 3.4.2.2 Germline and somatic variant calling and copy number alteration 
                             estimation        86 
                 3.4.2.3 Purity and ploidy estimation      88 
                 3.4.2.4 Variant interpretation       88 
                 3.4.2.5 Homologous Recombination Deficiency (HRD)  
                 score calculation        89 
8 
 
    3.5 RNA sequencing         90 
         3.5.1 Total RNA sequencing        90 
         3.5.2 Total RNA sequencing analysis      94 
         3.5.3 Pathway analysis of known genes identified as differentially expressed in 
                  Total RNA sequencing        96 
         3.5.4 Targeted RNA sequencing       97 
         3.5.6 Targeted RNA sequencing analysis in cohort AI    98 
         3.5.7 Targeted RNA sequencing analysis in cohort BI    99 
4. Results           100 
    4.1 Pathway analysis         101 
         4.1.1 Cohorts’ description        102 
         4.1.2 Identification of a regulatory network associated with response  
                 to therapy         105 
         4.1.3 Network validation        111 
         4.1.4 Prognostic performance of SI signature         115 
         4.1.5 Signature SII validation across an external dataset    117 
         4.1.6 Signature combination        119 
         4.1.7 Conclusion         121 
    4.2 Analysis of genomic instability       123 
         4.2.1 AI and BI cohorts’ description      124 
         4.2.2 Characterization of HGS-EOC snap-frozen biopsies   125 
         4.2.3 Mutational status of BRCA1 and BRCA2 genes    128   
         4.2.4 Developing an HRD score       131 
         4.2.5 Conclusion         135 
    4.3 Transcriptomic analysis        136 
         4.3.1 Identification of differential expressed transcripts in Pt-r versus  
                 Pt-patients         137 
         4.3.2 RNA targeted sequencing validation      141 
9 
 
         4.3.3 Conclusion         145 
5. Discussion and conclusion        147 
   5.1 Pathway analysis         148 
   5.2 Genomic instability analysis        151 
   5.3 Transcriptomic analysis        153 
   5.4 Future prospectives         156 
6. Appendix           158 
7. References          197 




                     
             
             
             
                    






            
          
10 
 
   
List of Tables  
1. Introduction: 
Table 1.1: International Federation of Gynaecology and Obstetrics (FIGO) 
                 staging criteria         24 
Table1.2: Type I and type II EOC features      26 
Table 1.3: Standard first-line treatment for EOC      33 
3. Material and Methods: 
Table 3.1: Components of qRT-PCR reaction      77 
Table 3.2: Sequences of qRT-PCR reverse and forward primers   79 
4. Results: 
Table 4.1: Clinical and demographic description of cases enrolled in cohorts A,  
                 B and C          104 
Table 4.2: Elements of the network       107 
Table 4.3: Differential expression evaluated by qRT-PCR between PT-r and Pt-s 
                samples of the 23 selected genes in cohort A     113 
Table 4.4: Differential expression evaluated by qRT-PCR between PT-r and Pt-s 
                samples of the 23 selected genes in cohort B     114 
Table 4.5: Univariate and multivariate survival models of the 17 DEG elements  
                enrolled within the SI signature          116 
Table 4.6: Univariate and multivariate survival models of SII signature in 
                cohort C          118 
Table 4.7: TP53 clonal mutations and MDM2/MDM4 amplification status in  
                cohorts AI and BI        125 
Table 4.8: Mutational status of BRCA1 and BRCA2 genes in cohort AI and BI 128 




Table 4.10: DETs confirmed with targeted RNA sequencing in cohorts AI  
                  and BI          143 
Table 4.11: List of validated DETs with complete match with intron chain  145 
6. Appendix 
Table 6.1: Differentially expressed transcripts derived from total RNA sequencing 
                 analysis          159  
12 
 
List of figures 
1. Introduction 
Figure 1.1: The heterogeneous nature of EOC      23 
Figure 1.2: IHC staining for HGS-EOC       28 
Figure 1.3: Global profile of genomic alteration of HGS-EOC in comparison with 
                  other cancer types        29 
Figure 1.4: Common molecular abnormalities in HGS-EOC     30 
Figure 1.5: Patients’ classification on the basis of their response to  
       platinum-based chemotherapy       36 
Figure 1.6: Intrinsic and acquired Pt-resistance      40 
Figure 1.7: Barnett Rosenberg and cisplatin structure     41 
Figure 1.8: Cisplatin activation process       42 
Figure 1.9: Binding between platinum-derivatives activated complex and DNA 43 
Figure 1.10: Mechanism of action of platinum-compounds    44 
Figure 1.11: Mechanisms of pre-target platinum resistance    47 
Figure 1.12: Mechanism of action of Homologous Recombination (HR) pathway 
                    to repair double-strand break DNA      50 
Figure 1.13: Genetic and epigenetic alterations in DNA repair pathways 
                    In HGS-EOC         52 
Figure 1.14: Calculation of Homologous Recombination Deficiency score  54 
Figure 1.15: Epithelial to Mesenchymal Transition process (EMT)   57 
2. Aims  
Figure 2.1: Study overview                  63
           
3. Material and Methods 
 
Figure 3.1: Schematic workflow of microarray experiment    70 
Figure 3.2: Schematic principle of oligonucleotide microarray    71 
Figure 3.3: Probe design strategy to evaluate microRNA expression by 
                 microarray technology        72 
Figure 3.4: qRT-PCR cycle         77 
13 
 
Figure 3.5: Amplification curve of a qRT-PCR experiment    78 
Figure 3.6: Schema design of OneSeq Constitutional Research Panel   82 
Figure 3.7: Capture-based enrichment       84 
Figure 3.8: Workflow of RNA sequencing library preparation    93 
Figure 3.9: Workflow of differential expression analysis for annotated 
                  transcripts         94 
4. Results 
Figure 4.1: Workflow of the pathway analysis of the study    101 
Figure 4.2: Regulatory network associated to Pt response    106 
Figure 4.3: Kaplan Mayer curves of the combination of the expression values  
                  of PRKG1, SDF2L1 and PPPR12A      120 
Figure 4.4: Kaplan Mayer curves of the combination of the expression  
                  values of PRKG1 SDF2L1 and PPPR12A with stratification by 
                  patient TR status        121 
Figure 4.5: HRD score in 30 high quality samples to set the cut-off   132 
Figure 4.6: HRD score threshold set       133 
Figure 4.7: HRD score distribution in Pt-s and Pt-r cases    134 
Figure 4.8: Gff Compare’s class codes       138 
Figure 4.9: DETs’ class code        139 
Figure 4.10: Validation of 1730 DETs       142 








Publications by the candidate 
 
Papers as first/co-first author: 
 
• L. Paracchini*, L. Beltrame*, A. Inglese et al., Genome-wide copy number alterations 
in circulating tumor DNA as a novel biomarker for high grade serous ovarian cancer 
patients. Jul 2020, under review. 
• L. Paracchini*, C. Pesenti*, M. Delle Marchette, L. Beltrame, T. Bianchi, T. Grassi et 
al., Detection of TP53 clonal variants in Papanicolaou test samples collected up to 6 
years prior to high-grade serous epithelial ovarian cancer diagnosis. JAMA Network 
Open. 2020 Jul 1; 3(7): e207566-e207566 
• G. Benvenuto*, P. Todeschini*, L. Paracchini*, E. Calura, R. Fruscio, C. Romani et 
al., Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and 
prognostic factors for therapy response and survival in high‐grade serous ovarian 
cancer. International Journal of Cancer. 2020 Jul 15; 147(2): 565-574 
• L. Paracchini, L. Beltrame, L. Boeri, F. Fusco, P. Caffarra, S. Marchini et al., Exome 
sequencing in an Italian family with Alzheimer’s disease points to a role for seizure-
related gene 6 (SEZ6) rare variant R615H. Alzheimer’s research & therapy. 2018 Dec 
1; 12(1): 106 
• P. Todeschini*, E. Salviato*, L. Paracchini*, M. ferracin, M.Petrillo, L. Zanotti et al., 
Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker 
in high-grade serous ovarian carcinoma: A validation across two independent cohorts. 
Cancer Letters. 2017 March 1; 388: 320-327 
• P.Martini*, L. Paracchini*, G. Caratti, M. Mello-Grand, R. Fruscio, L. Beltrame et al., 
lncRNAs as novel indicators of patients' prognosis in stage I epithelial ovarian cancer: 
15 
 
A retrospective and multicentric study. Clinical Cancer Research. 2017 May 1; 23(9): 
2356-2366 
• L. Paracchini*, L. Mannarino*, I. Craparotta, C. Romualdi, R. Fruscio, T. Grassi et al., 
Regional and temporal heterogeneity of epithelial ovarian cancer tumor biopsies: 




• E. Calura, R. Fruscio, L. Paracchini, E. Bignotti, A. Ravaggi, P. Martini et al., miRNA 
Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities. Clinical 
Cancer research. 2013 Aug 1; 19(15): 4114-4123 
• R. Dossi, R. Frapolli, S. Di Giandomenico, L. Paracchini, F. Bozzi, S. Brich et al., 
Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host 
TIMP‐1 and TIMP‐2 and tumor thrombospondin‐1. International Journal of Cancer. 
2014 Jun 10; 136(3): 721-729 
• L. Beltrame, M. Di Marino, R. Fruscio, E. Calura. D. Chapman, L. Clivio, et al., Profiling 
cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted 
next-generation sequencing: a retrospective study. Annals of Oncology. 2015 Jul 1; 
26(7): 1363-1371 
• M. Petrillo, G.F. Zannoni, L. Beltrame, E. Martinelli, A. Di Feo, L. Paracchini et al., 
Identification of high-grade serous ovarian cancer miRNA species associated with 
survival and drug response in patients receiving neoadjuvant chemotherapy: a 
retrospective longitudinal analysis using matched tumor biopsies. Annals of Oncology. 
2016 Apr 1; 27(4): 625-634 
16 
 
• F. Pischiutta, L. Brunelli, P. Romele, A. Silini, E. Sammali, L. Paracchini, et al., Protection 
of Brain Injury by Amniotic Mesenchymal Stromal Cell-Secreted Metabolites. Critical 
Care Medicine. 2016 Nov 1; 44(11): e1118-e1131 
• E. Calura, L. Paracchini, R. Fruscio, A. Di Feo, A. Ravaggi, J. Perrone et al., A prognostic 
regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis 
assessment. Annals of Oncology. 2016 Aug 1; 27(8): 1511-1519 
• V. Iori, A. M. Iyer, T. Ravizza, L. Beltrame, L. Paracchini, S. Marchini et al., Blockade of 
the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model 
of acquired epilepsy. Neurobiology of disease. 2017 March 1; 99: 12-23 
• C. Belgiovine, E. Bello. M. Liguori, I. Craparotta, L. Mannarino, L. Paracchini et al., 
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour 
microenvironment in preclinical models. British Journal of cancer. 2017 Aug; 117(5): 
628-238 
• L. Mannarino, L. Paracchini, I. Craparotta, M. Romano, S. Marchini, R. Gatta et al., A 
systems biology approach to investigate the mechanism of action of trabectedin in a 
model of myelomonocytic leukemia. Pharmacogenomics Journal.2018 Jan; 18(1): 58-
63 
• E. Calura, M. Ciciani, A. Sambugaro, L. Paracchini, G. Benvenuto, S. Milite et al., 
Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric 




List of Abbreviation 
 
OC: Ovarian Cancer 
EOC: Epithelial Ovarian Cancer 
FIGO: International Federation of Gynaecology and Obstetrics 
TVS: Transvaginal Ultrasound  
CA-125: Cancer Antigen-125 or Carbohydrate Antigen-125 
MMR: MisMatch Repair 
HGS: High-Grade Serous 
LGS: Low Grade Serous 
HPF: High-Power microscopic Fields 
IHC: ImmunoHistoChemistry 
HR: Homologous Recombination 
Mb: Mega Bases 
CT: Computed Tomography 
MRI: Magnetic Resonance Imaging 
Pt: PlaTinum 
PDS: Primary Debulking Surgery 
RT: Residual Tumour 
NACT: NeoAdjuvant ChemoTherapy 
IDS: Interval Debulking Surgery 
FDA: Food and Drug Administration 
CBDCA: Carboplatin 
PAC: PAClitaxel 
VEGF: Vascular Enothelial Growth Factor 
18 
 
PFS: Progression-Free Survival 
OS: Overall Survival 
PARP: Poly (ADP-Ribose) Polymerase 
PARPi: Poly (ADP-Ribose) Polymerase inhibitor  
HR: Hazard Ratio 
CI: Confidence Interval 
HRD: Homologous Recombination Deficiency 
PLD: Pegylated Liposomal Doxorubicin 
EMA: European Medical Agency 
ET-743: Trabectedin 
CDDP:cisplatin 
NER: Nucleotide Excision Repair 
FA: Fanconi Anemia 
HR: Homologous Recombination 
HRD: Homologous Recombination Deficiency 
dsDNA: Double Strand DNA 
CTR1: Copper TranspoRter 1 
ABC: ATP Binding Cassette 
MRP: Multi-Resistance associate Protein 
cMOAT: Canalicular Multispecific Organic Anionic Transporter 
GSH: Glutathione 
MT: Metallothioneins 
DSB: Double Strand Break 
ssDNA: Single Strand DNA 
19 
 
HJ: Hollyday Junction 
LOH: Loss of Heterezygosis 
TAI: Telomeri Allelic Imbalances 
LST: Large-Scale Transition 
EMT: Epithelial to Mesenchymal Transition 
TGF: Transforming Growth Factor  
PFI: Platinum Free Interval 
Bp: Base Pairs 
gDNA: Genomic DNA 
lncRNA: Long Non-Coding RNA 
miRNA: Micro RNA 
RLE: Relative Long Expression 
DE: Differentially Expressed 
dNTP: DeoxyriboNucleotide TriPhosphates 
tDNA: Tumour DNA 
 
FDR: False Discovery Rate 
Cy3: Cyanine 3 
logFC: log Fold Change 
DEG: Differentially Expressed Genes 
DET: Differentially Expressed Transcripts 
AF: Allelic Fraction 















1.1 Malignant Epithelial Ovarian Cancer 
 
1.1.1 Epidemiology and risk factor 
Ovarian cancer (OC) is the 6th more lethal cancer among females representing 4,4% of cancer-
related deaths among women (1). The American Cancer Society has estimated approximately 
21,750 new cases and 13,940 deaths in the USA in 2020. The proportion between new OC 
cases/year and deaths due to OC/year highlights the aggressiveness of this kind of tumour, and 
support the notion that OC can be considered as the most lethal gynaecological cancer among 
women (2). 
Epithelial Ovarian Cancer (EOC) is the most common type of ovarian tumour, making up 90% 
of all primary ovarian cancer and it is considered as an age-related disease (median age of 
disease onset 65 years), as in sporadic forms its incidence increases in post-menopausal women 
(3). Despite ovarian cancer survival has almost doubled in the last 40 years in UK (4) due to 
the evolution of modern medicine, including improvements in surgery procedures, the overall 
5-years survival rate still remains low and ranges between 30%-40%. This high mortality rate 
is due to many different factors that will be addressed only in part in this chapter. First, the 
majority of EOC (about 70%) is diagnosed when the disease is already metastatic, that means 
that it has already spread into the abdominal cavity (International Federation of Gynaecology 
and Obstetrics -FIGO- Stage III/IV): in these cases, the 5-years survival rate is about 29%, in 
comparison to 92% when the tumour is limited to the ovary (FIGO, stage I) (5). The tumour 
stage, which is a measure of the spread of the disease in the abdominal cavity is currently the 
main prognostic parameter (see paragraph 1.1.2). 
Nowadays there are no effective strategies or screening tests for EOC early disease diagnosis. 
A prospective study made on a cohort of more than 100000 women in the United Kingdom (6) 
demonstrated transvaginal ultrasounds scans (TVS) and the measurements of CA-125 serum 
22 
 
protein levels, two assays routinely used in clinic for EOC screening, have a low positive 
predictive value, being unable to differentiate benign from malignant EOC in the case of TVS 
(7), or have low specificity and sensitivity in the case of CA-125 (8). 
The strongest risk factor for EOC is constituted by hereditable genetic conditions, which are 
responsible of 15%-20% for EOC cases (9).  
Among these hereditable syndromes the most common (65%-75%) is represented by the 
Breast-Ovarian cancer syndrome, which is an autosomal dominant genetic syndrome that 
increases the risk to develop EOC (high-grade serous histotype, see paragraph 1.2) and breast 
cancer during the life-time. This syndrome is due to germline mutations that lead to loss of 
function of two proteins codified by BRCA1 (chromosome 17q21) and BRCA2 (chromosome 
13q12-13) genes. In these patients the cumulative EOC risk is 44% and 17% for patients with 
germline mutation in BRCA1 and BRCA2 genes respectively  (10) instead of the 1.5% of the 
general population (11).  
Another genetic syndrome that accounts for the 10-15% of hereditary EOC, is the Lynch 
syndrome that is typically associated with endometrioid and clear cell histotype (see paragraph 
1.1.2). Lynch syndrome is a genetic autosomal dominant syndrome regarding germline 
mutations in Mismatch Repair (MMR) genes (MLH1, MSH2 and MSH6), that is associated with 
an increased risk of colon-rectal, endometrial, breast, urinary tract, small bowel and EOC. In 
these patients the cumulative risk to develope EOC within 70 years is about 20% for MLH1 
and MSH2 germline mutation carriers (11). 
Other genetic syndromes associated with hereditary EOC include Peutz-Jegher (germline 
mutations in STK11/LKB1 genes) and other rare disorders, such as Gorlin syndrome (germline 







Other non-genetic EOC risk factors (9) include: 
- the number of lifetime ovulations (early age of menarche, late age of menopause, 
absence of pregnancy). The hypothesis of the “incessant ovulation” in fact, points that 
each ovulatory cycle is associated with an increase rate cellular division to repair the 
surface epithelium, leading to the arise of spontaneous DNA mutations 
- smoking 
- benign gynaecological conditions (i.e. polycystic ovary syndrome, endometriosis) 
- use of talcum powder (12), although results about this point are controversial. 
 
1.1.2 Classification 
As previously state (paraghraph1.1.1) the term “EOC” is nowadays considered as a misleading 
term, as it does not refer to a single disease, but an heterogeneous subset of malignancies 
involving the ovary, characterized by different clinical, anatomo-pathological, etio-pathogenic, 
and molecular features (figure 1.1) (13) (14). 
 




This extremely complex nature of EOC has led to different EOC classification systems that 
depend on the basis of the features considered (clinical, biological or genetics). 
Independently from the histopathological classification, that identifies five main subtypes of 
EOC (high-grade serous –HGS-, low grade serous –LGS-, endometrioid, clear cells and 
mucinous), from surgical point of view EOC can be classified upon the extent and diffusion of 
the disease at time of diagnosis. The International Federation of Gynaecology and Obstetrics 
(FIGO) criteria identified four different stages and eight substages, the features of which are 
detailed in the table 1.1 (15). 
Stage I: confinement to the ovary 
IA Tumour limited to one ovary with an intact capsule or to Fallopian tubes. 
IB 
Tumour limited to both the ovaries with intact capsules or to both the 
Fallopian tubes. 
IC 
Tumour limited to one or both ovaries or Fallopian tubes, but with the 
capsule rupture 
or the presence of malignant cells on the epithelial surface. 
Malignant cells are also present in the ascites or peritoneal washing. 
Stage II: involvement one or both ovaries or Fallopian tubes, with pelvic 
extension or 
primary peritoneal cancer  
IIA 
Tumour is extended and/or implanted on the uterus and/or Fallopian tubes 
and/or ovaries. 
IIB Tumour has extended to other pelvic intraperitoneal tissues. 
Stage III: involvement one or both ovaries or Fallopian tubes, or primary 
peritoneal 
cancer with spreading to the peritoneum outside the pelvis 




Cytologically or histologically proven positive retroperitoneal lymph nodes 
only 
or microscopic extrapelvic peritoneal involvement 
III
B 
Macroscopic peritoneal metastasis beyond the pelvis up to 2 cm diameter 
with or  
without metastasis to retroperitoneal lymph nodes 
III
C 
Macroscopic peritoneal metastasis beyond the pelvis more than 2 cm 
diameter with or  
without metastasis to retroperitoneal lymph nodes 
Stage IV: presence of distant metastasis, with malignant cells present in the 
pleural effusion and involvement of abdominal organs with parenchymal 
and extra-abdominal metastasis 
 




Another type of EOC classification is based on the grade of tumour cell differentiation. 
Comparing the tissue and cancer cells to healthy ones, parameters as the tissue architecture, the 
degree of nuclei atypia and the mitotic index are considered. 
On the basis of these parameters EOC can be classified in three different grades of 
differentiation (“three-tier grading”): G1, well differentiated; G2 moderately differentiated; G3 
poorly differentiated. This “three-tier grading” could be not used for serous EOC, for which a 
“two-tier” grading system was adopted (high grade for poorly differentiated and low grade for 
well differentiated forms) (16). 
Over the last years, with the development of more accurate and sensitive technologies to study 
genetic and genomic alterations that characterized EOC, new classification criteria have 
emerged. In particular the “dualistic model” proposed by Kurman and colleagues has been 
proposed to explain the pathogenesis and classified EOC on the basis of origin, clinical, 
biological and molecular features. According to this classification EOCs are subdivided into 
two groups named “type I” and “type II” tumours, the main characteristics of which are reported 















Features Type I Type II 
Stage Frequently early stage Almost always advanced stage 
Tumour grade Low grade High grade 
Histological 
subtypes 
Serous, Clear Cells, 
Endometrioid, Mucinous, 
malignant Brenner tumour, 
seromucinous carcinoma 





Generally low Always high 
Ascites Rare Common 
Response to 
chemotherapy 
Fair Good (with recurrence within 18 
months in the majority of cases)                
Early detection Possible Challenging 







Mutations KRAS, BRAF, PTEN, CTNNB1, 





Rarely defective Frequently defective 
Actionable 
mutations 
Can be present Rare 
 




As reported in table above type II EOC is mainly characterised by most common and aggressive 
EOC histotype: the High Grade Serous (HGS) EOC. As HGS-EOC represents the focus of this 
thesis work, the other EOC histotypes are not considered in this context. 
 
1.2 High-Grade Serous Epithelial Ovarian Cancer: clinical 
and molecular features 
 
High-Grade Serous Epithelial Ovarian Cancer (HGS-EOC) is the most common type of EOC 
(about 80% of all EOC cases) and in 90% of cases it is diagnosed when tumour has already 
spread into the abdominal cavity and in intra- or extra- pelvic organs. The late diagnosis, the 
rapid growth and the aggressiveness of HGS-EOC explain the poor prognosis related to this 
specific EOC subtype (5-years survival rate about 30%).  
From a histopathological point of view HGS-EOC is characterized by papillary or solid growth 
with slit-like glandular lumens pattern. Tumour cells appear with an intermediate size, with, 
prominent nucleoli and high mitotic index (activity greater than 12/10 high-power microscopic 
fields, HPF). A great numbers of immuno-histological biomarkers are used to better distinguish 
the HGS-EOC from the other EOC subtypes including WT1, ER, PR and PAX8 (14) but in 
particular the p53 protein. In fact, HGS-EOC is associated to an abnormal 
immunohistochemistry (IHC) staining for p53, that can be both overexpressed (figure 1.2 panel 
A) or completely absent (figure 1.2 panel B), depending on the nature of TP53 clonal mutation 






Figure 1.2 IHC staining for HGS-EOC. Panel A: high grade serous ovarian cancer with strong and diffuse 
immunoexpression of p53 (100% positive cells). Panel B: high grade serous ovarian cancer with completely 





The abnormal ICH staining for p53 is due to the fact that about the 96% of HGS-EOC cases, is 
characterized by a clonal pathogenic mutation in TP53 gene (19). In the remaining mutation 
negative HGS-EOC cases (4%), it has been demonstrated that the dysfunction of p53 pathway 
that characterized HGS-EOC, is related with chromosomal gain in MDM2 and MDM4, which 
are involved in the degradation of p53 protein (20).  
Somatic mutations in genes other than TP53 occurs in no more than 5%-8% HGS-EOC cases, 
and they mainly involved BRCA1, BRCA2, CDK12 and Homologous Recombination (HR) 
pathway-related genes (21). 
As reported by Ciriello and collegues (22) few years ago in fact, the HGS-EOC is not 
characterized by high prevalence of somatic mutations (with the exception of clonal TP53 
alterations) or methylation events, but by multiple recurrent chromosomal gains and losses, 
which include the clonal somatic amplification in 8q24 and 3q24 genomic loci (23), CCNE1 
locus amplification (15% of HGS-EOC cases) that is mutually exclusive with BRCA1/BRCA2 
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gene mutations, and losses in important oncosoppressor genes as NF1, RB1, PTEN (figure 1.3 
and figure 1.4) (9).  
 
 
Figure 1.3 Global profile of genomic alteration of HGS-EOC (OV) in comparison with other cancer types. 
BLCA: bladder urothelial carcinoma, BRCA: breast invasive carcinoma, COADREAD: colon and rectum 
adenocarcinoma, GBM: glioblastoma multiformae, HNSC, head and neck squamous cell carcinoma, KIRC: 
kidney renal clear-cells carcinoma, LAML: acute myeloid leukemia, LUAD: lung adenocarcinoma, LUSC: lung 
squamous cell adenocarcinoma, UCEC: uterine corpus endometrioid carcinoma). A: Copy Number Alternation 







Figure 1.4 Common molecular abnormalities in HGS-EOC (9) 
 
About ten years ago HGS-EOC was classified on the basis of gene expression profile in four 
main subtypes (C1-mesenchymal, C2-immune- C4-differentiated and C5-proliferative) (24). 
However, recently another type of HGS-EOC classification was proposed on the basis of copy 
number signature. In particular, Macintyre and colleagues subdivided HGS-EOC in seven 
different subclasses, considering six fundamental copy number features (break point count for 
10 Mb, copy number, copy number change point, breakpoint count for chromosome arm, length 
of chains of oscillating copy number, segment size). These seven copy number signatures are 
associated with different mutational profile (25) and different prognosis, although a prospective 
validation is required to be used in a prognostic way (26). 
All the studies reported above, as well as molecular features that are usually considered in clinic 
(i.e. BRCA mutations for PARPi treatment, paragraph 1.3.3) are based on the analysis of single 
biopsies taken in the primary tumour site at time of diagnosis. However, it is well known that 
HGS-EOC is characterized by high intra-tumoural, inter-tumoural, and temporal heterogeneity.  
Few years ago our group has in fact demonstrated that from a mutational point of view the 
primary tumour site and its synchronous lesions show an overlap of only 5% (27). Moreover a 
longitudinal analysis between matched primary tumour and tumour relapse have revealed that 
only 2% of mutations were conserved (28). 
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The late diagnosis that characterized HGS-EOC is due to the fact that symptoms associated to 
the presence of the disease are not specific, and that is the reason why often the EOC is 
defined as “silent killer”. Symptoms include abdominal bloating, nausea, change in bowel 
function, early satiety, abdominal distension, back pain, urinary symptoms, fatigue and loss of 
weight, and they generally appear months before EOC diagnosis. The initial investigation 
based on the measures of CA-125 serum protein levels and the TVS, should be associated to 
Computed Tomography (CT) of chest, abdomen and potentially to pelvic-abdominal 
Magnetic Resonance Imaging (MRI) to define the disease extension (29). 
Once confirmed the EOC diagnosis, the standard EOC treatment is a multidisciplinary 
approach, based on the association of surgical intervention and a poly-pharmacological 




Since 1980s, in the majority of cases patients initially undergo to a Primary Debulking Surgery 
(PDS) followed by six cycles of chemotherapy. The PDS has both a diagnostic and a therapeutic 
aim. In fact, on one hand allows to obtaine i) the tumour biopsies that will be analysed by the 
anatomo-pathologist for the histological EOC classification and ii) to determine the staging of 
the disease, and on the other hand to remove the tumour masses. The PDS include a variety of 
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surgical procedures including hysterectomy, bilateral salpingo-oophorectomy, omentectomt, 
lymph nodes sampling and the debulk of macroscopic tumour lesions that could lead i.e. to 
peritoneal resection, diaphragm stripping, partial pancreatic and hepatic resection or 
splenectomy. The extension of surgical procedures performed during PDS depends on the 
extension of the diseases, the location of tumour masses, the patients’ general condition and 
comorbidities (30). The goal of the PDS is the complete resection of the macroscopic disease, 
as it is well demonstrated that the residual tumour (RT) at the end of the surgical intervention 
represents one of the main prognostic parameters (31). Another type of surgical approach is the 
administration of three cycles of chemotherapy, defined as NeoAdjuvant ChemoTherapy 
(NACT), followed by an interval debulking surgery (IDS) and finally other three cycles of 
chemotherapy. However, there are no specific clinical criteria that establish to adopt PDS rather 
that IDS, and the choice between the two approaches is still controversial. 
 
1.3.3 Chemotherapy 
1.3.3.1 First-line chemotherapy 
Front line platinum-based chemotherapy is the mainstay for patients with diagnosis of EOC. 
Historically, ovarian cancer was one of the first malignancies to be successfully treated with 
cytotoxic chemotherapy. In particular, the alkylating agents developed in 1950s represented the 
first class of cytotoxic drugs used for the ovarian cancer treatment. Although many of these 
drugs, including melphalan, thiotepa and cyclophosphamide, demonstrated a good single-agent 
activity, it was promptly observed that the most effective strategy would be to employ these 
agents in combination, both to exploit a synergistic effect and to reduce the risk of the disease 
acquiring chemoresistance. Following a temporal progression, in the 1970s many combinations 
of drugs were in use for the treatment of ovarian cancer, with the most popular protocol 
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consisting of the use of cyclophosphamide and doxorubicin, in addition to methotrexate and 5-
fluorouracil (32). 
However, since the late 1970s the interest has headed to platinating agents for the treatment of 
ovarian cancer, so much so that in the last decades the standard-of-care for EOC has been 
referred to as “platinum-based chemotherapy”. Cisplatin was the first platinum agent approved 
by FDA (Food and Drug Administration) in 1978 and it was tested for the EOC treatment either 
as a single agent or in combination with other drugs, mainly cyclophosphamide. During the 
1980s another platinum compound was developed, the carboplatin (CBDCA), which 
demonstrated a comparable efficacy but a more favourable toxicity profile than cisplatin. As 
well as cisplatin, also carboplatin was tested for EOC treatment in combination with other 
cytotoxic agents, in particular with a new class of drugs that act as mitotic inhibitors stabilizing 
microtubules structures, the taxanes, of which paclitaxel (PAC) is still the prototype. 
It was demonstrated by two independent randomized trials that cisplatin-paclitaxel combination 
had an 11% of advantage in overall-survival comparing with cisplatin-cyclophosphamide (33). 
Considering these results and several trials that demonstrated that CBDCA has comparable 
effectiveness but with a far more favourable toxicity profile than cisplatin (34) (35) (36), the 
standard first-line chemotherapy treatment for EOC, independently from the histotype, is 
represented by the association between CBDCA and PAC by intravenous administration every 
three weeks for 6 cycles (table 1.3):  
 
Standard first-line chemotherapy treatment 
Carboplatin (CBDCA) [area under the curve 5-6] + Paclitaxel* (PAC) [175 mg/m2 over 3h]  
Intravenous administration 
Once every three weeks 6 cycles 
 
Table 1.3 Standard first-line chemotherapy treatment for EOC (32). * In cases with an increased risk of 





More recently in addition to this standard treatment, it is possible to administer concomitantly 
and then as maintenance therapy an antibody directed to the Vascular Endothelial Growth 
Factor (VEGF), Bevacizumab, that is an FDA anti-angiogenic drug approved for ovarian cancer 
treatment. 
In fact, two randomised trials (GOG0218 and ICON7) have suggested a benefit in terms of 
Progression Free Survival (PFS) (GOG0218: HR 0.9; CI 95%, 0.79 to 1.04 and ICON7: HR 
0.8; CI 95%, 0.70 to 0.94), but not in terms of Overall Survival (OS) with the addition of 
Bevacizumab to CBDCA and paclitaxel every three weeks followed by maintenance 
monotherapy (37) (38). 
Another class of compounds that is just recently included in clinical practice and is now under 
study as maintenance treatment after first-line chemotherapy is the one of poly (ADP-ribose) 
polymerase (PARP) inhibitors. 
An international, randomized phase III clinical trial (SOLO-1) has demonstrated the efficacy of 
the PARP inhibitor Olaparib (Lynparza®) as a maintenance treatment in patients with newly 
diagnosed advanced HGS-EOC, endometrioid ovarian cancer, primary peritoneal cancer, or 
fallopian tube cancer with somatic or germline BRCA1/BRCA2 mutations who had a complete 
o partial clinical response on the basis of RECIST 1.1 criteria (39) after first-line Pt-based 
chemotherapy. In particular, it was demonstrated that after a median follow-up of 41 months 
the risk of disease progression or death was 70% lower in patients treated with Olaparib (300 






1.3.3.2 Treatments at recurrence disease 
The clinical response to first-line chemotherapy is heterogeneous and not predictable at time of 
diagnosis. Despite more than 80% of HGS-EOC patients initially respond to first-line 
chemotherapy treatment, the majority of them relapse within 18 months. Actually, there are no 
clinical or molecular biomarkers able to predict the sensitivity to Pt-based treatment of the 
recurrent disease, and it is empirically based on the time lagging between the end of first-line 
therapy and tumour relapse (figure 1.5). On the basis of time to relapse after Pt- based treatment 
patients can be classified in: 
 
I. Platinum sensitive: patients relapsing after more than 12 months from the end of 
chemotherapy. Generally at time of relapse those patients are re-treated with Pt-
based therapy, showing a response rate to platinum re-challenge that is over than 
50%  (41). 
 
II. Partially sensitive: patients relapsing within 6-12 months from the last cycle of 
chemotherapy. For the second line-therapy they are generally challenged again with 
platinum, although the response rate is lower in comparison to platinum-sensitive 
patients. 
 
III. Platinum resistant: patients relapsing within 6 months from the end of therapy. They 
are not treated with platinum again. 
 
IV. Platinum refractory: patients showing a stable or a progression of disease (PD) 
during Pt-based treatment. The PD is defined by Response Evaluation Criteria In 
Solid Tumour version 1.1 (RECIST 1.1) as an increase of at least 20% in the sum of 
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diameters of target lesions taking as reference the smallest sum on study. Also the 
appearance of one or more new lesions is considered progression (42). 
 
 





On the basis of this classification different therapeutic options are available at time of 
recurrence: 
• Generally platinum sensitive patients are retreated with CBDCA-PAC chemotherapy. 
Alternatively to PAC it is possible to administrate in combination with CBDCA, 
gemcitabine or pegylated liposomal doxorubicin (PLD, Cealix®), that have 
demonstrated both improvement in PFS (HR 0.82, CI 95%, median PFS 11.3 vs 9.4 
months) and a better toxicity profile compared with the standard treatment CBDCA-
PAC (43). Moreover, in addition to Pt-based chemotherapies described above, in 
platinum sensitive recurrence is possible to administer other two classes of drugs: anti-
angiogenic agents and PARPi. Several clinical trials had demonstrated the efficacy in 
terms of PFS combining CBDCA-PAC (GOG213 trial) and CBDCA-gemcitabine 
(OCEANs trial) with bevacizumab followed by maintenance monotherapy (44) (45). 
Results of MITO16B-MaNGO-OV2B-ENGOT OV17 trial, presented at ASCO 2018, 
demonstrated that the re-challenge with bevacizumab in combination with platinum-
based doublets is associated with a significantly prolonged PFS also in patients treated 
with bevacizumab in the first-line/maintenance chemotherapy. 
Regarding the use of PARPi, results reported in literature derived from mainly two 
clinical trials, indicate that, although the major benefit derived from their administration 
are obtained in BRCA mutated and Homologous-recombination deficient (HRD) 
positive patients, as expected (46), improvement in PFS is also observed in BRCA wt 
and HRD-negative cases. To these reasons, niraparib (Zejula®) and rucaparib 
(Rubraca®) have been approved by FDA and European Medical Agency (EMA) as 
maintenance therapy of platinum sensitive ovarian cancer recurrence in response to 
platinum-based treatment, independently from BRCA genes and HRD status (47) 
(ARIAL3 trial, (44)). Also, olaparib (Lynparza®) has been approved as maintenance 
therapy for adult patients with recurrent HGS-EOC who are in complete or partial 
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response to Pt-based treatment. 
• Platinum partially sensitive patients with disease recurrence, can be treated using the 
same pharmacological settings available for platinum sensitive cases, included the 
maintenance treatments with bevacizumab, rucaparib, niraparib or olaparib. 
The combination of trabectedin (ET-743, Yondelis®) with PLD is considered a valid 
therapeutic FDA/EMA-approved approach for relapsed platinum partially sensitive 
patients. The INOVATYON phase III trial is aimed at demonstrating whether there is 
an OS advantage by the sequential use of trabectedin/PLD followed, at relapse, by 
platinum re-challenge, over carboplatin/PLD combination. The primary results analysis 
of INOVATYON trial are expected in August 2020. 
• For platinum refractory and resistant patients the therapeutic approaches are based on 
single agent-treatment. The chemotherapeutic agents usually administered in these cases 
are PLD, gemcitabine, taxol (high-dose density, weekly administration) or topotecan. 
The AURELIA trial has demonstrated a benefit in terms of PFS and quality of life with 
the association of PLD, gemcitabine or taxol with bevacizumab followed by 
maintenance therapy until progression of the disease, for patients which have never been 
received bevacizumab before (AURELIA) (48). This association is approved by EMA. 
 
1.4 The issue of drug resistance in High-Grade Serous 
Epithelial Ovarian Cancer 
 
The main problem related to HGS-EOC is the resistance to Pt-compounds that sooner or later 
patients develop.  
In fact, although about 80% of patients are initially sensitive to the first-line Pt-based therapy 
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the majority of them relapse with a recurrent disease that usually follows a frequent relapse-
response pattern before becoming definitely resistant to Pt-based treatment. Although our 
knowledge about the mechanisms underlying the therapy resistance in EOC is increased over 
the past decades, we are only beginning to appreciate the complexity of this issue. The 
complexity is both clinical, as there are no biomarkers able to predict the response to Pt-based 
treatment and biological, due to the various mechanisms involved and to the marked molecular 
heterogeneity that characterized HGS-EOC.  
Since the most important drugs for treatment of HGS-EOC are platinum compounds, in this 
thesis the attention will be focused on the resistance mechanisms related to this class of drugs. 
Considering the timing of Pt-resistance development it is possible to distinguish two different 
types of resistance (figure 1.6): 
i) intrinsic (or primary)  





Figure 1.6 Intrinsic and acquired Pt-resistance. Mo, months 
 
The primary resistance to Pt-compounds, involving about 15-25% of HGS-EOC patients, is 
referred to those tumours that do not respond or relapse within 6 months from the end of the 
first-line platinum-based treatment (paragraph 1.3.3.2). The primary resistance, is also named 
“intrinsic” resistance, as the biological features related to non-response to therapy are already 
present in some cells (intratumoural heterogeneity) composing the tumour masses at time of 
diagnosis (49). 
In contrast, the acquired platinum resistance has been defined as the failure to respond to 
subsequent treatment having previously demonstrated sensitivity to one or more lines of pt-
based chemotherapy.  
The multiple biological mechanisms involved in platinum resistance will be described in detail 
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in paragraph 1.4.2, after a brief description regarding the mechanism of action of platinum drugs 
(paragraph 1.4.1).  
 
 1.4.1 Mechanism of action of platinum compounds 
It was in the 1960s that Barnett Rosenberg (figure 1.7) at the Michigan State University 
accidentally discovered cisplatin (CDDP), the first platinum-derivate compound approved for 
clinical use. While he was studying the effects of electric dipole fields on cell division, he 
noticed that a product released by platinum electrodes due to electrolysis reaction, was able to 
inhibit DNA synthesis in microorganisms.  
 
 
Figure 1.7 Barnett Rosenberg (1926-2009) and cisplatin structure 
The following detailed chemical analysis purified and identified the compound, named as 
cisplatin (cis-[Pt(II)(NH(3))(2)Cl(2)] ([PtCl2(NH3)2] or CDDP) (50). Cisplatin is a metallic 
(platinum) coordinator compound with a square-planar geometry. It contains two chloride 
leaving groups in cis dispositions, that remain bound to the platinum in the plasma due to its 
high chloride concentration (about 100 mM). Once inside the cell, where the chloride 
concentration sharply decreases (4-12 mM), the cisplatin undergoes aquation of one or two of 
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the two chloride leaving groups (figure 1.8), leading to the formation of activated complexes 
[Pt(NH3)2Cl(H2O)]
+ and [Pt(NH3)2(H2O)2]
2+. To note the chemical reaction that generates the 
activated aqua platinum species is the same for cisplatin and for both carboplatin and 
oxaliplatin, the only two FDA approved cisplatin-derivatives.  
 
Figure 1.8 Cisplatin activation process (51). 
 
These activated complexes are able to bind RNA, DNA, proteins and membrane phospholipids, 
although they preferentially bind the genomic DNA inside the cellular nucleus. In particular, 
the most common binding site is represented by the N7 atom of purine bases, with a very 
predominant preference of guanine over adenine. Although the chemical structure of activated 
complexes allows monofunctional bindings to a single purine base, or DNA-protein cross-link, 
the anticancer activity of platinum-compounds is related to the formation of intra- (binding of 
two guanines located on the same DNA strand) and inter- (binding of two guanines located on 
opposite DNA strand strands) covalent bis-adducts (figure 1.9) (52). Although inter-strand 
crosslinks are formed less frequently than intra-strand crosslink, damages induced are more 
toxic for cells. In fact, as inter-strand crosslinks involve both complementary strands, they result 
more inhibitory to DNA replication and transcription compared to the intra-strand crosslinks 
(53) (54). 
 




Figure 1.9 Binding between platinum-derivatives activated complex and DNA (modified from (55)) 
 
The formation of Pt-induced DNA adducts leads to a block of DNA synthesis and transcription, 
which in turn triggers to an intricate intracellular signal transduction cascade aimed to eliminate 
the lesions. While intra-strand cross-links cause a distortion of double helix and activate mainly 
the nucleotide excision repair pathway (NER), inter-strand cross-links rely upon the interaction 
among different DNA repair pathways including NER, the Fanconi Anemia (FA) and the 
Homologous Recombination (HR) pathway, which is involved in the repair of DNA double 
strand (dsDNA) breaks induces by platinum compounds (56). In order to provide adequate time 
to DNA repair mechanisms to remove the lesions, cell cycle is arrest, but in case of impaired 





Fig.1.10 Mechanism of action of platinum-compounds (modified from (55)) 
 
 
1.4.2 Mechanisms of resistance to platinum compounds 
The issue of primary and acquired resistance to platinum compounds is extremely intricate and 
involved many biological processes. 
In this section the major biological mechanisms involved in Pt-resistance are cited, but a 
particular attention will be paid to the role of BRCA1/BRCA2 and the HR pathway. The 
mechanisms are classified on the basis of alterations that: i) involve the steps upstream the 
platinum-DNA bound (pre-target resistance); ii) are directly related to the formation and 
recognition of Pt-DNA adducts (on-target resistance); iii) concern the lethal signalling pathways 




1.4.2.1 Mechanisms of pre-target resistance  
There are three fundamental mechanisms by which the cells can elude the potential cytotoxic 
activity of platinum compound (figure 1.11), inhibiting the interaction between the drug and its 
main target (DNA):  
i) reduction of intracellular accumulation of Pt  
ii) increase of Pt efflux  
iii) increase of Pt intracellular sequestration   
 
Although for long time it has been believed that cisplatin entered into cytoplasm cells’ through 
passive diffusion, in the last decades transmembrane proteins involved in copper homeostasis 
have emerged to play a very significant role in cisplatin uptake and its consequent intracellular 
accumulation (57). In particular low expression levels and polymorphisms (58) of the copper 
transporter 1 (CTR1), which is mainly responsible of cisplatin uptake, are associated with 
resistance to Pt-based treatment both in vivo and in vitro (59) and with a poor OS and PFS (60). 
Moreover the exposure to clinical relevant concentration of cisplatin has been reported to lead 
to CTR1 internalization and degradation, contributing at least in part for multiple instances of 
acquired resistance  (61). 
The resistance to DDP is also be related to increase drug export. There are two main classes of 
transporters involved in cisplatin cellular export: the ATP binding cassette (ABC) transporters 
and P-type ATPase transporters. Multi resistance associated proteins (MRP), belonging to ABC 
transporter are transmembrane proteins responsible for the efflux of glutathione-platinum 
conjugates. In particular, many years ago, several studies had pointed out the role of MRP2 
(also known as cMOAT, canalicular multispecific organic anionic transporter) as the major 
transmembrane protein responsible for DDP efflux (62). Although the association between 
overexpression of MRP2 and resistance to platinum-based chemotherapy has been 
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demonstrated years ago in several solid tumours i.e. colorectal, oesophageal, hepatocellular (63) 
(64) (65), only recently it has been confirmed also in ovarian cancer (66). As previously 
anticipated another class of transmembrane proteins are involved in cisplatin efflux that is the 
copper (Cu) extruding P-type ATPase transporters class, in particular ATP7A and ATP7B 
transporters. Their up-regulation is associated to resistant phenotype to cisplatin in ovarian 
cancer cell lines and it was demonstrated to be associated to prognosis in ovarian cancer patients 
(67). The altered activity and expression of ATP7A and ATP7B transporter seems to be related 
with the intracellular copper concentration, indicating that intracellular Cu homeostasis would 
influence the efficacy of platinum-based drugs (68). 
Finally, the last pre-target mechanism of resistance to DDP regards the cytoplasmic conjugation 
of aquated cisplatin with nucleophilic species including glutathione (GSH) and the binding with 
metallothioneins (MT) proteins. Both in vivo and in vitro models, have demonstrated that 
elevated levels of GSH, of the enzymes that are involved in GSH synthesis (-glutamycysteine 
synthetase) or of enzymes that coniugate the aquated-DDP and GSH (glutathione S-
transferase), are associated to DDP resistance. The conjugation of aquated-DDP with GSH, in 
fact, leads to the cellular export by MRP transporters (69). Also the metallothioneins, in 
particular MTI and MTII, are involved platinum resistance, due to their capabilities to act as 
cytoplasmic DDP scavengers. It has demonstrated that their overexpression is related to 





Figure 1.11 Mechanisms of pre-target platinum resistance 
 
1.4.2.2 Mechanisms of on-target resistance  
Once overcome the pre-target resistance mechanisms described above, DDP is able to carry out 
its cytotoxic activity by binding DNA and forming Pt-DNA adducts. As DNA represents the 
main target of Pt -based drugs, the sensitivity/resistance to therapies is strictly related to the 
capability of the cells to recognize and repair the platinum-induced DNA damages. For these 
reasons, alterations (mutations, copy number or epigenetic changes) of genes involved in DNA 
repair mechanisms are associated with increased or reduced drug sensitivity.  
The on-target resistance in HGS-EOC is mainly due to: 
- increased nucleotide excision repair (NER) proficiency 
- mismatch repair (MMR) deficiency 




As alterations in NER, MMR involve small percentage of HGS- EOC (8% and 3% respectively) 
(71) and nowadays no drugs are available to target or exploit defects in these pathways, they 
will be very briefly described. On the contrary, a particular attention will be paid to defects in 
HR pathway, which involved about 50% of HGS-EOC patients and whose alterations are 
exploited by a new class of drugs (PARPi) recently approved for HGS-EOC treatment (see 
paragraph 1.3.3). 
The majority of DDP-induced lesions, both intra and inter-strand, are removed by NER, which 
is the main DNA repair pathway involved in the resolution of “bulky lesions”. In this setting, 
after the formation of platinum-induced adducts, the damaged nucleotides are excised from 
DNA upon cleavage of both sides of the lesion (XPG-3’ and XPF-ERCC1-5’ nuclease), 
followed by DNA synthesis. 
Early reports correlate an increased in expression levels of mRNA ERCC1, with the platinum 
resistance in ovarian cancer cell lines and tumour tissue (72). However, conflicting results 
published in literature regarding the expression of ERCC1 and platinum response are most 
likely due to the facts that 1) many studies did not investigate the specific ERCC1 isoform 
(ERCC1-202) involved in the formation of active XPF-ERCC1 complex (73) 2) the evaluation 
of expression levels of a single protein involved in a complex DNA repair system such as NER 
could not totally reflect the status of entire pathway. Further detailed pre-clinical and clinical 
investigations are still needed. 
In contrast to NER, defects in MMR were associated to resistant phenotype, for the ability of 
MMR-related proteins, in particular MSH2 and MLH1 often mutated or underexpressed, to 
recognised the DNA damages and activate apoptotic processes (74).  
However also in this case results reported in literature are discordant in associating MMR 
deficiency with Pt-resistance in HGS-EOC, and the role of MMR inactivation in treatment 




To resolve the formation of inter-strand crosslinks and the double strand break (DSB) DDP-
induced, another important mechanism of DNA repair is involved: the homologous 
recombination (HR) pathway. 
HR is an error-free pathway, strictly activated in phase S-G2, that requires the presence of sister 
chromatid as a template to solve the double strand breaks (DSB) (figure 1.12). In particular, 
once that DSB has been recognized by MRE11A-NBS1-RAD50 (MRN complex), ATM 
recruitment and ATM-mediated phosphorylation lead to MRN activation. This event causes the 
resection of 5’ strand-ends on either sides of DSB determining, via BRCA1-dependent 
processes, the exposure of the two 3’ single-strand DNA (ssDNA) regions. Through the action 
of BRCA2 and PALB2 proteins, RAD51 is able to bind the exposed ssDNA 3’end and to invade 
the double helix of the intact homologous stretch of DNA on the sister chromatid. DNA 
polymerases use the 3’-ssDNA end as a primer for the synthesis of the new DNA strand, using 
the homologous DNA sequence as a template with the formation of a displacement loop (D-
loop) (76). Now the second DSB end can be captured forming an intermediate structure with 
two Holliday junctions (HJ). The structure is now solved by DNA Polymerases and DNA 
ligases at the HJ level through a crossover or non-crossover mode, that means with or without 
the exchange of genetic material between two homologous chromosomes non-sister 
chromatids. Alternatively, it can proceed to the annealing of the ssDNA-end portion, followed 




Figure 1.12 Mechanism of action of Homologous Recombination (HR) pathway to repair double-strand break 
DNA (77). 
 
As previously anticipated, HR is involved in the resolution of inter-strand adducts that lead to 
DSB, so as expected an increase in HR activity allows cells to repair DNA damages induced 
by DDP, thus reducing DDP cytotoxic activity. On contrary defects in HR make the tumour 
cells unable to repair Pt-induced DNA damage, leading to an increase genomic instability, that 
causes activation of apoptosis pathways or mitotic catastrophe (78).  
As reported in figure 1.13, about 50% of HGS-EOC cases are characterized by defects in HR 
pathway. In particular, two key genes for HR system, that are BRCA1 and BRCA2 are mainly 
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involved and account for the 30% of all HR deficient cases. BRCA1 and BRCA2 are affected 
by germline mutations, associated to Breast-Ovarian cancer syndrome (paragraph 1.1.1) in 8% 
and 6% of HGS-EOC cases, whereas somatic mutations are detected in about 3% of cases for 
both genes (19). The majority of these mutations are frameshift or indel (insertion or deletion) 
and are frequently associated to heterozygous loss (LOH) (81% in BRCA1 and 72% in BRCA2), 
indicating that both alleles are inactivated, so the function of the proteins is completely lost 
(79). Mutations in BRCA1 and BRCA2 are mutually exclusive with BRCA1 epigenetic silencing, 
that occurs via promoter hypermethylation (about 10% of cases). Other somatic mutations that 
affect the proficiency of HR include mutations in CDK12 (3% of cases), which lead to HR 
deficiency through transcriptional suppression of several HR genes included BRCA1, RAD 50, 
RAD51, RAD51C, RAD54L. Other mutations were observed in DNA damage response genes 
involved in HR (ATM, ATR, CHEK1 and CHEK2) and Fanconi Anemia (FA) genes (mainly 
PALB2, FANCA, FANCI, FANCL and FANCC).   
Moreover, alterations that affect genes that indirectly regulate HR activity are reported. For 
example focal deletion in genomic region (10q23.31) that include PTEN gene, which is reported 






Figure 1.13 Genetic and epigenetic alterations in DNA repair pathways in HGS-EOC. 
  
From data published in literature it was well established that HGS-EOC patients with somatic 
or germline mutations in BRCA1 and BRCA2 genes are associated with increased sensitivity to 
platinum compound and PARPi and with an improved survival outcome (80) (46). Pathogenic 
mutations in BRCA1 and BRCA2 are most commonly associated with the Homologous 
Recombination Deficiency (HRD), however alterations in other HR-related genes can cause the 
dysfunction of the entire pathway. In the last years the increasing interest in PARPi, has led to 
considere not only the mutational status of BRCA1/2 but also the entire status of HR DNA 
repair pathway. Although initially a gene expression signature associated to HR status was 
discovered analyzing by microarray approach on HR-proficient and HR-deficient cell lines (81) 
the development of next generation sequencing technology allowed to study more in details the 
HR status, analyzing genomic alterations (genomic “scars”) that represent a consequence of 
increase in genomic instability due to HR dysfunction. 
The three scars considered are: 
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- loss of heterozygosis (LOH) in genomic region >15 Mb, but that not involve the entire 
chromosome (82)  
 
- telomeric allelic imbalances (TAI) of at least 1 Mb 
 
 
- large-scale transition (LST) that is a chromosomal break between adjacent regions of 
  at least 10 Mb, with a distance between them no longer that 3 Mb 
 
 
On the basis of these three genomic features, it is possible to calculate an HDR score (figure 
1.14), defined as the unweight sum of the number of LOH+TAI+LST. This approach is used 
by FDA-approved Myriad’s test (myChoice®) to select patients eligible for PARPi treatment 
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(HRD score < 42= HRD negative, HRD score > 42= HRD positive). 
 
 
Figure 1.14 Calculation of Homologous Recombination Deficiency score 
 
Up to now, it has been described the association between deficiency in homologous 
recombination pathway and the increased sensitivity to pt-compounds and PARPi, however 
resistance can develop through restoration of HR DNA repair system’s functionality. In fact, it 
was demonstrated that in germline mutation carrier patients the acquisition of secondary 
somatic mutations in BRCA1/2 genes, which are able to restore the open reading frame and so 
the protein function (revers mutations), is a common mechanism to shift from HRD to HR 
proficient phenotype (about 33% of acquired resistance cases) (83) (84). These reverse 
mutations, as well as the decrease in promoter BRCA1 methylation (85), probably due to a 
selective pressure related to prolonged platinum exposure, are mechanisms that can explain the 







1.4.2.3 Mechanisms of post-target resistance  
In this chapter will be shortly addressed some molecular features that allow cells to avoid 
cellular death as a consequence of the formation of Pt-DNA adducts in HGS-EOC. Mainly, 
post-target resistance to Pt-compounds regards general alterations in mechanisms involved in 
the apoptotic pathway of signal transduction that is activated in response to DNA damage as 
well as in problems with the cell death executioner machinery itself. These post-target 
mechanisms of resistance are common to many cytotoxic agents and are based on a 
disequilibrium between pro- and anti-apoptotic cellular factors, which allows cells to avoid 
cellular death by increasing its genomic instability. 
For example it was demonstrated in pre-clinical and clinical studies that the overexpression of 
several anti-apoptotic protein such as Bcl-2, Bcl-XL, and MLC-1 correlate with platinum 
resistance and tumour recurrence (86) (87) (88). Also the overexpression of proteins belonging 
to the inhibiting apoptotic proteins family (IAP), such as cIAP1 and XIAP, has been 
demonstrated in preclinical studies to suppress apoptosis, supporting the chemoresistance in 
HGS-EOC (89).   
The majority of the studies focusing on alterations in apoptotic pathways as post-target 
mechanism of platinum resistance, have been conducted on HGS-EOC cell lines, some of which 
appear to be misclassified or contaminated and that certainly represent useful but limited pre-
clinical model that are not able to fully capture the complexity and the heterogeneity that 
characterized HGS-EOC. For this reason, it is getting clear that the translational research 
focusing on study directly tumour biopsies derived from patients and correlate biological 
features with prognostic and predictive parameters, represents a more realistic approach to 





1.4.3 Transcriptional signatures associated to platinum response  
For many years the issue of resistance to Pt-based compounds have stimulated the research of 
molecular biomarkers that would help to stratify patients’ risk of relapse at time of diagnosis, 
and thus avoiding unnecessary treatments to those patients who are intrinsically resistant (see 
figure 1.6). 
As a general comment, overall data reported till now in literature showed that a single gene 
approach failed to identify the few key regulatory genes responsible for therapy resistance, and 
this is mainly due to the complexity of regulatory mechanisms underlying therapy resistance 
and the high molecular heterogeneity of HGS-EOC (see paragraph 1.2). As a consequence, the 
scientific community was forced to move from a single gene to a pathway-level analysis. 
Using integrated multi -omics approaches, Patch and colleagues, evidenced differences in the 
genomic profile of Pt-sensitive (Pt-s) and Pt-resistant (Pt-r) cases. In particular, as previously 
anticipated by Tothill (24), it was confirmed that the presence of the molecular signature 
C1/mesenchymal (see paragraph 1.2) was associated with both primary and acquired resistance, 
early relapse and poor OS (90). 
Integrating genes and miRNAs expression analysis from four independent datasets, Yang and 
colleagues, reduced the Tothill’s molecular sub-classification to two different groups associated 
with prognosis: the integrated mesenchymal subtype (iM) and the integrated epithelial subtype 
(iE). The iM subtype, significantly characterized by a shorter OS in comparison with the iE 
subtype , was biological defined by eight key regulatory miRNAs, including miR-200 and miR-
141, which were directly or indirectly involved in the Epithelial to Mesenchymal Transition 
(EMT) process (91). 
The EMT is a complex biological pathway involved in tissue embryogenesis that have increased 
importance in tumour biology over the last years. Although is beyond the scope of this thesis a 
detailed discussion of the role of the EMT in tumour progression towards malignancy, some 
57 
 
features will be briefly reviewed with a special focus on EMT’s effects on platinum drug 
resistance. 
The EMT process is characterized by a loss of epithelial cells morphology and cytoskeletal 
reorganization with acquisition of mesenchymal features, one of which is the ability of tissue 





Figure 1.15 Epithelial to Mesenchymal Transition (EMT) process. In figure are reported the main markers of 
epithelial and mesenchymal phenotype, and the pathways involved in the EMT activation 
 
The role of EMT in HGS-EOC Pt-resistance has long been discussed in literature. Gene 
expression data generated from our laboratory using 23 matched patients’ biopsies, who were 
sensitive to Pt at time of primary surgery and became resistant after several pt-lines therapy 
demonstrated and validated the presence of a Pt-resistance signature indicative of EMT 
activation, induced by the transforming growth factor β (TGFβ) (92). In particular, as further 
demonstrated by Parikh et al., the activation of TGFβ-mediated EMT in HGS-EOC, occurs 
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through miR-181a-5p activity, by inhibiting its functional target SMAD-7, a regulatory 
inhibitor element of pathway, leads to increase in cellular survival, migration, invasion and drug 
resistance. In fact, high levels of miR-181a-5p and phosphorylated SMAD2 protein (SMAD2-
p) which represent a key element of EMT TGFβ-mediated cascade, were associated to shorter 
time of recurrence and poor outcome in HGS-EOC patients (93). These results were confirmed 
by a more recent work published by our group in collaboration with the clinicians of Policlinico 
Gemelli in Rome (Italy), that demonstrated the prognostic and the predictive role of miR-181a-
5p and SMAD2-p in HGS-EOC patients underwent NACT (94). 
It is plausible that due to the complex and heterogeneous nature of Pt resistance, EMT pathway 
is just one of the molecular pathways that can explain the issue of drug resistance in HGS-EOC.  
In the last years research focused on the role of miRNA, as general controller of different 
molecular pathways in the cell. The miRNAs expression analysis conducted on HGS-EOC 
biopsies taken at time of primary surgery, identified a molecular signature (MIROvaR) that is 
predictive of risk of progression or relapse. In particular this signature, composed by 35 
miRNAs, which does not include miR-181a-5p but involved most members of the miR-200 
family that are key regulators of EMT process, is able to classify patients in “high” and “low” 
risk of recurrence (95).  
Many other studies were conducted analyzing genome methylation profile (96) or copy number 
expression signatures (97) however nowadays no biological, molecular parameters or 
transcriptional signatures have been established in the clinical practice. 
Considering all these data published in literature however it has become evident that the 
investigation of molecular mechanisms related to resistance needs an integrated -omic 
approach, which have to consider genomic and transcriptional aspects of the disease, 
investigating not only coding and non-coding genes, but also known and unknown transcripts. 
These could lead to the identification of a complete molecular signature that is able predict 
response to Pt-compounds at time of patients’ diagnosis and to understand the biological 
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features already present in primary tumour masses that will characterized the resistance disease, 




























The high mortality rate that characterised HGS-EOC is mainly caused by the resistance that 
tumour sooner or later develops towards Pt-based compounds. Although hundreds of studies 
have been published over the last years in order to identify molecular biomarkers able to predict 
resistance to platinum-based drugs, none of these is currently used in clinical practice. 
The identification of a biological signature associated to Pt response would help stratify 
patients’ risk of relapse at time of diagnosis, thus avoiding unnecessary treatments to those 
patients who are intrinsically resistant towards Pt-based drugs. 
To achieve this ambitious goal, the aim of this thesis is to contribute to the identification of a 
molecular signature associated with intrinsic platinum resistance, investigating the entire 
transcriptome and some genomic aspects in retrospective cohorts of cases opportunely selected 
as Pt-sensitive (Pt-s) and Pt-resistant (Pt-r). 
 
As graphically summarised in figure 2.1, this study is subdivided into three main parts that are: 
pathway identification, genomic instability and transcriptome analysis. As it can be seen, the 
three steps are based on the use of different technological approaches. In fact, when this study 
begun the array technology was the gold standard to investigate gene expression profile. When 
NGS technology became popular and implemented in our laboratory, it allowed:  i) an absolute 
quantification of the transcripts’ abundance and a reconstruction of unknown or partially 
unknown transcripts and ii) to obtain data regarding Copy Number Alteration (CNA) and 
mutational profile. However due to the limits of access to NGS, RNA and DNA sequencing 
data were not obtained on the entire cohorts exploited for array-based experiments, but only in 
a subgroup of them. 
Gene and miRNA expression data generated and confirmed using three independent cohorts of 
HGS-EOC patients (Materials and Methods section, paragraph 3.1), named as cohort A (n=99), 
B (n=143) and C (n=838, curatedOvarianData database) were integrated using an in house 
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developed algorithm (micrographite) to identify biological pathways driving Pt resistance and 
that could impact on patients’ prognosis.  
To integrate data obtained with mutational and more detailed transcriptional information, both 
DNA and RNA sequencing experiments were not performed on the entire cohorts A and B, but 
only on a sub-group of them named AI (n=28) and BI (n=55), best balanced in terms of Pt 
sensitivity (Results section, paragraph 4.3.1). 
It is known from literature that the status of the genes belonging to the Homologous 
Recombination (HR) pathway can influence response to Pt compounds (98) so to test these 
evidences, using NGS approach DNA sequencing experiments were performed both in Cohort 
AI and BI (Figure 2.1). Data obtained were analysed in order to define, set and test an HRD 
score, able to discriminate HR proficient from HR deficient cases and to correlate this status 
with the response to Pt based chemotherapy. 
In the last part of this study the entire transcriptome was sequenced (total RNA sequencing) to 
identify in cohort AI known or novel transcripts that are differentially expressed between Pt-
sensitive and Pt-resistant HGS-EOC patients. RNA sequencing results obtained were then 
validated using a sequencing targeted approach both in cohort BI (technical validation) and in 










Figure 2.1 Study Overview: workflow of the study in which is briefly summarized the three main tasks faced in 
this thesis represented by the pathway analysis (1), the analysis of the genomic instability (2) and the analysis of 
the transcriptome (3). For each task the type of analysis performed and the technical method applied are 
reported. Moreover, for each of the three aspects investigated the cohorts (A, B, C, AI and BI) on which the 






















3.1 Tissue Sample Collections 
 
A total number of 242 HGS-EOC tumour samples, derived from two independent cohorts of 
patients (named A and B) were selected for this thesis work. All biopsies selected derived from 
HGS-EOC patients, naïve to chemotherapy, underwent debunking surgery and staging 
procedure according to the FIGO (International Federation of Gynecological and Obstetrics) 
guidelines. For this work only FIGO stage III/IV were selected. Based on the time lagging 
between the end of first line platinum-based therapy and relapse, patients from cohort A and B 
were classified into i) Pt-s, platinum-sensitive ii) Pt-ps, partially-sensitive and iii) Pt-r platinum-
resistant as detailed described in the introduction (paragraph 1.3.3.2). Relapse after first-line 
platinum-based therapy was clinically identified (i.e. raise of CA-125 serum marker) and 
always radiologically confirmed with computed tomography (CT) scan. Data obtained from the 
analysis of cohorts A and B were tested in silico in another independent cohort (cohort C). In 
cohort C the time between the end of first line treatment and relapse is not available, thus, the 
stratification among Pt-r, Pt-s and Pt-ps was not possible. 
Cohort A is composed by 99 snap-frozen HGS-EOC biopsies obtained at the Division of 
Obstetrics & Gynecology, ASST Spedali Civili, University of Brescia, between 2003 and 2013. 
Biopsies are stored in the biobank located at the “A. Nocivelli” Institute, ASST Spedali Civili 
of Brescia. A subset of this cohort (n=28, cohort AI) was selected balancing Pt-s and Pt-r cases, 
for Next Generation Sequencing experiments (see “Results” section paragraph 4.2.1). 
Cohort B is composed by 143 snap-frozen tumor biopsies derived from HGS-EOC patients 
underwent debulking surgery at the Obstetrics and Gynecology Dept., San Gerardo Hospital 
(Monza, Italy). Biopsies are stored in the Pandora tumor tissue collection located at Mario Negri 
Institute for Pharmacological Research (Milan). A subset of this cohort (n=55, cohort BI) was 
selected on the basis to keep best balancing Pt-s and Pt-r cases, for Next Generation Sequencing 
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experiments (see “Results” section paragraph 4.2.1). 
For both cohorts A and B clinical and anatomopathological information were registered and 
follow-up data were obtained from periodical gynecologic and oncological check-ups. Tumor 
samples were collected during cytoreductive surgery and frozen within 15 minutes in liquid 
nitrogen and stored long term at -80°C. The tumor content of the biopsies collected was 
evaluated with hematoxylin and eosin staining and only samples containing more than 70% of 
epithelial tumor cells were used for downstream analyses.  
The local scientific ethical committees approved the collection and usage of all tumour samples 
and a written informed consensus was obtained from all the patients enrolled (study reference 
number NP1676 and NP1065). The study has been carried out following the Declaration of 
Helsinki (99). 
Cohort C is composed by 838 samples obtained through the curated ovarian cancer dataset 
publicly available through the Bioconductor platform gathering together the TCGA data plus 
other ovarian datasets. The curated ovarian database as reported in the “curatedOvarianData” 
Bioconductor package was used as a first external independent validation set (Cohort C). The 
curatedOvarianData database (100) contains several normalized and batched-corrected ovarian 
datasets. Among these, we selected studies with platinum treated patients and complete follow-
up for both progression free (PFS) and overall survival (OS). Unfortunately, the progression 
free interval (PFI) defined as the time between the relapse and the end of platinum-based 
therapy is not available. For this reason, samples of the curatedOvarianData cannot be stratified 
according to Pt-s and Pt-r. Here we will use PFS as a proxy of platinum resistance. The selection 
leads to 5 datasets (GSE30161, GSE9891, GSE49997, TCGA microarray and also 





3.2 Nucleic Acid extraction 
 
3.2.1 RNA extraction  
Total RNA enriched in miRNA fraction was extracted starting from about 30 mg of snap-frozen 
tumour tissue biopsies using miRNeasy mini kit (Qiagen®).  
The RNA extraction procedure was subdivided in two main phases:  
i) tissue homogeneization and cell lysis 
ii) RNA purification  
The homogeneization of snap frozen tissue was obtained through mechanic disruption 
(TissueLyser LT, Qiagen) using a phenol-guanidium thiocyanate solution (QIAzol Lysis 
Reagent, Qiagen®), which promotes the cell lysis and inhibits RNase activity. The subsequent 
addition of chloroform, followed by centrifugation (15 min at 12000g, 4°C), allowed to 
obtained three different phases: an upper colourless aqueous phase containing total RNA 
containing miRNA, a white interphase (DNA) and a lower red organic phase which contains 
lipids and proteins. The upper aqueous phase, after the addition of 1.5 volumes of 100% ethanol, 
which promotes RNA precipitation, was transferred into a silica membrane spin column 
(miRNeasy mini spin column, Qiagen®) for the purification steps that for this thesis work were 
performed automatically on QIAcube system (Qiagen®). The membrane’s pores size allowed 
to retain all nucleotides > 18 base pairs (bp), so total not degraded RNA and miRNAs (22-25 
bp). A series of washes with dedicated buffer followed by centrifugations purified the RNA 
extracted, and finally RNA enriched in miRNA fraction was eluted in 30 μl of RNase-free 
water.  
The amount of RNA extracted was evaluated with a fluorimetric analysis (Qubit RNA BR assay 
kit, Thermo Fisher®) and the integrity quality control was performed through a commercial 
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automated capillary electrophoresis instrument (Tape Station 4200, Agilent Technologies®). 
 
3.2.2 DNA extraction from snap-frozen tumour tissue biopsies 
DNA was extracted from about 25-30 mg of snap-frozen tumour tissue biopsies using QIAamp 
DNA mini Kit (Qiagen®).  
The protocol included the following steps: 
- Chemical tissue lysis and enzymatic protein digestion of snap-frozen tumour tissue, 
exploiting dedicated SDS-buffer (ATL buffer) and Proteinase K, through an overnight 
incubation at 56°C. 
- Addition of RNase A (100mg/ml) to remove RNA residual contamination 
- Transfer of the material into a silica membrane spin column (QIAamp mini spin 
columns, Qiagen®) for the DNA purification steps that for this thesis work were 
performed automatically on QIAcube system (Qiagen®). In particular, DNA is adsorbed 
onto the QIAamp silica membrane during a brief centrifugation (800 rpm for 1 min), 
and following the washes with dedicated buffers ensured that proteins and other 
contaminants were not retained with DNA on the QIAamp membrane. 
- Elution of purified DNA in 200 l of distilled water. 
 
The amount of DNA extracted was evaluated with a fluorimetric analysis (Qubit DNA assay 
kit, Thermo Fisher®) and the integrity quality control was performed through a commercial 







3.2.3 DNA extraction from blood samples 
Genomic DNA (gDNA) was extracted from whole-blood samples using Maxwell RSC Blood 
DNA Kit (Promega®). The protocol included the following steps: 
- Cellular lysis and enzymatic protein digestion of 300 l of whole-blood sample, through 
incubation (20 min at 56°C) of samples with lysis buffer and Proteinase K. 
- Automatic purification of genomic DNA obtained using Maxwell RSC instrument 
(Promega®), which exploiting paramagnetic cellulose-based particles, allowed to 
capture and wash the gDNA extracted. 
- Elution of purified gDNA in 50 l of Elution Buffer. 
 
Also in this case the amount of DNA was evaluated using fluorimetric assay (Qubit DNA assay 
kit, Thermo Fisher®) and the integrity of gDNA obtained was checked through a commercial 
automated capillary electrophoresis instrument (Tape Station 4200, Agilent Technologies®). 
 
 
3.3 Pathway analysis 
 
3.3.1 Gene and microRNA expression profile  
Microarray mRNA and miRNA expression experiments were performed on the 99 HGS-EOC 
cases composing the cohort A, through microarray approach exploiting commercially available 
kits (G4851B human whole GE kit and G4470B Human miRNA kit, Agilent Technologies®), 
which allowed to investigate 26083 mRNA, 30606 lncRNA and 799 miRNAs. 






Figure 3.1 Schematic workflow of microarray experiment 
 
Briefly, in gene and lncRNA expression microarray experiments 100 ng of total RNA were 
retrotranscribed in single strand cDNA exploiting reverse transcriptase enzyme in the presence 
of primer olig-dT bound to the poly-A tail of mRNA. Through a T7 RNA polymerase’s activity, 
that recognized a specific sequence at 3’ end of the second strand cDNA, the complementary 
RNA (cRNA) was synthetized and marked through the incorporation of cytosine conjugated 
with a fluorophore (Cyanine 3, Cy3). The conversion from cDNA to cRNA was necessary due 
to the major stability of DNA-RNA rather than DNA-DNA hybrids. In order to remove 
unbound Cy3 a purifiction step exploiting silica membrane spin columns (RNeasy mini kit, 
Qiagen®) was performed. 
The concentration and the Cy3 incorporation efficiency in cRNA defined as “specific activity”, 
71 
 
was calculated using NanoDrop ND-1000 (Thermo Fisher®) using the following formula: 
(Cy3 concentration/cRNA concentration) x 1000 = pmol Cy3 for g cRNA 
At this point, cRNA was fragmented in order to prevent cross-hybridization or the formation of 
secondary structures which could affect the hybridization with probes. Once reaction was 
stopped through basic solution (pH 11), fragmented cRNA samples were put on the 
commercially available microarray glass slides, where were spotted clusters of 60 bp probes. 
The hybridization reaction between marked cRNA and spotted probes took place at 56C for 
17 hours with a rotation speed of 10 rpm.  
 
 
Figure 3.2 Schematic principle of oligonucleotide microarray. Two different probes were spotted on microarray 
slide (A). The hybridization of fluorophore (Cy3)-labeled cRNA with the immobilized probes (B) occured 
following the base paring Watson and Crick’s model, resulting in a perfect and total pairing or in a mispair (C). 
After stringent washes which allowed to remove unbound or mispair labelled-cRNA sequences from the slide (D), 
fluorescence was detected after fluorophore excitation (ecc = 550 nm) (E). (modified from (101)) 
 
 
At the end of incubation slides were washed with dedicated solution. 
Microarray slides were then inserted in G2565 Scanner (Agilent Technologies®) and exploiting 
the fluorescence properties of Cy3 (ecc = 550 nm and em = 570 nm), the intensity of 
fluorescence signal due to the presence of hybridized marked (Cy3) cRNA was registered 
(figure 3.2). 
A dedicated software (Feature Extraction version 11, Agilent Technologies®) was exploited to 
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associated fluorescence signal to the corresponding specific gene or lncRNA. 
Regarding miRNA expression profile, as microRNA are characterized by a short nucleotide 
sequence (20-25 bp) it was necessary to develop a technical artefact to allow their specific 
hybridization on microarray slide. In particular, as schematically reported in figure 3.3, to 5’ 
end of microarray probe (black sequence), was added by manufacturer a guanine (G) residue 
(black), complementary to Cy3-labeled pCp existing at 3’ end of the target molecule (red), and 




Figure 3.3 Probe design strategy to evaluate microRNA expression by microarray technology. In black is 
reported the probe’s sequence that was characterized at 5’ end by the presence of a guanine (G, black) and an 
hairpin sequence structure (blue) able to stabilized and to improve the specificity of probe-target (red) 
hybridization. Modified from (102). 
 
Starting from 100 ng of total RNA containing microRNA fraction, samples were firstly 
dephosphorylated through Calf Intestinal Phospatase (CIP)’s activity (37C, 30 min). After 
denaturation phase (100C, 5-10 min), Cyanine 3 (Cy3) pCp was added to the 3’ end exploiting 
T4 RNA ligase. After a purification phase on silica membrane spin columns to remove reaction 
reagents (i.e. DMSO) and unbound Cy3-pCps, samples were dried for 3 hours at 55C using a 
vacuum concentrator and then resuspended in nuclease-free water. After a denaturation step, 
samples were put on the microarray slide and were hybridized, following the same principle 
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previously described, at 55C for 20 hours with a rotation speed of 10 rpm. Slide washes and 
the fluorescence analysis performed occurred as described above for gene expression 
microarray experiments. 
 
3.3.2 Microarray data processing 
Data generated by microarray experiments, were analyzed by the bioinformatic team 
coordinated by Prof. Chiara Romualdi (Biology Department of University of Padova, Italy).  
 
3.3.2.1 Filtering steps 
Raw mRNA, lncRNA and miRNA expression signal was quantified using Agilent 
FeatureExtraction software. gProcessedSignal and gTotalGeneSignal were used as expression 
measures respectively for mRNAs and miRNAs. A first step of filtering was set up using the 
Agilent flag gIsPosAndSignif for mRNAs and lncRNAs and gIsGeneDetected for miRNAs. 
Probes with more than 60% of low-quality values were removed. A second step of filtering was 
performed on samples using Relative Log Expression (RLE) plot (103). Samples with RLE 
distribution markedly different from the general trend were removed from the following 
analyses. Probes mapping on the same gene annotation were averaged. Finally, data have been 
log transformed and quantile normalized. Coefficient of variation (CV) was used to select the 








3.3.2.2 RUV normalization 
In data with large scale gene expression studies, the observations are commonly contaminated 
by sources of unwanted variation such as platforms or batch effects. These unwanted variations 
during analysis can lead to weak associations and to missing important signals. Using RUV 
normalization (104) negative control genes and replicate samples was used to estimate 
unwanted variation data. The proposed method was translated on microarray data and 
implemented in the bioconductor package RUVnormalize (105). They generally manage to 
remove unwanted variation without losing the signal of interest and compare favorably to state-
of-the-art corrections. RUVnormalize, using positive and negative control probes (n=48), was 
applied (with number of normalizing factor k=2) to remove unwanted variation and batch effect. 
Hereafter, differentially expressed (DEs) coding and non-coding elements between Pt-r and Pt-
s were identified using permutational moderated t-test, as implemented in samr R package 
(permutational number set to 1000).  
 
3.3.2.3 Network analysis Micrographite 
In order to integrate miRNAs in pathway analysis, micrographite (106) (107) gave us a lot of 
advantages: (i) the possibility to integrate and (ii) analyze miRNA and mRNA expression 
profiles using pathway information and (iii) to biologically contextualize miRNA–mRNA 
validated and predicted interactions. In our study, micrographite was used to identify integrated 
circuits of mRNAs and miRNAs associated to the therapy response (Pt-r vs Pt-s).  
Pathway topologies derived from graphite (108), a Bioconductor package developed to store, 
manage and convert pathway annotations into gene–gene networks. graphite is a pathway data 
interpreter that, following biologically driven rules, is able to solve the complexity of the 
pathway modules to generate interaction networks suitable for topological pathway analyses. 
KEGG pathways as available through graphite (108) and miRNA-target gene interactions 
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available on “TargetScanHuman” database release 7.1 (109) were considered for the analysis.  
Only miRNA-target interactions characterized by a Pearson correlation coefficient |r| ≥ 0.4 and 
q-value ≤ 0.05 were included into pathway annotation. Then, the topological pathway analyses 
used in micrographite are a modified version of CliPPER (106) (110). CliPPER is a 
Bioconductor package that implements a topological pathway. This approach is based on two 
steps. In the first step, pathway graphs were compared in terms of means and variance between 
groups. On these selected pathways, it identifies portions of the pathway mostly associated with 
the phenotype. Into details, path identification is based on the graph decomposition into small-
connected components, called cliques. Each clique is tested independently (according to the test 
on the means and/or concentration matrices) and then a significant level (p-value) for each 
clique is obtained, creating a path as a list of adjacent significant cliques. Clipper is able to 
identify and score all of these paths in the graph. Paths obtained have a score that is a function 
of all the p-values of the cliques contributing to the path and to the higher score correspond the 
better path. Then, the upper-scored 10th percentile of the portion of significant pathways (in 
mean and variance with p<0.1 and 10 000 permutation) are combined into a non-redundant 
meta-pathway. Finally, the portion of the meta-pathway mostly associated to the phenotype is 
revealed.  
 
3.3.2.4 Network analysis: meta-pathway extension 
A significant portion of genes is not annotated into KEGG pathways, and then is not considered 
by micrographite pipeline. In absence of this information, we considered the construction of 
networks having all the protein-protein interactions using computational methods for signalling 
pathways and protein complex identification in specific diseases. Studies have also shown that 
proteins with larger number of interactions can include families of enzymes, transcription 
factors, and intrinsically disordered proteins, among others.  
Thus, to extend our network taking into consideration the excluded genes, we used STRING 
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(111) and BioGRID (112) databases: differentially expressed genes without KEGG annotation 
were added to the network if at least one of their interactors (as reported by STRING and 
BioGRID) were present in the network. Cytoscape (113) was used to visualize the integrated 
regulatory network. 
 
3.3.3 Gene retrotrascription and qRT-PCR validation 
The validation of gene expression data obtained from microarray experiments was performed 
in 242 HGS-EOC cases (cohort A and cohort B) exploiting an independent technique, the 
quantitative real-time PCR (qRT-PCR). 
Firstly, up to 10 g of total RNA obtained from samples (see paragraph 3.2.1) was 
retrotranscribed in cDNA, using commercially available kit (High Capacity cDNA Archive Kit, 
Applied Biosystem®). The retrotranscription phase consisted in the addiction to each RNA 
sample of a master mix composed by a reverse transcriptase enzyme, deoxyriboNucleotide 
TriPhosphates (dNTPs), random primers able to bound the polyA tail of mRNAs and a 
dedicated buffer, followed by a thermacycler incubation (25C for 10 min, 37C for 120 min). 
RNA retrotranscription was followed by qRT-PCR reaction that was prepared in 384 well 
reaction plates followed the manufacturer’s indications (QuantiFast SYBR Green, Qiagen®) 
exploiting an automatic liquid handling system (EpiMotion 5075LH, Eppendorf®). qRT-PCR 









Reagents Final concentration 
2x QuantiFast SYBR Green PCR Master Mix 1X 
Primer FW (100 M) 1 M 
Primer RV (100 M) 1M 
cDNA < 100 ng 
Nuclease-free Water To adjust final volume 
 
Table 3.1 Components of qRT-PCR reaction. QuantiFast SYBR Green Master Mix included the HotStar DNA 
polymerase, SYBR Green dye molecules, dNTPs and reaction buffer containing KCl and (NH4)2SO4 to optimize 
reaction’s condition. FW, forward. RV, reverse. 
 
Briefly, The qRT-PCR reaction allows the amplification of specific cDNA sequences through 
the repetition (40 cycles) of three fundamental steps: i) denaturation of ds cDNA by heat (95C 
for 10 sec) ii) the annealing of gene-specific forward and reverse primers able to bound 
complementary sequences flanking DNA target region, which permit the addition of 
oligonucleotides into the rising DNA strand and iii) the extension of the new  DNA strand 
through a DNA polymerase activity (annealing and extension phases were performed 
simultaneously at 60C  for 30 sec) (figure 3.4). 
 
 
Figure 3.4 qRT-PCR cycle. In figure are reported the three fundamental steps composing each qRT-PCR cycle: 
the denaturation, the annealing and the extension phase. 
 
During the polymerization phase SYBR Green dye molecules (ecc = 488 nm and em = 522 
nm) became intercalated within the double strand DNA product. When excited SYBR Green 
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intercalated within dsDNA was able to emit a fluorescence signal 1000 over then the one 
emitted from the free unbound SYBR Green, representing so an optimal indicator of total DNA 
product obtained during each PCR cycle. 
Results obtained at the end of a qRT-PCR experiments were represented by an amplification 
curve (figure 3.5) where was manually set a threshold that intersected the amplification curve 
at a specific point, threshold cycle (CT), representing the level of a significant increase in 
fluorescence due to DNA amplification. For each gene, CT values obtained were normalized by 
subtracting to the mean value of specific sample the mean value of housekeeping genes (CT). 
 
 
Figure 3.5 Amplification curve of a qRT-PCR experiment. On x-axis is reported the number of PCR cycles, on 
y-axis the relative fluorescence units (RFU) registered at the end of each PCR cycle. Threshold manually set 




qRT-PCR experiments reported in this thesis work were performed using Applied Biosystem® 
7900 instrument. Each one of the 242 samples analysed was run in triplicate and three 
housekeeping genes (GAPDH, HPRT1 and PPIA) were used for the normalization of data 
obtained. 
The list of primers used, which were design using Primer-blast 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/) and Primer3 (http://primer3.ut.ee/) 
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FW primer sequence 
 





GAPDH AGGTCGGAGTCAACGGATTT TTAAAAGCAGCCCTGGTGAC 60 58 
HPRT1 TGAATACTTCAGGGATTTGAATCAT CTCATCTTAGGCTTTGTATTTTGC 60 76 
PPIA GCGTCTCCTTTGAGCTGTTT CCTTTCTCTCCAGTGCTCAGA 60 79 
NOTCH2 GAAGGCAGGTCTCCTGTGTC ATCTTCTGTGCAGTCAGCCC 60 145 
HLA-A ATGAAGGCCCACTCACAGAC GTGAGAACCGTCCTCGCTC 60 81 
TOPORS GAAGAAATAGGGCCTTTCCG TGCCATTATCATGAAGCCAGT 60 128 
EYA4 GTAAACCAGTTTGAAAAATGTTCTGT AATAGCCGAAAACCCACTTT 60 50 
NPY GGGGATTTTCCCTTG AAAACCAAAATGTCTTTCTCTCCA 60 50 
FANCI TACGGGTAACGGAAGTGTGG TCACAGAACTCCGCCACAAA 60 70 
FANCA GAAGAGGCCTTCCTGCATGT GGTTGCCCTGACCCTTGAG 60 127 
PPP1CA GACCGTGGCGTCTCTTTTAC TCTTCTACCACCTGGTGTGCT 60 101 
PIGR AGAGGCAGGGGTTACCAACT TCCTGTGCAATGTTTTAGCCAC 60 89 
HLA-F GCTGCAGTGTGAGACAGCTT TGTATGTTCGTGAGGCACAA 60 87 
CACNA1C CGTGGCTGCTCCTCCTATTA CATAGTTGGAACCTTGGTGGTT 60 97 
CREB3 CTTTCTGAGGTACCGAGCGA GAGAATGTTCAACGACGCTG 60 81 
STAT1 AACCTCGACAGTCTTGGCAC GAGACATCCTGCCACCTTGT 60 96 
BAD1 TGTGGACTCCTTTAAGAAGGGAC CACCAGGACTGGAAGACTCG 60 102 
FLCN GGACCGGATCTACCTCATCA AACGCCAAACTGGGAGAAG 60 103 
APOL6 TTTCTCCAGCCCAGACACTC TCAAATGATTTTCTTCTCTCCACG 60 139 
ROCK2 GGTGATCGTATTCTTCCAGTGA TTTTGGGCCATCATATTTCA 60 51 
ETV7 CAAGCCAGATGTGAAGCTCA CTGGATGCGGAGTCTTCCT 60 78 
PRKG1 GCAGATCCAGGAGATTGTGG CAACCTTACCATCTTCCATGACA 60 116 
SDF2L1 GTCCAACAACCAGGAGGTGA TGACGGAACACAGAGGTGC 60 145 
GCH1 GGTTGAAGCAACACACATGTG CCAACGCACACACACTGAAT 60 164 
PPP1R12A AAGGTGAAGTTCGACGATGG TCATCAATGCAAGCCTGGT 60 149 
CREB5 CTAAGTCCAGAGAGTAGCCCTCC CCAGGTCTGATGGTGCATT 60 187 
 
Table 3.2 Sequences of qRT-PCR reverse and forward primers. For each gene validated are reported the 
sequences of forward (FW) and reverse (RV) primer, the annealing temperature of primers (TA) and the 









Data obtained by qRT-PCR experiments (CT) were analysed using “R” platform by 
bioinformatics and statistic group coordinated by Prof. Chiara Romualdi (University of Padova, 
Italy). In particular, T-test was used to test the mean difference between Pt-r and Pt-s samples 
on log transformed qRT-PCR expression values.  
 
 
3.3.4 Statistical analysis 
Statistical analysis reported in this thesis work were entirely performed by statistic group 
located at Dept. Biology of the University of Padova (Italy). 
Kaplan-Meyer curves were used to visualize patients’ survival. Univariate analysis was 
performed with the log rank test, multivariate analysis was performed using Cox proportional 
hazard model as implemented in survival R package. Overall survival (OS) was calculated 
considering the time lagging between the diagnosis and the death for any cause or the last 
follow-up. Instead, progression free survival (PFS) is defined as the time from diagnosis to 
disease progression or last follow-up. The optimal cutoffs of gene expression values were 
estimated using i) the maximally selected rank statistics as implemented in the survMisc R 
package for survival analysis and ii) the maximum value of specificity and sensitivity using 
ROC curves for prediction of Pt-r and PT-s patients. Residual tumour and age were used as 
covariates in the multivariate analysis. Samples with missing survival data were excluded from 
the analysis. Results are reported as p-value, hazard ratio (HR) and 95% confidence intervals 
(CI). Multivariate logistic regression has been performed using the glm and brglm R packages 
while odd ratio statistics have been obtained using fmsb R package. 
 P-values combination in cohort C has been performed using the Tippett’s method as 
implemented in metap R package.  
The combination of SIII genes has been performed separately for cohort A and B using the 
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standardized expression profiles within cohort to minimize batch effect. All the analyses were 




3.4 Genomic instability analysis 
 
3.4.1 Next generation sequencing of tumour and genomic DNA 
Next Generation sequencing experiments on DNA extracted from snap-frozen tumour tissue 
samples (tumour DNA, tDNA) and where available from matched whole-blood samples 
(genomic DNA, gDNA) were performed exploiting OneSeq Constitutional Research panel 
(Agilent Technologies®), which allow studying genome-wild Copy Number Variations (CNVs) 
and LOH, and evaluating the presence of indel and single nucleotide variants (SNVs) in 6000 













Figure 3.6 Schema design of OneSeq Constitutional Research Panel (Agilent Technologies®). OneSeq targets a 
functional copy number resolution of 300 kilo bases (kb) in the genome-wide backbone, with an even higher 
resolution of 25-50 kb targeted in disease-associated regions defined by ClinGen. Moreover, the panel targets 
exonic regions of 6000 disease-related genes for detection of indels or point mutations at high reads depths. 
 
Following the manufacturer’s instruction, the following steps were performed for libraries 
construction: 
 
1- Mechanic shearing of tumour and genomic DNA, that was performed exploiting 
Bioruptor ultrasonicator (Diagenode®). In particular 200 ng of purified DNA in a total 
volume of 100 l diluted in TRIS10mM pH8 was sheared by ultrasonication (30 sec 
ON + 90 sec OFF for seven cycles) and purified using 1.8X AMPure XP beads 
(Beckman Coulter®). After elution in distilled water, the fragment size of sheared DNA 
was checked using Tape Station 4200 (Agilent Technologies®). DNA fragment size 
peak was expected between 200-300 bp. 
2- End repair, which consisted in the blunt of both 3’ and 5’ end trough the activity of a 
DNA polymerase. At the end of this step a purification of sample with AMPure XP 




3- Adenylation of 3’ end of the DNA fragments, in which dATP at 3’ was added at 3’ ends 
of the blunt DNA fragments to prevent concatemerization and to allow the ligation of 
adapters with complementary dT overhangs. Also at the end of this step, purification 
with AMPure XP beads (Beckman Coulter®) to remove reaction components was 
performed. 
 
4- Adapter ligation, which through DNA ligase activity, allowed assigning to each sample 
a specific and unique barcode sequence (8 bp).  Exploiting AMPure XP beads (Beckman 
Coulter®), purification of samples was performed at the end of this step.  
 
5- Pre-capture PCR amplification in order to amplify the adaptor ligated libraries prepared, 
following the thermal cycler program reported in the protocol. Purification of libraries 
at the end of PCR reaction was required. 
6- Assessment of quantity (Qubit®) and quality (Tape Station 4200, Agilent 
Technologies®) of libraries obtained. The fragment size peaks were between 225 to 275 
bp, as expected. 
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7- Pooling of 15 library samples with different barcode, to obtain a 750 ng DNA in 3.4 l 
of volume. 
8- Overnight hybridization of pool (denaturation step followed by 65C for 16-20 hours, 
lid 105C) with commercial biotinylated-probes (see the beginning of this paragraph) 
9- Capture of the biotinylated-probes that bound during the night the specific sequences 
targets, through streptavidin beads (figure 2.7). 
 
 
Figure 3.7 Capture-based enrichment. Bound of biotinylated probes with target cDNA sequence, and 
subsequent interaction between probes-cDNA with streptavidin beads. 
 
10- Amplification of captured libraries followed by purification of them using AMPure XP 
beads (Beckman Coulter®). 
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11- Qubit® quantification and evaluation of the quality of libraries obtained performed 
exploiting Tape Station 4200 (Agilent Technologies®). As expected, the average 
fragment length obtained was between 250-350 bp, with a peak at approximately 300 
bp. 
  
Considering the capacity of a single flow cell and the average coverage necessary for the 
specific aims (i.e. analysis of germline or somatic mutations) 15 sample libraries per run were 
sequenced on NextSeq-500 sequencing system (Illumina®) using High-output 300-cycles or 
Mid-output 300-cycles cartridge/flow cell in the cases of libraries derived from tumour DNA 
or genomic DNA respectively. 
 
3.4.2 DNA sequencing data analysis 
 
Data generated by DNA sequencing experiments, were analyzed by the bioinformatic team 
coordinated by dr. Sergio Marchini at Dept. of Oncology of the Institute. 
 
3.4.2.1 Quality control and alignment to the genome 
Raw sequenced fragments from the instruments (reads) were first of all subject to quality 
control. Samples were checked for the average length of the reads versus the expected lengths 
(150 bp) and for the quality of the base calls (Q30, percentage of bases with a quality score 
equal or above 30, that is 99.9% confidence of a correct base call).  
After the initial quality control, raw reads were aligned to the human reference genome, build 
19 (hg19), using the Burrows-Wheeler Aligner (BWA) (114). At this point bases with low 
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quality were masked and excluded from subsequent analysis, without actually removing them 
from the data (“soft clipping”). 
The PCR steps used in library preparations can cause a percentage of artifacts (ranging from 5 
to 10% of the total data) show up in the data as duplicate, identical reads: thus, during the 
alignment, duplicate reads from artifacts were removed.  
 
3.4.2.2 Germline and somatic variant calling and copy number alteration 
estimation 
The aligned data from blood samples were used to initially estimate germline variants occurring 
in the BRCA1 and BRCA2 genes. To this aim, the Genome Analysis Toolkit (GATK;(115)), 
version 4, was used to call gemline variants, using the Haplotype Caller. 
For each variant, the chromosomal position, the reference base, the alternate (variant) base, the 
sequencing depth, the genotype and the fraction of variant versus reference reads were reported. 
The resulting variants were then annotated to add information on the gene they were falling in, 
the effect on the protein, and prevalence in the general population: this was done with the 
Variant Effect Predictor (VEP; (116), a tool which queries the Ensembl database and associated 
data sources (such as Uniprot and ClinVar) to obtain detailed annotation.  
Germline variants were screened in the BRCA1 and BRCA2 genes with these criteria: minimum 
allelic fraction (ratio of variant reads versus normal reads) of at least 25%; presence in the 
general population less than 1% (as reported in the 1000 genomes data set and the gnomAD 
population database); unambiguous definition of pathogenicity from ClinVar (that is, only 
variants classified as “pathogenic” or “likely pathogenic”).  
Subsequently, the blood samples were used to build a reference data set used for both somatic 
variant calling in tumor biopsies (to remove normal variants occurring in the population) and 
for somatic copy number variant detection, to provide a robust baseline. Samples with detected 
BRCA1/BRCA2 germline variants were not included in the reference. 
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MuTect 2 (117) was used to generate raw variant calls from the blood samples, which were 
then processed to only include variants occurring at least in five or more samples, following the 
best practices for variant calling outlined by the Broad Institute. This call set was then used as 
reference for the subsequent analyses. 
With regards to copy number, a pooled reference was generated with CNVkit (118). Briefly, 
the reads from the blood samples were divided into “bins” of roughly 200bp in size (average 
length of an exon) and counted for each bin. Then, information from public databases and from 
the genome sequence was used to correct the numbers for GC content and for mappability (as 
the sequence content of some genomic regions may be inherently harder to align to opposed to 
others).  
Once the reference data were ready, we performed the variant calling and copy number analysis 
on the tumor samples. For the former case, we used two different variant calling software: 
 
• MuTect 2 
• VarDict (119) 
 
As reference, we used both the matched blood sample (if available) and the pooled reference 
we built. Variants were then annotated with the VEP as described above, and collected into a 
database (GEMINI; (120)) for further annotation and analysis. 
Copy number analysis was performed with CNVkit, using the pooled reference previously built. 
Reads were binned and counted in the same manner as the blood samples, then bin counts were 
compared to the reference to generate copy number ratios, which were then converted to log 
base 2, after removing all the bins which were too noisy or with too low coverage (< 4X).  
 As the bins were by nature rather small, we collapsed them into segments of equal copy number 




3.4.2.3 Purity and ploidy estimation 
In order to estimate in silico the tumor content and the ploidy of each sample, we used an 
approach which combined both the state of heterozygous SNPs across the whole genome and 
the genome-wide copy number.  These in turn were fed to a mathematical and probabilistic 
model to infer purity, ploidy, and the state of loss of heterozygosity (LOH).  
To this aim we used PureCN (122) which used the calls from VarDict, including the calls 
marked as germline, and the copy number data from CNVkit. Firstly, we built a reference in 
the same fashion as the previous analyses, using the copy number and the germline variant data 
from the pooled blood samples. Subsequently, each sample was analyzed with  PureCN: the 
software used an iterative approach of searching the most likely ploidy / purity combination 
from the copy number and variant data, followed by optimizing and fitting until the most likely 
solution was found.  
The analysis yielded estimated purity and ploidy, LOH state across the whole genome, purity 
and ploidy corrected copy number calls and variants.  Each sample was also checked for noisy 
data or other problematic metrics and flagged specifically if so.  
 
3.4.2.4 Variant interpretation 
Variants from Mutect2, VarDict, and PureCN were filtered to remove low depth of coverage 
calls (likely sequencing artifacts) and then filtered to remove common polymorphisms, 
synonymous variants, and likely variants of unknown significance using a “prioritization” 
approach which measures the presence of a specific variant in common sequence databases 
such as Ensembl, gnomAD, and the 1000 genomes project. Variants with fractions lower than 
5% were also removed. 
The resulting calls were screened for variants in genes of interest and candidate variants were 
then manually confirmed by viewing the wild type versus variant reads for each locus of interest 




3.4.2.5 Homologous Recombination Deficiency (HRD) score calculation 
We used the copy number data and the variant data from PureCN to calculate the homologous 
recombination deficiency (HRD) score as described by Telli et al. (124) and as implemented by 
Sztupinszki et al. (125). To do so, we extracted from the PureCN data the copy number values 
for each allele for every variant identified: the copy number of the major allele (“major copy 
number”) and the copy number for the minor allele (“minor copy number”).  
We then built segments of homogeneous total (major + minor) copy number from the individual 
points. At this point, we calculated the three measures which are part of HRD: 
 
• Loss of heterozygosity (LOH): count of every segment with LOH (minor copy number 
= 0) if it is greater or equal than 15 Mbp; 
 
• Telomeric allelic imbalance (TAI): Count of contiguous segments which start from the 
telomeric region up to the centromere (but not including the whole chromosome) that 
exhibit allelic imbalance between the major and minor alleles; 
 
• Large scale transitions (LST): The number of copy number transitions (that is, when 
two adjacent segments have different copy number) between segments of at least 10Mbp 
in length, not spanning the centromere. 
 
The final HRD score was calculated as the simple algebraic sum of LOH, TAI and LST. The 
thresholds for HRD were made in a group of 30 high quality samples (predicted tumor fraction 
greater than 30%, not flagged for bad data quality) comparing the distribution of the HRD score 
between the germline BRCA1/2 mutated samples (the true positives) with the controls. The 
threshold was set as the 5th percentile of the distribution of the HRD scores in BRCA1/2 mutated 
90 
 
samples. Samples were called HR deficient if their score was greater than the threshold, 
otherwise they were called HR proficient. 
 
 
3.5 RNA sequencing 
 
3.5.1 Total RNA sequencing  
Total RNA sequencing experiments were performed using TruSeq stranded total RNA kit 
(Illumina®). 
The first step for RNA sequencing, was the synthesis of a cDNA library from total RNA.  
This step is mandatory because RNA molecules can not be directly sequenced due to their low 
chemical stability.  
The major steps in library preparation, schematically represents in figure 3.8, involves the 
following: 
1) Preparation of a total RNA input ranging from 0.1 to 1 µg, considering the Qubit 
quantification.  
2) Deplation of rRNA from total RNA (Ribo-Zero Gold kit, Illumina). This step was done 
by annealing the total RNA to oligo-dT magnetic beads. As rRNA is the most abundant 
component of RNA (80-90%) its depletion was necessary in order to focus on more 
informative parts of the transcriptome. At the end of this step a clean-up was performed. 
3) Enzymatic fragmentation of the purify RNA, in order to break the RNA strands into 
multiple small fragments 
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4) Reverse-transcription of the RNA fragments using a reverse transcriptase, and random 
hexamer primers, thus producing the first strand cDNA. The addition of Actinomycin 
D to the reaction mix, inhibits DNA-dependent synthesis, while allowing RNA-
dependent synthesis, improving strand specificity. 
5) Syntheses of the second/opposite strand of the cDNA and remove the RNA template. 
This strand was generated incorporating dUTP in place of dTTP. The incorporation of 
dUTP quanches the second strand during amplification, because the polymerase did not 
incorporate past this nucleotide. After the synthesis a clean-up was performed in order 
to separate the ds cDNA from the second strand reaction reagents. At the end of this 
process a blunt-ended double strand cDNA was obtained. 
6) Adenylation of 3’ ends of the blunt fragments to prevent them from the ligating to one 
another during the adapter ligation reaction. A corresponding single “T” nucleotide on 
the 3’ end of the adapter provides a complementary overhang for ligating the adapter to 
the fragment 
7) Ligation of adapters to both ends of the ds cDNA. Each adapter had a six-nucleotide 
difference in adaptor sequence. The use of a different index for each library reaction 
allowed to pool libraries later for sequencing, yet still allowing for tracing the sequence 
back to the original library based on the adaptor sequence. At the end of this step a 
clean-up was performed. 
8) Enrichment of the library by polymerase chain reaction (PCR) amplification using 
sequences from the adaptor as primers. At the end of this step clean-up was performed 







9) Evaluation of library obtained. In order to Qubit (Termo Fisher®) quantification of DNA 
library templates the quality control analysis, which evaluate by a capillary 
electrophoresis the size distribution of the libraries (the final product should be a band 
at approximately 260 bp) 






Figure 3.8 Workflow of RNA sequencing library preparation. Modified from (126).  
 
In order to obtain at least 80 millions of reads for patient, eight sample libraries per run were 
sequenced outsourcing (Personal Genomic S.r.l. spin-off of the University of Verona, Verona 
Italy) on Hiseq 2500 Ultra High-Troughput Sequencing System (Illumina®).  
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3.5.2 Total RNA sequencing data analysis 
Data generated by RNA sequencing runs, were analyzed by the bioinformatic team coordinated 
by Prof. Chiara Romualdi (Biology Department of University of Padova, Italy).  




Figure 3.9 Workflow of the differential expression analysis for annotated transcripts 
 
On the basis of figure 3.9 a brief description of each step is reported above. 
Step 1, quality control of the reads: in the first step a general quality control analysis was 
performed automatically on the Illumina® platform. This look at the overall quality of the reads 
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(in FASTQ format, that is an extension of the standard FASTA format for sequences with the 
addition of a confidence score, called Phred score, for each called base). Reads were scanned 
i.e. for low-confidence bases, biased nucleotide composition, adapters, duplicates. The output 
of this step was basic statistics such as the number of reads and the quality information, which 
guides the pre-processing, decisions in the subsequent step. 
Step 2, pre-processing of the reads: the goal of this step was to remove low-quality bases and 
artefacts such as adapter sequences from individual reads. Experimental artefacts were also 
removed. For example, poly A tails were removed since they interfere with analysis steps later. 
Reads were also trimmed to remove adaptors or low quality bases. After pre-processing, the 
data were in a cleaned and polished form and they were able to undergo the next data analysis 
steps. Also this step was automatically performed on the Illumina® platform. 
Step 3, alignment of reads to a reference genome: the goal of this step was to find the point of 
origin for each read. To this aim, in this project a two-pass alignment strategy using STAR 
(Spliced Transcripts Alignment to a Reference) package was exploited (127). Reads were 
mapped to a reference genome sequence (H. Sapiens, hg38.p2 version) and annotated (Ensembl 
79). The output of this step was an alignment file (Binary Alignment File; BAM) for each 
patients, in which were indicated the mapped reads and their related positions in the reference. 
Step 4, transcriptome assembly: in this project this step was performed using StringTie (PMID: 
25690850) (128), that is able reconstruct and identify automatically for each patient known and 
unknown transcripts (.gtf form file), giving for each one information as the start and the end 
position, confidence score or feature type (i.e. exon, transcript, mRNA). Cuffmerge and 
cuffcompare (PMID: 20436464) were respectively used to create a consensus transcriptome 
(output: a single merged.gtf file starting from the .gtf files previously generated) and to compare 
the reconstructed transcripts with existing annotations. 
Step 5, calculating transcripts’ expression levels: in order to estimate the transcripts abundance, 
in this project RSEM (RSEM version 1.2.21) was exploited (129). The .gtf file previously 
obtained (step 4) was used to map all the reads generated (FASTQ files) on reconstructed 
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transcripts. For each transcript and for each patient the number of raw reads count was 
calculated. Transcripts with less than 10 counts in at least 60% of samples per class were filtered 
out. 
Step 6, comparing gene expression between conditions: before the comparative analysis, a 
normalization procedure is required because of possible differences in read numbers and 
transcriptome composition. In this project data were normalized using full quantile 
normalization as implemented in the edgeR (130) software package (R version 3.2, 
Bioconductor version 3.2, edgeR version 3.12.0). This tool calculated for class a mean value of 
each transcript identified and considered as differentially expressed those with a corrected p-
value (q-value or false discovery rate, FDR) < 0.05.  
 
 
3.5.3 Pathway analysis of known genes identified as differentially expressed 
in total RNA sequencing 
Known genes were tested with functional enrichment with REACTOME (https://reactome.org) 
that is an open-source, open access, manually curated and peer-reviewed pathway database. 
The p-values resulted from the test were corrected for multiple testing using the False Discovery 
Rate (FDR) as transcripts could not be considered as independent entities. The pathways 
reconstructed by DAVID were called significant, whether its corrected p-value (q-value or 









3.5.4 Targeted RNA sequencing  
A custom targeted RNA sequencing panel (SeqCap RNA enrichment System, Roche), designed 
on the basis of the differentially expressed transcripts identified, was used to confirm total RNA 
sequencing results.  
The steps for the construction of targeted RNA sequencing libraries are quite similar to those 
that characterized the preparation of the total RNA sequencing ones (paragraph 3.5.1). In fact, 
starting from 100 ng of purified total RNA (input: 10-1000 ng), RNA underwent to enzymatic 
fragmentation in order to break the RNA strands in smaller fragments, and directly the synthesis 
of the 1st and 2nd strands cDNA was performed. After a clean-up double stranded cDNA aimed 
to eliminate the 2nd strand reaction reagents, the adenylation at 3’end of blunt fragments to 
prevent concatemerization and to allow the ligation of the adapters with complementary dT 
overhangs occurred. After the ligation of adapters, that were formed by six nucleotides and 
difference one from each other for nucleotide sequence, a double clean-up was performed. The 
bound of sample-specific adapters for each library reaction allowed pooling 7-10 for the 
subsequent hybridization capture. In fact, after a pre-capture PCR amplification and a clean-up 
aimed to eliminate PCR reagents, a overnight hybridization (95C for 10 min + 47C for 16-20 
hours) with custom biotinylated-probes designed to cover and capture all the 1730 transcripts 
identified as differentially expressed in paragraph 3.5.2 was performed. Once ended the 
hybridization phase, the biotinylated-probes that bound during the night the specific sequences 
targets, were isolated using streptavidin beads. In fact, streptavidin beads were able to capture 
and isolated the biotinylated probes plus bound target cDNA. 
After subsequent washes with dedicated buffers to eliminate reaction reagents and unbound 
fragments, streptavidin beads-biotinylated probes with bound target cDNA underwent PCR 
reaction as reported in manufacturer’s user’s guide. The PCR allowed i) to release the target 
cDNA from the beads-probles complex (the denaturation step: 98C for 45 sec), and ii) 
amplified the target cDNA captured. At the end, after a final clean-up and the elution of purified 
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target fragments, Qubit quantification evaluation of the quality of libraries obtained was 
performed exploiting Tape Station 4200 (Agilent Technologies®). As expected, the average 
fragment length obtained was between 150-500 bp, with a peak at approximately 300 bp.  
  Considering the capacity of a single flow cell (high-output 300 cycles, Illumina®) and the 
barcoding procedures applied during the libraries preparation, seven (for cohort AI, see Results 
section, paragraph 4.2.1) and ten (for cohort BI, Results section, see paragraph 4.2.1) libraries 
per run were sequenced on Nextseq Sequencing System (Illumina®). 
 
3.5.6 Targeted RNA sequencing analysis in cohort AI 
Also in this case, data generated by targeted RNA sequencing were analysed by bioinformatics 
group coordinated by Prof. Chiara Romualdi (Biology Department of University of Padova, 
Italy). 
After quality control and processing of reads generated, that occurred automatically on 
sequencing system, in order to assess the target capture strategy efficacy, reads (FASTQ file) 
were aligned on the genome sequence (hg38.p2 version) and annotated (Ensemble 79) using 
STAR package (as described in paragraph 3.5.2, “Step 3”). Transcripts quantification was then 
obtained aligning the reads on the reconstructed transcript sequences derived from the deep 
total RNA sequencing analysis. This process was performed using Salmon (PMID: 28263959) 
that is a tool for wicked-fast transcripts quantification, which requires a set of target transcripts 
either from a reference or from de novo assembly (FASTAQ files), as in this case, to quantify 
(131). In this RNA sequencing analysis transcripts with less than ten counts in at least 60% of 
samples per class were filtered out. In order to reduce artefacts and biases that affect the 
resulting expression measures, data obtained were normalized exploiting EDA (Exploratory 
Data Analysis) Seq (PMID: 22177264) (104). The EDAseq tool is based on a within-lane 
normalization followed by a between-lane normalization procedure. The within-lane (or intra-
sample) normalization procedure adjusts samples’ data for their GC-content effect, basing on 
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the principle that CG-content differs between genes but not between samples. The between-
lane normalization instead, corrects for distributional differences in libraries/samples that can 
affect the counts and lead to variation (i.e. sequencing depth).  
Using the normalized data, differential expression analysis was computed using edgeR (R 
version 3.2, Bioconductor version 3.2, edge R version 3.12.0) and only transcripts with a 
corrected p-value (q-value o FDR) <0.05 were considered as differentially expressed between 
pt-r and pt-s classes.  
A in silico depths dilution, simulating different sequencing depths starting from 40 millions 
reads for sample, was performed through multiple (n=1000) read resamplings approach in order 
to set up the sequency depth optimization for the targeted RNA sequencing in cohort BI which 
represented the clinical validation of results obtained. This test allowed to estabilish a threshold 
of 20 million of reads per sample to obtain robust and riproducible RNA sequencing results. 
 
3.5.7 Targeted RNA sequencing analysis in cohort BI 
Targeted RNA sequencing in cohort BI was performed multiplexing 10 samples per run to have 
an average 20 millions of paired reads per sample. 
Transcript quantifications have been performed with Salmon (PMID: 28263959), using the 
reconstructed transcript sequences derived from the deep total RNAseq analyses. Transcripts 
with less than 5 counts in at least 30% of samples per class were filtered out.  
Expression data normalization was carried out with the package EDASeq (PMID: 22177264) 
(see paragraph 3.5.6). Differential expression was computed using edgeR (R version 3.2, 
Bioconductor version 3.2, edge R version 3.12.0) and transcripts with a corrected p-value (q-



































4.1 Pathway analysis 
In the first part of this work, three independent cohorts of patients were analysed to identify a 
regulatory network, composed from both coding and non-coding genes, shaping the different 
biology of Pt-s and Pt-r cases and to investigate its association to prognosis in terms of Overall 
Survival (OS) and Progression Free Survival (PFS). 
In figure 4.1 is reported a schematic workflow of the study. In the first part of this work, using 
data obtained from array experiments in cohort A, an integrated approach considering both 
coding and non-coding genes were exploited to identify a regulatory network associated with 
Pt response. In order to test the robustness of data obtained 23 out of 136 elements were selected 
and tested using an independent technique (qRT-PCR) in cohort A and B. Confirmed the 
association of these elements with Pt response, their prognostic value (overall survival, OS and 
progression free survival, PFS) were evaluated and tested both in cohort A+B and in a larger 
cohort of HGS-EOC patients that is considered the benchmark for HGS-EOC (cohort C). 
 





4.1.1 Cohorts’ description 
To the aim of this part of the work, a total number of 242 ovarian cancer biopsies derived from 
two independent cohorts (cohorts A and B) of patients, were selected for the aim of this study. 
Results obtained from the analysis of cohort A and B were later tested in silico in a larger cohort 
of patients (cohort C). Clinical-pathological features of HGS-EOC patients belonging to cohort 
A (n=99), B (n=143) and C (n=838, Curated Ovarian Cancer dataset), are shown in table 4.1. 
All the biopsies selected were collected at primary surgery, before chemotherapy, from patients 
with diagnosis of HGS-EOC stage III and IV, according to FIGO (Federation International of 
Gynecology and Ostetrics) criteria. The median age at diagnosis was 63 years (cohort A), 57 
years (cohort B) and 59 years (cohort C), respectively. The median follow-up time was 3 years 
for cohorts A and B, and 2 years for cohort C. Demographic and disease characteristics reported 
for cohort A are comparable to those reported in literature for HGS-EOC patients (cohort C), 
whereas for cohort B they are characterized by longer OS and PFS compared to the HGS-EOC 
benchmark (cohort C).  
Differently from that reported in the cohort C, cohort A and B are enriched in patients (60% 
both in cohort A and B and 34% in cohort C, respectively) with suboptimal residual tumour 
(RT), that is defined as a tumour mass > 1 cm, that was not possible to eradicate from the 
abdominal cavity with the surgery. This discrepancy could be due to two main reasons: i) RT 
is subjectively determined by surgeons during the surgical procedure and ii) the cohort C cases 
were enrolled from 90’s, when an optimal debulking surgery was considered when RT<2 cm. 
Regarding the Pt response, both in cohort A and B patients were best balanced on the basis of 
their Pt sensitivity. In particular, patients defined as Pt-s, Pt-r, and partially sensitive (Pt-ps) 
were 36%, 42% and 19% in cohort A, respectively.  In cohort B they were 48%, 34% and 17%, 
respectively. Unfortunately, information regarding the Pt Free Interval (PFI) is not available for 
cohort C, thus patients have been indirectly classified into Pt-s and Pt-r using Progression Free 
Survival (PFS) measure, in particular patients were defined Pt-s with PFS>12 months and Pt-r 
103 
 
with PFS<6 months. Being PFS as a rough estimation of PFI, data regarding the number of Pt-
s and Pt-r patients, is not reported in table 4.1.  
In the table 4.1 are also reported the clinical-pathological information relative to cohorts AI and 
BI, that are sub-cohort of the larger cohorts A and B. Cohort AI and BI, used for both DNA and 
































Table 4.1 Clinical and demographic description of cases enrolled in cohorts A, B and C. PFS, Progression Free 
Survival. OS, Overall Survival. RT, Residual Tumour. In cohort C the Pt status is not available. * Calculated on 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.1.2 Identification of a regulatory network associated with response to 
therapy 
 
Overall data reported in literature have shown that a single gene approach signatures failed to 
stratifying HGS-EOC patients’ risk of relapse at time of diagnosis, a compendium of 
transcriptomic data, including both coding and non-coding genes, was generated to characterize 
the different biology of Pt-s and Pt-r tumours. Pt-s (n=36) and Pt-r (n=41) cases have been 
retrospectively selected from cohort A and, on the basis of array experiments, mRNA, miRNA 
and lncRNA profiles analysed using micrographite algorithm, that allows to move from a list 
of single genes towards a comprehensive map of functionally related networks. Micrographite 
analysis resulted in a network composed of 131 mRNAs and 5 miRNAs (Figure 4.2, Table 4.2). 
The network wired five different major functional processes that are: i) transcription regulation, 
ii) transmembrane ion transport (such as calcium ion transport and sodium ion export), iii) cell 
cycle regulation and response to damage, iv) fatty acid metabolism, v) antigen presentation. 
The above five functional processes are interconnected by PRKG1 gene, which acts as hub of 





Figure 4.2 Regulatory network associated to Pt response. Integrated (mRNA and miRNA) network obtained 
through the comparison of Pt-s and Pt-r samples in cohort A, using pathway-based approach. The colours of the 





As the cell network interactions can be characterized not only by great changes in expression 
levels of genes (differentially expressed genes, DEG) but also by fine regulations well 
connected one to each other, micrographite algorithm selected not only DEG or genes with 
significant logFC value (≤ 0.5 or ≥ 0.5) but also genes and miRNAs with interconnection 
functions or with in silico predicted interactions. 
Tables 4.2 A, B, C, D, E and F reports the 131 genes and five miRNAs composing the network, 
subdivided on the basis of their role in one or more functional processes identified. Three 
functional areas are particularly enriched in elements of the network that are the i) fatty acid 
metabolism (29 elements, 21%) ii) cell cycle and response to damage (46 elements, 34%) and 
iii) transmembrane ion transport (33 elements, 24%) process. The antigen presentation and 
transcription processes (Table 4.2 B and D) are identified by the presence of respectively 10 
(7%) and 14 (10%) elements. Moreover, there are another eight genes that do not belong to any 




Functional Area Gene Name 
Validation criteria 
DEG logFC Literature evidence 
Fatty acid metabolism 
FANCI 0.029     
FLNC 0.029 1.3 - 
CIDEA       
FLCN       
GMPS       
PRKAG2       
PRKAA2       
PRKAB1       
PRKAB2       
PRKAG1       
PRKAG3       
PRKAA1       
AGRP       
SLC2A1       
G6PC3       
IRAK1       
FANCA 0.017     
CAMKK2       
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ACACB       
NPY - - Medeiros PG et al., Int J Cancer 2012 
Medeiros et al., Peptides, 2013 
PCK2       
PIGR 0.038 -1.93   
SLC2A4       
PCK1       
STK11       
HSP90AA1       
KIF23       
PSMB4       




Functional Area Gene Name 
Validation criteria 
DEG logFC Literature evidence 
Antigen presentation 
SIN3A       
PML       
HLA-E       
HLA-F 0.017 - - 
HLA-A 0.11 - - 
B2M       
TAPBP       
HLAC       
STAT1 <0.001 - - 




Functional Area Gene Name 
Validation criteria 
DEG logFC Literature evidence 
  H2AFX       
  MAPK1       
  PRKCE       
  TIAM1       
  GTF2I       
  DNAJA1       
  EYA4 0.077 2.1 - 
  NFYA       





3p       
  has-mir-107       
  BATF2       
  GABBR1       
  TREX2       
  TOPORS 0.11     
  BATF       
  WARS       
  CDK1       
  
PPP1R12A - - 
Serrano I. et al., Nature Comm 2013 
  
Zhang C. et al., Mediators of 
inflamm 2015 
  
PPP1CA - - 
Wang et al., Plos One 2011 
  Xia et al., Plos One 2014 
Cell cycle PPP1CB       
  PPP1CC       
and BIRC5       
  ACAT2       
Response to damage VASP       
  ROCK2 - - Zhong et al., Oncogene 2018 
  ROCK1       
  KANK1       
  MKI67       
  MYT1       
  FANCG       
  AURCA       
  KIF24       
  NSUN2       
  NUSAP1       
  CDC25A       
  CLOCK       
  VCP       
  GBP1       




Douglas C. et al., Clin Canc Res 
2011 
  APOL6 <0.001 - - 
  
has-mir-
148B-3P       
BCL21L       
RAF1       




Functional Area Gene Name 
Validation criteria 
DEG logFC Literature evidence 
Transcription 
ACAT2       
CREB3L2       
CREB1       
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CREB3 - - Shanyang He, et al., Oncol Lett 2017 
DACH1       
SPRY1       
UHRF1BP1       
CREB3L4       
CREB3L1       
CREB5 - - ProteinAtlas 
CREB3L3       
KPNA2       
has-mir-127-3p       




Functional Area Gene Name 
Validation criteria 
DEG logFC Literature evidence 
  CACNA1C   0.5 - 
  CACNA1S       
  CACNA1D       
  CACNA1F       
  KCNMA1       
  KCNMB2       
  KCNMB4       
  KCNMB1       
  KCNMB3       
  PLN       
  ATP1A1       
  ATP2B4       
  TPM3       
  ATP2B1       
Transmembrane ATP1B1       
  ATP2B3       
ion EZH2       
  ATP2A2       
transport ATP2A1       
  ATP2A3       
          
  ATP1A2       
  GCH1 0.053 -0.5 - 
  ATP1A4       
  GCH1       
  ATP1A4       
  ATP1A3       
  ATP1B2       
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  ATP2B2       
  ATP1B3       
  SDHA       
  NOTCH2 0.077 -0.5 - 
  PXYLP1       




Functional Area Gene Name 
Validation criteria 
DEG logFC Literature evidence 
Hub PRKG1   0.8 Hub of the network 
  STAT3       
  IL2RB       
Interconnection ETV7 <0.001 -1.08   
  SLC8A1       
nodes FXYD2       
  GTF2IRD1       
  ATF6B       
 
Table 4.2 A, B, C, D, E and F. Elements of the network. In tables 4.2 are reported the name of genes and miRNA 
composing the network subdivided for functional area: fatty acid metabolism (table 4.2A), antigen presentation 
(table 4.2B), cell cycle and response to damage (table 4.2C), transcription (table 4.2D), transmembrane and ion 
transport (table 4.2E). Table 4.2F reported the genes representing nodes or hub of the network. Genes 
highlighted in yellow colour are those for which orthogonal validation was performed (see paragraph 4.1.3). The 
criteria for the selection are reported: DEG (q-value), logFC (Fold Change) and literature evidence (First author, 




4.1.3 Network validation  
To demonstrate the robustness and the reproducibility of the identified network, 23 out of 136 
elements of the circuit were arbitrary selected and their different expression orthogonally 
validated by an independent technique (qRT-PCR), in both cohort A (technical validation) and 
in cohort B (biological validation). The 23 elements have been selected on the bases of at least 
one of those three criteria:  
112 
 
i) DEG (q-value<0.15) 
ii) log fold change greater than ± 0.5  
iii) literature evidence 
The genes selected for orthogonal validation are highlighted in yellow in tables 4.2 A, B, C, D, 
E, and F and for each one the principle for the selection is reported. Data obtained in cohort A 
confirmed 20 out of 23 elements (87%) of the network as differentially expressed between Pt-























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 4.3 Differential expression evaluated by qRT-PCR between Pt-r and Pt-s samples of the 23 selected genes 
in cohort A. For each gene, the mean average expression value of Pt-s and Pt-r samples and t-test p-value is 
reported. In cohort A the thresholds are the best expression cut-off that maximize specificity and sensitivity and 
Pred Pt-s/Pt-r (%) is the percentage of predicted Pt-s and Pt-r patients obtained using these thresholds. In gray 
are reported those genes that were not validated. Table is divided in up and down regulated genes in order to 
have odd ratios always greater than 1: for genes up-regulated in Pt-r patients the reference group is Pt-r, for 
genes up-regulated in Pt-s the reference group is Pt-s. 
 
Biological validation experiments in cohort B confirmed differences in the expression value 
between Pt-s and Pt-r cases for 17 out of the 20 genes (85%) genes (Table 4.4). 
 COHORT B 
 
















CACNA1C <0.001 3.23 1.00 53.06 92.65 76.07 
ETV7 0.56 1.09 1.25 2.04 97.06 57.26 
EYA4 <0.001 5.52 3.87 87.76 39.71 59.83 
FLNC <0.001 4.90 2.23 79.59 75.00 76.92 
GCH1 0.87 1.68 1.73 30.61 63.24 49.57 
NPY 0.88 1.10 1.04 100.00 0.00 41.88 
PPPR12A <0.001 6.14 3.16 83.67 66.18 73.50 
PRKG1 <0.001 4.80 2.18 73.47 75.00 74.36 















APOL6 <0.001 3.30 5.27 42.86 98.53 75.21 
BAD1 <0.001 4.81 5.92 8.16 98.53 60.68 
CREB3 <0.001 3.40 4.81 20.41 98.53 65.81 
CREB5 0.99 6.80 4.64 4.08 88.24 52.99 
FANCA <0.001 2.25 3.58 48.98 75.00 64.10 
FANCI <0.001 3.63 5.32 28.57 94.12 66.67 
HLA-A <0.001 5.19 6.60 0.00 100.00 58.12 
HLA-F <0.001 3.48 5.18 16.33 98.53 64.10 
NOTCH2 0.02 4.73 5.30 4.08 94.12 56.41 
PIGR <0.001 1.51 3.23 67.35 60.29 63.25 
PPP1CA <0.001 5.11 6.34 2.04 98.53 58.12 
ROCK2 0.99 6.81 5.37 0.00 95.59 55.56 
SDF2L1 <0.001 3.00 5.03 18.37 89.71 59.83 
TOPORS <0.001 1.54 3.99 75.51 63.24 68.38 
 
Table 4.4 Differential expression evaluated by qRT-PCR between Pt-r and Pt-s samples of the 23 selected genes 
in cohort B. Average expression of Pt-s and Pt-r samples and t-test p-value is reported. In cohort B, Pred Pt-s/Pt-
r (%) is calculated based on the threshold of cohort A, and the accuracy is the total number of patients classified 
correctly. In gray are reported those genes that are not validated. Table is divided in up and down regulated 
genes in order to have odd ratios always greater than 1: for genes up-regulated in Pt-r patients the reference 




In order to quantify the prediction power of these 17 genes, we estimated the expression 
threshold (defined as the expression cut-off maximizing the sum of specificity and sensitivity) 
for each gene in cohort A and evaluated the accuracy of the prediction in cohort B using these 
thresholds. As expected, in cohort A all the 17 genes showed excellent levels of specificity (min 
75% - max 100%) and sensitivity (min 75% - max 95%), while in cohort B we observed high 
levels of accuracy, defined as correctly predicted classes on the total number of testing classes, 
(>70%) for CACNA1C, FLNC, PPPR12A, PRKG1, APOL6 genes. The list of 17 validated 
genes is referred from now onwards to as SI signature. 
 
4.1.4 Prognostic performance of SI signature 
The presence of an association between signature SI and the intrinsic resistance to Pt-based 
chemotherapy does not directly implicate that signature SI is also associated with survival 
parameters. Thus, to verify whether any of the elements of signature SI could have an additional 
prognostic role, qRT-PCR expression values have been associated with prognostic parameters 
(PFS and OS) both in cohort A and B. To increase the sample size, analysis was performed 
including also Pt-partially sensitive (Pt-ps) patients enrolled in cohort A (n=19) and in cohort 
B (n=25). To test the association between signature SI and OS a total number of 242 patients 
derived from cohort A and B were considered. Since in cohort B PFS follow up information are 
missing for four patients, the association between signature SI and PFS was investigated on 138 
cases. The univariate and the multivariate Cox proportional hazards models adjusted for age 
and RT were used to access the prognostic significance of each gene. As reported in table 4.5, 
14 out of the 17 genes (82%) composing signature SI are associated with both PFS and OS in 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 4.5 Univariate and multivariate survival models of the 17 DEG elements enrolled within the SI signature. 
For each gene the hazard ratio (HR) with 95% confidence interval and p-value (P) is reported for either OS and 
PFS. In grey are highlighted the three genes not associated with level of significance in uni and multivariate 
analysis to both OS and PFS. 
 
PIGR shows a non-significant correlation in univariate analysis with OS (p-value = 0.02). 
However, as PIGR have demonstrate a very strong association with OS in multivariate analysis 
(p-value < 0.001), it has been considered to have prognostic significance. The 14 genes with 
prognostic relevance identified have been defined as signature SII.  
 
4.1.5 Signature SII validation across an external dataset 
 
To further confirm the prognostic relevance of signature SII we used gene expression profiles 
of an external cohort of HGS-EOC patients (cohort C, Curated Ovarian Cancer Dataset). From 
the entire Curated Ovarian Cancer Database (n=2970), 838 Pt-treated patients with complete 
follow-up including PFS and OS information have been selected for this study.  
As anticipated in paragraph 4.1.1, samples selected from cohort C do not have PFI information 
required for the correct Pt-s and Pt-r classification. As a proxy of PFI, PFS has been used to 
classify patients into Pt-s (with PFS>12 months) and Pt-r (with PFS<6 months). Although this 
approach is clearly biased, it will give us an indication of the prognostic potential of our 
signature. By comparing the expression data available for the 838 cases, we observed that the 
expression profiles of ten out of 14 genes of SII signature (71%) resulted as differentially 
expressed between Pt-s and Pt-r cases (Table 4.6). Finally, three out these ten genes, namely 
PRKG1, SDF2L1 and PPP1R12A we significantly associated with level of significance in both 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 4.6 Univariate and multivariate survival models of SII signature in cohort C. In the first column the 
Tippet’s combined p-value of Youen t-test between Pt-s and Pt-r samples is reported. For each gene the HR 
value with 95% confidence interval and p-value (P) is reported for either OS and PFS. In bold is reported the list 
of ten genes the expression level of which is different between Pt-s and Pt-s cases in cohort C. In yellow are 
highlighted the three genes (PRKG1, SDFL1 and PPP1R12A) associated with level of significance in both uni 
and multivariate analysis to both OS and PFS. These three genes constitute the SIII signature. 
  
 
Patients with high expression levels of PRKG1 and PPP1R12A and low expression levels of 
SDF2L1 had a shorter survival than those with low levels of PRKG1 and PPP1R12A and high 
levels of SDF2L1 (Table 4.6). 
These three genes are referred from now onwards to as SIII signature. 
 
4.1.6 Signature combination 
In order to test a possible synergistic effect among the three genes composing the signature SIII, 
patients have been stratified into three classes: 
- high risk: high levels of PPPR12A and PRKG1 and low levels of SDF2L1 
- low risk: low levels of PPPR12A and PRKG1 and high levels of SDF2L1 
- intermediate risk: all the other combinations of expression values 
On the basis of this classification the ability of the combination of three elements of the 
signature SIII have been tested (figure 4.3). KM curves demonstrated significant differences in 
terms of PFS and OS between patients with high (red line) and low risk (green line) both in 
cohort A and in cohort B. Patients characterized by an intermediate risk (blue line) are, as 




Figure 4.3 Kaplan Mayer curves of the combination of the expression values of PRKG1, SDF2L1 and 
PPPR12A. Kaplan Mayer curves and log-rank test p-values of the combination of the expression values of 
PRKG1, SDF2L1 and PPPR12A genes either using OS (panel A) and PFS (Panel B) as survival measures. 
 
As the most important prognostic factor in HGS-EOC is represented by RT after surgery, the 
robustness of signature SIII in patients’ prognosis has been also verify considering this 

































































































































































































































































































































































































































































































on signature SIII is maintained even when the RT status is considered. 
 
 
Figure 4.4 Kaplan Mayer curves of the combination of the expression values of PRKG1, SDF2L1 and PPPR12A 
with stratification by patient TR status. Kaplan Mayer curves and log-rank test p-values of the combination of 
the expression values of PRKG1, SDF2L1 and PPPR12A genes either using OS and PFS as survival measures, 
with stratification by patient TR status. (HL = "High-PRKG1 High-PPP1R12A Low-SDF2L1"; LH = "Low-
PRKG1 Low-PPP1R12A High-SDF2L1") 
 
 
This result confirms that the combination of expression level of genes belonging to the SIII 
signature is able to significantly stratify patients with different prognosis both in OS and PFS. 
 
4.1.7 Conclusion 
The goal of this first part of the work was to identify a regulatory network built up by annotated 
coding genes and non-coding genes able to explain part of the complex biological mechanisms 
underlying the intrinsic Pt resistance in HGS-EOC patients. To this aim, a network composed 
by 131 genes and five miRNAs, that belong to five different and interconnected biological 
processes, has been identified. Three genes of this network, including the hub represented by 
122 
 
PRKG1 gene, had been demonstrated both predictive of Pt response and prognostic in OS and 



























4.2 Analysis of genomic instability 
 
Since the data reported in the literature demonstrate associations between alterations in DNA 
repair mechanisms (i.e. Homologous recombination, HR) and Pt response (80) (132) (84), in 
this second part of this result section mutational status of BRCA genes and HR pathway were 
evaluated in a sub-cohorts of our HGS-EOC patients (AI=28 and BI=55).  In particular, 
studying the “genomic scars” due to HR deficiency (see Introduction section, paragraph 
1.4.2.2), such as large-scale transition (LST), loss of heterozygosis (LOH) and telomeric allelic 
imbalances (TAI). An in-house protocol for HRD score was calculated and a threshold set and 
tested in order to verify its ability to discriminate Pt-s from Pt-r cases. The association of HR 
deficiency/proficiency status calculated on the basis of our HRD score with Pt response could 
have independent value with other predictive biomarkers in stratifying HGS-EOC patients on 




4.2.1 AI and BI Cohorts’ Description 
Cohorts AI and BI are derived from previously selected cohorts A and B (paragraph 4.1.1). 
The median age at diagnosis was 66 and 54 years for cohort AI and BI, respectively (table 4.1), 
and the median follow-up time was respectively two and four years for cohort A and cohort BI, 
respectively. Being the clinical parameters comparable with those reported in literature 
(Curated Ovarian dataset, table 4.1) it was possible to assume that our cohorts well represented 
the clinical features of HGS-EOC. In our cohorts, the Progression Free Survival (PFS) was 10.9 
and 20.4 months and the Overall Survival (OS) was 31.8 and 48.5 months in cohort AI and BI, 
respectively. The majority of patients in both cohorts showed a suboptimal residual tumour 
(RT) after surgery (64% in Cohort AI and 69% in Cohort BI), that means that the tumour mass 
still remaining after surgery is > 1cm (R2). Moreover, as the study is based on the identification 
of molecular signatures associated to Pt response, patients of the two cohorts were best balanced 
in terms of platinum sensitivity. In particular, 14 and 30 Pt-sensitive and 14 and 25 Pt-resistant 
patients were selected in Cohort AI and BI respectively. HGS-EOC patients that were refractory 
or partially sensitive to chemotherapy were excluded. 
Clinico-pathological features of HGS-EOC (FIGO stage III/IV) patients composing Cohort AI 
(n=28) and Cohort BI (n=55), are summarised in table 3.7. Although there are differences in 
terms of PFS and OS between the two cohorts, likely due to the low number of cases and the 
specific patients selection (extremely sensitive and extremely resistant patients), they are not 






4.2.2 Characterization of HGS-EOC snap-frozen biopsies 
 
The starting material exploited for the biological experiments reported in this section of the 
thesis is represented by nucleic acids extracted and purified from HGS-EOC snap-frozen 
biopsies. These samples were analysed for: 
i) Tumour purity 
ii) Ploidy 
iii) TP53 clonal mutation or MDM2/MDM4 amplifications 
 
Tumour purity and the ploidy were investigated in silico both to have an indication of tumour 
continent of biopsies analysed and to correct the results obtained from mutational and CNV 
analysis. Moreover, the TP53 clonal pathogenic (IARC TP53 database) mutations and the 
MDM2/MDM4 amplifications (log-ratio >|0.1|), were respectively evaluated as they represent 
two clonal events that characterize HGS-EOC disease, providing a genetic confirmation of the 
histological tumour classification. 
Table 4.7 reports for each case the above mentioned parameters. 
 
Cohort ID Purity Ploidy TP53 MDM4 MDM2 
AI 
SC-1 80% 1,82 - AMP AMP 
SC-12 63% 1,92 c.712T>C (44.46%); LOH - AMP 
SC-13 54% 1,92 - AMP DEL 
SC-15 88% 1,94 c.2077G>A (9.37%); LOH - - 
SC-16 68% 1,91 c.159G>A (66.63%); LOH - - 
SC-22 73% 4,13 c.401T>G (80.45%); LOH AMP AMP 
SC-23 88% 3,11 - AMP AMP 
SC-25 38% 3,52 c.1013_1014insA (33.93%); LOH AMP AMP 
SC-31 95% 1,74 c.524G>A (95.20%); LOH - - 
SC-32 56% 3,13 - AMP AMP 
SC-40 83% 1,84 - AMP - 
SC-43 81% 2,87 c.743G>A (80.99%); LOH AMP AMP 
SC-50 67% 3,12 c.659A>G  (73.29%); LOH   
SC-51 73% 1,88 c.993+1G>A (51.08%); LOH - AMP 
126 
 
SC-52 73% 2,99 - AMP AMP 
SC-54 56% 3,07 c.524G>A (63.73%); LOH AMP AMP 
SC-56 58% 4,59 c.646G>A (84.05%); LOH AMP AMP 
SC-58 45% 1,75 c.661G>T (43.93%); LOH - - 
SC-62 21% 1,85 c.736A>G (8.55%); LOH - - 
SC-67 40% 3,40 c.548C>G (38.13%); LOH AMP AMP 
SC-72 28% 1,80 c.526T>A (50%) - - 
SC-74 66% 3,77 c.527G>T (76.93%); LOH AMP AMP 
SC-77 50% 3,56 - AMP AMP 
SC-87 81% 2,57 c.734G>T (75.75%); LOH AMP AMP 
SC-96 28% 2,69 c.579dup (27.12%); LOH - AMP 
SC-97 18% 2,05 - - AMP 
SC-98 31% 2,49 c.714dup (26.50%); LOH AMP AMP 
SC-99 78% 1,75 c.319del (62.26%); LOH - - 
BI 
10023 61% 1,77 c.578A>G (46.14%); LOH AMP - 
10104 92% 3,96 - AMP AMP 
20006 55% 2,33 c.469G>T (57.99%); LOH AMP AMP 
20041 79% 3,17 c.517G>A (78.96%); LOH AMP AMP 
20132 81% 2,98 - AMP - 
20155 55% 3,00 - AMP AMP 
20614 17% 1,78 - AMP - 
20768 81% 2,55 c.722C>T (90.78%); LOH AMP - 
20777 90% 2,05 - AMP - 
20789 44% 3,18 c.707A>G (51.83%); LOH - AMP 
20828 64% 1,91 - AMP  DEL 
20829 48% 3,40 - AMP AMP 
20830 60% 1,99 c.949C>T (55.26%); LOH - - 
20935 48% 3,32 - AMP AMP 
20937 90% 2,78 c.713G>T (92.07%); LOH AMP AMP 
20956 42% 3,90 c.653T>G (47.34%); LOH AMP AMP 
20974 41% 2,90 c.432_446del (32.80%); LOH AMP AMP 
20976 94% 5,08 c.488A>G (78.53%); LOH AMP AMP 
20979 30% 1,73 c.713G>T (18.78%); LOH - - 
20983 15% 2,02 c.280dup (5.22%); LOH - - 
21021 69% 1,96 c.742C>T (48.76%); LOH - - 
21047 71% 1,88 c.584T>C (56.15%); LOH - - 
21089 22% 2,31 - AMP - 
21095 95% 2,70 c.637C>T (95.30%); LOH AMP AMP 
21096 50% 2,99 c.743G>A (43.58%); LOH AMP AMP 
21113 78% 4,07 c.733G>A (82.09%); LOH AMP AMP 
21117 72% 3,43 c.686_687del (78.89%); LOH AMP AMP 
21118 71% 2,68 c.637C>T (75.00%); LOH AMP AMP 
21121 95% 5,47 - AMP AMP 
21128 18% 1,96 c.1116A>C (67%) - - 
21140 63% 3,63 c.586C>T (66.77%); LOH AMP AMP 
21141 15% 2,07 c.529_546del (62%) - - 
21150 76% 3,47 - AMP AMP 
21151 65% 2,64 c.536A>T (67.90%); LOH AMP AMP 
21157 40% 2,99 - - AMP 
21159 48% 1,90 c.637C>T (34.61%); LOH - - 
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21171 75% 1,86 c.437G>A (57.40%) - AMP 
21175 18% 2,02 c.1014C>T (92.3%) - - 
21189 48% 3,98 c.162_165dup (59.20%); LOH AMP AMP 
21193 23% 1,89 c.919+1G>T (16.39%); LOH - - 
21197 28% 2,11 c.240del (25.37%); LOH AMP - 
21232 49% 2,90 c.524G>A (44.99%); LOH AMP AMP 
21238 64% 1,82 c.568C>A (48.85%); LOH - AMP 
21239 36% 1,87 - AMP AMP 
21251 59% 2,18 c.527G>A (66.76%); LOH - - 
21272 55% 2,90 c.584T>C (48.08%); LOH AMP AMP 
21288 55% 2,56 c.659A>G (39.89%); LOH AMP AMP 
21291 44% 1,67 c.1024C>T (49.35%); LOH - DEL 
21296 95% 3,58 c.775G>T (46.08%); LOH AMP AMP 
21311 47% 1,88 c.638G>T (37.19%); LOH AMP - 
21329 82% 1,86 c.919+1del (77.42%); LOH - DEL 
21331 20% 2,14 c.672+1G>T (14.50%); LOH AMP - 
21343 70% 1,98 c.924G>T (45.7%) - - 
21350 55% 2,74 c.743G>A (45.25%); LOH AMP - 
21358 34% 2,75 - AMP AMP 
 
Table 4.7 TP53 clonal mutations and MDM4/MDM2 amplification status in cohort AI and BI. In table are 
reported the sample ID and the cohort to which they belong. For each sample the tumour percentage (purity) and 
the ploidy value are reported. In column TP53 is reported the clonal mutation identified for each samples, the 
allelic fraction (%) and, where reported, the loss of heterozygosis (LOH), MDM4/MDM2 copy number status is 
also reported (AMP = amplification, DEL = deletion). “-“ Indicates that neither clonal TP53 mutation nor 
MDM4/MDM2 amplification/deletion were identified. 
 
The tumour purity of the samples selected ranges from 18% to 95% and from 15% to 95% in 
cohorts AI and BI respectively, revealing a great variability in tumour content of biopsies 
analysed.  Considering the ploidy as an important parameter that need to be taken into account 
in particular for CNV calculation, results obtained indicated that ploidy values ranging from 
1,7 to 4,6 in cohort AI and from 1,7 to 5,5 in cohort BI. 
The clonal pathogenic TP53 was identified in 20 (71%) and in 41 (74%) cases of cohorts AI 
and BI respectively, whereas MDM2/MDM4 amplifications in all the other samples composing 
the two cohorts (table 4.7). Considering both cohorts, the allelic fraction (AF) of TP53 
mutations was variable, according to the tumour purity of sample analysed. 
Taking together these results confirm the impairment of the TP53 function as the main 




4.2.3 Mutational status of BRCA1 and BRCA2 genes 
As nowadays it is well established that tumours carrying somatic or germline pathogenic 
mutations in tumour suppressor BRCA genes are more responsive to DNA-damaging agents 
(i.e. Pt compounds), the mutational status of BRCA1 (Ch13) and BRCA2 (Ch17) was 
investigated (Table 4.8) 
Cohort ID 
BRCA mutational status 
Pt-status 
gBRCA  BRCA1m BRCA2m 
AI 
SC-1       Res 
SC-12       Sens 
SC-13 BRCA2     Sens 
SC-15   c.2077G>A (9.37%); LOH   Sens 
SC-16 BRCA2     Sens 
SC-22       Res 
SC-23       Sens 
SC-25       Res 
SC-31       Sens 
SC-32       Res 
SC-40     c.2971A>G (15.00%); LOH Sens 
SC-43 BRCA2     Sens 
SC-50   c.3748G>T (88.56%); LOH   Sens 
SC-51       Sens 
SC-52       Res 
SC-54   c.1067A>G (16.58%); LOH   Sens 
SC-56       Sens 
SC-58   c.649del (24.56%); LOH   Res 
SC-62       Res 
SC-67       Res 
SC-72 BRCA2     Res 
SC-74   c.2630del (68.57%); LOH   Sens 
SC-77       Res 
SC-87       Res 
SC-96       Res 
SC-97       Res 
SC-98       Res 
SC-99       Sens 
BI 
10023   c.2008G>T (42.98%); LOH   Sens 
10104       Res 
20006     c.1114A>C (99.04%); LOH Res 
20041       Res 
20132       Sens 
20155   c.2612C>T (77.49%); LOH c.1114A>C (15.90%); LOH Sens 
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20614       Sens 
20768       Res 
20777       Sens 
20789 BRCA1     Res 
20828       Res 
20829       Sens 
20830 BRCA1     Sens 
20935       Sens 
20937       Res 
20956       Sens 
20974       Sens 
20976       Sens 
20979       Res 
20983       Sens 
21021       Res 
21047       Sens 
21089       Res 
21095   c.1399A>T (100.00%); LOH   Sens 
21096       Sens 
21113       Res 
21117       Sens 
21118       Res 
21121       Res 
21128       Sens 
21140 BRCA1     Sens 
21141     c.6761_6762del (51.69%); LOH Sens 
21150       Sens 
21151       Res 
21157       Res 
21159       Sens 
21171       Res 
21175     c.1114A>C (5.70%); No LOH Res 
21189       Sens 
21193       Sens 
21197       Res 
21232       Res 
21238 BRCA1     Sens 
21239       Res 
21251       Sens 
21272 BRCA1     Res 
21288       Sens 
21291       Res 
21296       Res 
21311 BRCA1     Sens 
21329       Sens 
21331       Res 
21343       Res 
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21350       Sens 
21358       Res 
 
Table 4.8 Mutational status of BRCA1 and BRCA2 genes in cohort AI and BI. For each case is specified the 
nature of the pathogenic (BRCA Excange) BRCA mutation, germline mutation (gBRCA) or somatic mutation 
(BRCA1m and BRCA2m). The allelic fraction (AF) for BRCAm mutations are reported in paremtheses. Platinum 
status sensitivity is reported for each case (Res, resistant and Sens, sensitive). For cases highlighted in blue no 
matched blood sample was available. 
 
 
For those cases for whom the blood or normal matched tissue was available, pathogenic (BRCA 
Exchange) germline mutations in BRCA genes (gBRCA) were evaluated. For those cases with 
no normal reference DNA (five cases for cohort AI and seven patients for  BI) the presence of 
gBRCA mutations could be only speculated on the basis of high allelic fractions of BRCA 
somatic mutations obtained in their tumour biopsies. 
Considering the importance of these two BRCA genes in therapy response, somatic mutations 
were also considered. To identify BRCA mut in tumour biopsies, arbitrary stringent parameters 
were established: 
- at least four mutated reads out of the total number of reads that passed the quality control 
- a minimum coverage of 50X 
- AF>5% 
- Genetic variants reported as “pathogenic” or “likely pathogenic” in BRCA Exchange 
database 
On the bases of these criteria in cohort AI five somatic BRCA1 mutations with AF ranging 
between 9.37% and 88.56%, and one in BRCA2 genes (AF 15%) were identified. These six 
somatic BRCA mutations were predominantly identified in Pt-s patients (five out of six), 
whereas one (BRCA1 c.649del (24.56%) refers to Pt-r case. In cohort BI three BRCA1 (42.98% 
< AF < 100%) and four BRCA2 (5.70%< AF < 99.04) somatic mutations were respectively 
identified. Five out of seven BRCAmut derived from biopsies of Pt-s patients and the remaining 
two were associated to Pt-r cases.  
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Data reported above, confirmed that genetic mutations in BRCA1 and BRCA2 genes were not 
able to explain alone the sensitivity to Pt therapy, in fact, as reported, three patients with gBRCA 
mutations are clinically classified as Pt-r cases. For this reason, moving from single gene to 
pathway approach, the investigation regarding the status and the functional activity of the 
biological pathway in which BRCA1 and BRCA2 are involved in was needed. 
 
4.2.4 Developing an HRD score 
In paragraph 4.2.3 the germline and somatic status of BRCA1 and BRCA2 genes were tested, 
however these two genes are a small part of a more complex DNA repair pathway, the 
Homologous Recombination (HR). As the association between defects in HR pathway and Pt 
sensitivity has been already reported, in our cohort of patients a HR score able to discriminate 
HR deficient (HRD) from HR proficient cases was calculated and the distribution of patients 
according to their HR status was evaluated in association with their Pt response.  
Considering cohorts AI and BI together, HRD score was calculated on 70 out of 83 HGS-EOC 
patients. The remaining 13 samples were in fact excluded due to their tumour content, as tumour 
purity lower than 30% was not sufficient for HRD analysis.  
In order to set a HRD score threshold, 30 high quality sequenced samples were selected, and 
subdivided in two groups: the first group (n=11) characterized by a certain deficiency in HR, 
determined by the presence of somatic or germline pathogenic biallelic BRCA mutations and 
the second group (n=19) defined as HR proficient, as no somatic pathogenic biallelic mutations 
were identified in HR-related genes analysed. The biallelic condition imposed for the mutations 
considered, is due to the fact that some genes i.e. BRCA could maintain their functional activity 
also with the presence of only wt allele, so the application of this criteria allowed to clearly 
discriminate HR proficient from HR deficient cases. For each sample HRD scored was 




                                          
 
Figure 4.5 HRD Score in 30 high quality samples to set the cut-off. On the left (blue box-plot) the BRCA1/2 
mutated group and on the right (red box plot) samples without mutations in HR-related genes. For each group is 
reported the madian of value, the IRQ and the 5th and 95th percentile. 
 
In figure 4.5 on the x-axis the BRCA mutated (blue blox plot) group and the wt HR-related 
genes (red box plot) are reported, whereas in the y-axis is reported the HRD score calculated. 
As expected, the median of HRD score was higher in BRCA mutated group versus the group 
without mutations in HR genes group (median 66 ranging from 52 to 83 versus median of 47 
ranging from 18 to 67 respectively). In line with the threshold set in the gold standard HRD 
commercially available test (Myriad MyChoice) our cut-off defining HR deficient or HR 
proficient cases the was set at the 5th percentile of blue box plot (cut-off = 52). 
To test whether the score threshold set was able di discriminate BRCA mutated samples from 
samples without mutations in HR genes, the other 40 cases not including in the first part of 




cut-off decided, samples were subdivided into two groups, that are HRD score > 52 and HRD 
score < 52 (figure 4.6). 
 
 
Figure 4.6 HRD score threshold test. On the y-axis the HRD score value is reported and on the x-axis the two 
groups of cases (HRD score > 52, on the left, and HRD score < 52, on the right) are reported. Red dots represent 
cases with BRCA mutations and green dots cases without mutations in HR-related genes. 
 
The vast majority of BRCA mutated cases (green dots) was characterized by HRD score > 52 
(87%, seven out of eight) whereas only one had HRD score < 52. Although, the distribution of 
wt HR genes-related samples (red dots) was not so defined (47% HRD score > 52 and 53% 
HRD score < 52) from a statistical point of view the distribution of samples into the two groups 
remained significant (p-value= 0.05), validating the HRD score threshold decided.  
Basing on parameter defined (HRD score < or > 52), it was tested whether the deficiency or 
proficiency of HR was related to Pt sensitivity in the 70 cases selected for HRD analysis. To 




Figure 4.7 HRD score distribution in Pt-s (n=40) and Pt-r (n=30) cases. Median, IQR, 95th and 5th percentile are 
reported in the box plots. Each case (dot) is coloured on the basis of the figure legend reported according to its 
HRD score value and mutational status of HR-related and BRCA genes. 
 
 
As shown in figure 3.8 Pt-s cases (box plot on the left) were mainly characterized by the 
presence of sample with HRD > 52 (31 out of 40), that are composed from both samples that 
carry BRCA mutations and from samples for whom no mutations in HR genes are reported. On 
contrary, Pt-r cases were enriched in samples with HRD score < 52 (20 out of 30).  
This significant distribution (Fishers’ test, p-value 0.0004) of sample with HRD > 52 in Pt-s 
cases, in which are included both BRCA mutated and wt HR-related genes, demonstrated that 
the evaluation of genomic consequences due to HR deficiency defined by HRD score >52, is 
able to better stratify patients on the basis of their Pt response rather then the evaluation of 









In this second part of this work, the mutational status of BRCA1/2 genes and the functional 
activity of the homologous recombination pathway, to whom they belong were evaluated. 
Although the academic in-house HRD-test that we are still developing, to date suffers of some 
limitations that are detailed described in paragraph 4.2, it had demonstrated to have a predictive 
value in HGS-EOC patients. However, data reported above demonstrated that the HRD score 
represents an important feature significantly associated with therapy sensitivity, but it is not 
able to explain alone the complex biological mechanisms behind the Pt response. For this 
reason, genetic information obtained by DNA sequencing needed to be completed by 
transcriptional information regarding both the known and the unknown part of the 
transcriptome. The integration of results obtained by the analysis of these two different aspects, 
could increase our capability in predicting patients’ response to Pt therapy, and allow to better 





4.3 Transcriptomic analysis 
 
The gene expression analysis reported in the first part of this results section (section 3.2), 
allowed to identify a regulatory network associated to intrinsic Pt resistance. However, as 
results reported were obtained exploiting microarray technique, the transcriptomic scenario 
analysed was limited to the annotated genes, not providing results related to i.e. the genome 
editing. The development and the diffusion of RNA sequencing technology over the past years 
allowed to complete the missing information and obtain a more detailed analysis of the 
transcriptome fine structure, overcoming limitations related to the microarray-based 
approaches.  
To this aim, in this third part of this results section, the two sub-cohorts of HGS-EOC patients 
described in paragraph 4.2.1, named AI (n=28) and BI (n=55) were exploited. In particular, on 
cohort AI total RNA sequencing approach was used to identify differential expressed transcripts 
(DETs), both known and partially or total unknown, between Pt-r and Pt-s patients. To confirm 
results obtained a targeted RNA sequencing approach custom designed on DETs identified was 




4.3.1 Identification of differential expressed transcripts in Pt-r versus Pt-s 
patients  
 
Total RNA sequencing experiments were performed on Cohort AI (see Results, paragraph 
4.2.1). On the basis of the differential expression analysis in Pt-r versus Pt-s cases and with a 
FDR ≤ 0.05, a total of 1730 transcripts were identified as differentially expressed of which 1052 
DETs resulted up-regulated (2.11 < Log FC< 10.26) and 678 down-regulated (-8.72 < Log FC< 
-2.12) (See appendix Table 6.1). 
In order to better characterize the DETs identified, each transcript was reconstructed, compared 
to a reference annotation (Ensembl) and classified on the basis of the class codes reported in 







Figure 4.8 Gff Compare’s class codes. In figure are reported the 15 Gff compare’s class codes (=, c, k, m, n, j, e, 
o, s, x, i, y, p, r and u) that define the relationship between transcripts identified by RNA sequencing experiments 
and the closest reference transcript (where applicable). The class codes are shown in order of reference transcript 
similarity, form the complete match with reference transcript (class code =) to a completely unknown transcript 
which can not be associated with a reference sequence (class code “u”) 
 
 
In figure 4.9 is graphically represented the percentage of DETs for each class code. In particular, 
562 out of 1730 DETs (32%) are represented by transcripts that show a complete match with 
reference sequence (Gff compare class code: =), and thus are defined as known transcripts. 
However, the majority of DETs identified (1168 out of 1730, 68%) were defined as unknown, 
as they revealed a partial or none matched with the reference annotation. To go deeper in details, 
the majority (510 out of 1168, 44%) of unknown or partially unknown DETs, are transcripts 
which have at least a splice junction shared with the reference sequence (class code j), so they 
could represent novel isoform of known transcripts. Other well-represented classes of DETs are 
those constituted by transcripts that are retained in intron(s) and show partial or no intron chain 
match (class code n; 17%) and by transcripts completely unknown or that map in intragenic 
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regions (163 out of 1168, 14%) (class code u). The other DETs identified belong to minor 
represented class code groups, i.e. transcripts that contain the reference sequence (class code k, 
8%) DETs that show exonic overlap with the reference but in the opposite strand or a full 









 In order to better categorize the 562 known DETs identified according to their functional 










Known DETs Unknown or partially
unknown DETs
Differentially expressed transcripts (DETs)
s; likely mapping error
y; contains a reference with its
intron(s)
o; other same strand overlap with
reference exons
m;retained intron(s), full intron
chain match




n;retained intron(s), partial or no
intron chain match
j; multi-exonwith at least one
junction match
i; fully contained whitin a
reference intron
=; exact match with intron chain
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- FDR< 0.01 
- pathway size range: 5-400 entities 
 
Results provided by Reactome open source tool (Material and Methods section, paragraph 
3.5.3), and filtered on the basis of the arbitrary criteria idicated above, the following six 
biological pathway resulted  enriched in the DETs previously identified (3,09E-06 < FDR < 
0,0039): endosoma/vacuolar, ER-Phagosome, Antigen Processing-cross presentation, antigen 
presentation, Insuling-like growth factors binding proteins and collagen chai trimerization 
pathway (table 4.9). Considering the reference macro area for each pathway identified, three 
major biological processes emerged to be enriched in DETs: i) the immune system ii) the 
metabolism of RNA and iii) the extracellular matrix organization. As resported in table 3.10, 
the immune system macro area includes four out of six pathways identified. 
 
Macro Area Pathway name 
Entities Entities  
 pValue FDR 
 found total 
Immune 
system 
Endosomal/Vacuolar pathway 21 82 2,44E-09 3,09E-06 
ER-Phagosome pathway 25 165 1,663E-06 0,0005 
Antigen processing-Cross presentation 25 187 1,379E-05 0,0035 
Antigen Presentation: Folding, assembly  
21 102 9,5E-08 6E-05 
and peptide loading of class I MHC 
Metabolism 
Insulin-like Growth Factor-2 mRNA 
Binding Proteins 8 13 4,3E-07 0,00018 
of RNA  (IGF2BPs/IMPs/VICKZs) bind RNA 
Extracellular 
Collagen chain trimerization 11 44 1,9E-05 0,00397 matrix 
organization 
 
Table 4.9. Pathway analysis on the basis of known DETs. For each pathway identified by Reactome is reported: 
the macro area, the number of DETs that belong to the pathway (Entities found), the total number of genes that 










4.3.2 RNA targeted sequencing validation 
 
To confirm the robustness of total RNA sequencing results, DETs identified needed to be 
validated with another technical approach, both in the same cohort of patients (“technical 
validation”) as well as in an independent cohort with comparable clinical and pathological 
features (“clinical validation”). Considering the impossibility to exploit qRT-PCR approach to 
confirm all DETs identified (see Appendix Table 6.1), both for the high number of transcripts 
and for the impossibility to test the unknown transcripts, targeted RNA sequencing focused on 
the 1730 DETs was exploited to the aim of this part of the work. In fact, this kind of approach 
allows not only to test the 562 known transcripts identified, but also to reconstruct the sequence 
of other DETs that do not show a complete overlap with reference sequence. 
Results deriving from the “technical validation” revealed that 286 out 1370 (21%) of DETs 
tested were as differentially expressed (FDR< 0.05) between Pt-r vs Pt-s patients, on contrary 
1084 (79%) were not (figure 4.10 A). Of these 35% (100 out of 286) were known transcripts 
and 65% (186 out of 286) completely or partially unknown. 
Regarding the targeted RNA sequencing validation performed on cohort BI (“clinical 
validation”), data obtained show that only 82 out of 1370 (6%) of transcripts previously 
identified are able to discriminate with statistical significance (FDR < 0.05) Pt-r from Pt-s 
patients in this independent cohort (figure 4.10 B). In particular, 25% (21 out of 82) are 









Overlapping results deriving from both “technical” and “clinical” validation, only 25 transcripts 
out of 1370 (2%) were confirmed in both cohorts of patients with concordant logFC (FDR < 














DETs validation in cohort BIB
 
Figure 4.10 Validation of 1730 DETs. Piecharts reporting the percentage of DETs confirmed (dark 
blue and green color) or not (light blue and green color) as differentially expressed in Pt-r versus 




Table 4.10 DETs confirmed with targeted RNAseq in Cohort AI and BI. For each DET confirmed is reported the 
Ensemble reference gene ID (ref_gene_id), gene name, class cose (gffCompare), the relative logFC and FDR 
derived from total RNAseq analysis and targeted RNAsequencing analysis in Cohor AI (technical validation) 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Column chart reported in figure 4.11 shows that the majority of DETs confirmed (36%, 9 out 
of 25) are represented by known transcripts, which show a complete match with intron chain, 
whereas three are completely unknown. The remaining 13 DETs are represented by potential 
new isoforms of known transcripts (five out of 25), by transcripts that contain the 
reference sequence (three out of 25) or by transcripts that show a partially or total overlap with 




Figure 4.11 Validated DETs’ class codes. The 25 validated DETs were subdivided on the basis of their Gff 





The nine known transcripts identified and confirmed as DETs between Pt-r and Pt-s patients 
are constituted by eight transcripts derived from protein coding genes and one transcripts 
(LINC00662) that is a long intragenic non-protein coding RNA (lincRNA). Of these eight 




DETs with complete match with intron chain (class code: =) 
 
Chromosome Corresponding Gene 
Name 
Type of gene Expression in Pt-r 
vs Pt-s 
1 KIAA1324 Protein coding Down-regulated 
1 PRG4 Protein coding Up-regulated 
1 FLG Protein coding Up-regulated 
10 CH17-360D5.2 Protein coding Up-regulated 
11 IGF2 Protein coding Up-regulated 
15 CRABP1 Protein coding Down-regulated 
19 LINC00662 lincRNA Up-regulated 
20 LRRN4 Protein coding Up-regulated 
6 HLA-A Protein coding Down-regulated 
 
Table 4.11 List of validated DETs with complete match with intron chain. For each of the eight DETs validated 
is reported the relative chromosome, the name of corresponding gene, the type of gene and the differential 








In this third part of the Results section, the differences in trascriptomic profile between Pt-r and 
Pt-s HGS-EOC patients were investigated by RNA sequencing approaches.  
As overall technical comment, our results demonstrated that a double-step RNA sequencing 
approach, consisting in total RNA sequencing followed by a targeted RNA sequencing both in 
the same and in an independent cohort of patients, is necessary to obtain robust and reproducible 
data. In fact, considering the targeted RNA sequencing validation, the percentage of DETs not 
146 
 
validated in the same cohort of patients (AI) is 79% and further increased considering the results 
obtained from the independent cohort (BI), where the percentage of DETs confirmed is only 
6%. Moreover, overlapping data derived from cohort AI and BI, only 25 out of 1370 transcripts 
(2%) were confirmed as differentially expressed between Pt-r and Pt-s cases. 
Among those only nine out 25 (36%) are represented by transcripts derived from coding genes, 
confirming the limits of array-based approaches in investigating the fine transcriptional 
regulatory mechanisms underlying Pt resistance. Results presented in fact, clearly demonstrated 
that 64% of DETs identified are partial or completely unknown transcripts, that could not have 
been identify with the array technology.   
A functional investigation of elements composing this transcriptional signature, and the 
integration of these data with other independent Pt-predictive biomarkers, could allow in future 
to efficiently stratify patients at time of diagnosis and to better understand biological 



























The identification of molecular signatures that recapitulate the main biological discriminants 
between Pt-s and Pt-r cases with potential clinical utility has been the main goal of many studies 
conducted over the last decades. The results reported in this work of thesis would represent one 
step forward in the deciphering the complex molecular puzzle of Pt resistance in HGS-EOC.    
Considering the three aspects investigated and mentioned above, the discussion is organized in 
three main sections, at the end of which the future prospectives for this study are illustrated. 
 
5.1 Pathway analysis 
In the first part of this research project a three genes-based signature (PRKG1, SDF2L1, and 
PPP1R12A), called SIII signature, that reflects the biology of primary Pt-r tumors and predicts 
prognosis in HGS-EOC patients, was identified. 
The comparative transcription analysis of Pt-s and Pt-r cancer patients, in keeping with some 
previous reports (133), allowed us to identify a restricted number of mRNAs and miRNAs the 
expression of which discriminates between sensitive and resistant cases. The confidence of 
these findings was strengthened by the validation of 18 over 23 (78%) selected genes in a 
different cohort of cases from an independent tissue biorepository as well as in publicly 
databases, included TCGA. 
The core of our pathways wired 131 mRNAs and five miRNAs, with the PRKG1 gene playing 
a role as a hub of the entire network. In our network miRNAs do not seem to play a central role. 
It is difficult to explain the reasons for this result since it could be due to many factors from 
technical sensitivity to biological effects.  
miRNAs are modulatory molecules for which small expression changes might have big post-
transcriptional impact on many target genes, acting as mediators of different pathways. In this 
perspective we can speculate that their small modulations combined with the large biological 
variability of the tumour at least at the time of diagnosis could contribute to mask the miRNA 
effects in primary resistance. It is worth noting that some non-coding elements of the network 
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have been previously identified as prognostic in HGS-EOC. For example, miR-193-5p -highly 
expressed in Pt-r patients- is an element of the prognostic MIROvaR signature (95).  
Since primary resistance against Pt-based chemotherapy is associated with poor prognosis, we 
investigated the prognostic role of the SII signature in one of largest available databases of EOC 
expression profiles (the Curated Ovarian Database - cohort C).  
It is important to highlight that these retrospective databases were not originally intended to be 
used for studies of chemo-resistance as the primary purpose. We realized that the use of 
different gene expression technologies as well as metrics for optimal treatment response might 
introduce potential bias in the data and in the analyses. To minimize this bias and to reduce the 
impact of intra-patient tumor heterogeneity, we used very stringent statistical criteria to limit 
the risk of false positive predictive genes. This strategy identified three genes, PRKG1, SDF2L1 
and PPP1R12A, alias SIII signature -as prognostic biomarkers in HGS-EOC. Moreover, the 
combination of the expression profiles of SIII signature significantly predicts patient prognosis 
with a synergic effect.  
 
PRKG1 (chr: 10q11.23) is a cyclic GMP (cGMP)–dependent protein kinase (PKG), poorly 
characterized in terms of biological function, in particular in HGS-EOC. Recently the 
cGMP/PKG signaling pathway was found to play an important role as an antiapoptotic 
mechanism in ovarian cancer cell lines, by promoting cell survival, through interaction with the 
src gene. Moreover, the NO/cGMP/PKG signaling pathway has been reported to protect human 
ovarian cancer cells against both spontaneous and cisplatin-induced apoptosis (134).  
The SDF2L1 gene (chr: 22q11.21) encodes for a member of the stromal cell derived factors 
family (SDF) secreted by stromal cells, including fibroblasts. Our results are consistent with 
the evidence that low levels of SDF2L1 are associated to poor prognosis, relapse and metastasis 
in breast (135), colon (136) and ovarian cancer (137).  
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PPP1R12A (protein phosphatase 1 regulatory subunit 12A) (chr: 12q21.2-q21.31) belongs to 
the myosin phosphatase targeting protein (MYPT) family. It is also known as myosin 
phosphatase target subunit 1 (MYPT1). In cancer cells, PPP1R12A plays a critical role in major 
regulatory pathways such those pertaining to Wnt/β-catenin signaling (138) and PI3K/AKT 
(139). In has also been demonstrated that PPP1R12A is a key regulator of the Hippo pathway, 
and that triggered by external stimuli like EGF or TGF1 it modulates the nuclear localization 
and stability of YAP/TAZ, thus controlling cell growth, proliferation and EMT (140). Despite 
this important mechanistic role, few studies address the potential prognostic role of PPP1R12A. 
Genome instability in the PPP1R12A locus gene has been found as independent predictor of 
recurrence and overall survival in colorectal cancer patients receiving oxaliplatin-based 
adjuvant chemotherapy (141). Data as to its predictive/prognostic value in HGS-EOC has 
hitherto not been published. 
It is plausible to hypothesize that PRKG1, SDF2L1, PPP1R12A genes are part of a larger 
prognostic signature, the elements of which have not been identified here due to the stringent 
statistical thresholds applied and to the use of non-uninform technical platforms for data 
generation. For example, we have previously identified miR-181a-5p as positive regulator of 
TGFβ and EMT in HGS-EOC, and its expression levels are independent prognostic factors of 
survival 32. In our network we did not identify miR-181a-5p but rather STAT1 and STAT3, the 
former a modulator and the latter a target of miR-181a-5p. PPP1R12A has been reported to be 
activated by TGFβ a regulator of EMT, through miR-181a-5p (94), confirming the importance 







5.2 Genomic instability analysis 
The second result of this work of thesis derives from the correlation analysis between defects 
in Homologous Recombination pathway and sensitivity to DNA-damaging agents, like Pt 
compounds, which has become over the last years a key clinical relevant paradigm for HGS-
EOC treatment (142) (124). Initially the deficiency in HR pathway was defined only on the 
basis of the detection of germline or somatic mutations in BRCA1 and BRCA2 genes. For 
example previous studies have demonstrated a higher improvement in sensitivity to Pt-based 
therapy and also PARPi of ovarian cancer patients carrying BRCA1/2 mutations relative to 
BRCA1/2 wild-type tumours (142) (143).  
However, alterations that affect BRCA genes explain only the 50% of HR defects, indicating 
that alterations in other HR-related genes are responsible for deficiency in HR pathway (144) 
Whole-genome sequencing analysis following the trinucleotidic model proposed by 
Alexandrow and colleagues (145) has identified a specific mutational signature - “signature 3”- 
that was strongly associated to bi-allelic inactivation of BRCA1 and BRCA2 alterations and that 
was also able to identify HRD phenotype in a further 16% of cases not characterized by 
canonical HRD related defects (146). This approach would be useful to stratify HRD positive 
and negative patients, however its application in clinic seems to be limited both for the complex 
bioinformatic analysis required to generate the trinucleotidic signatures and for the costs of the 
experiments per patient. 
 
Thus, to develop a new approach applicable in clinical setting, the NGS assays to determine the 
HR status, were becoming focused on evaluation of the presence of large genomic effects 
induced by the genomic instability and on the mutational analysis of a minor number of target 
region. 
The two commercial tools to identify a genomic scar (see Inroduction, Section 1.4.2.2) are: i) 
“myChoice®” (Myriad) that tests for the presence of the three main structural genomic 
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alterations (loss of heterozygosis, telomeric allelic imbalances, large scale transitions) and ii) 
the “FoundationFocus CDx BRCA LOH” (FoundationOne
®) which detects the presence of 
mutations in BRCA1/2 genes and the percentage of genome affected by LOH. 
Using these assays, HRD status was investigated in many ovarian cancer clinical trials to select 
patients who could benefit from PARPi treatment (47) (147) (148), or in triple negative breast 
cancer trials to predict response to DNA-damaging agents or to evaluate the addition of 
carboplatin to standard chemotherapy (124) (149). 
To create a patent-free independent academic test to evaluate the status of HR pathway in the 
clinical setting, we started to develop an in-house HRD assay. Results reported in this thesis 
work represented an initial step for the setting of the assay that will be implemented and 
compared with the clinical commercial gold-standard for the evaluation of HR deficiency 
(MyChoice®, Myriad). 
In line with MyChoice® assay, we evaluated the sum of the three main genomic scars and, as 
described in Results section, we set a threshold of 52 to distinguish HRD positive (>52) from 
HRD negative (<52) patients. HRD analysis reported in this thesis work is preliminary and at 
the moment it suffers of three main limitations: 
i) As the limited number of BRCA germline mutated patients (n=10), that would 
represent our groundtruth set, the construction of ROC curves to validate the HRD 
score threshold decided was not feasible in this thesis work. ROC curves would 
allow to test different thresholds in order to establish the one associated with best 
values of specificity and sensitivity. To achieve this goal, it is planned to recruit at 
least 50 new BRCA germline mutated patients to have a robust groundtruth set (true 
positive cases) of comparison.  
ii) At the moment, the HRD in-house analysis has considered only the three genomic 
scars investigated by “MyChoice®”. To try to improve the sensitivity of the test 
proposed it is planned to integrate the evaluation of LOH, TAI and LST with 
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mutational information regarding HR-related genes and genes involved in Pt and 
PARPi resistance, such as ABCB1. 
iii) The academic test proposed has been developed and tested using the same cohorts 
of patients, but it has already planned to verify its predictive value on a larger and 
totally independent cohort. 
The integration approach that will be developed in-house for the identification of HGS-
EOC patients carrying defective in homologous recombination pathway would allow us to 
better identify patients who could benefit not only from PARPi treatment, but to give a 
contribution in the developing of a genetic/transcriptomic signature able to stratify patients 
on the basis of Pt sensitivity at time of diagnosis. 
 
5.3 Transcriptomic analysis 
 
As previously stated, a great number of transcriptional signatures associated to Pt-based therapy 
have been developed using array technology, which allowed to focus only on the known part 
of the transcriptome. 
However, despite a huge amount of data has been generated, the mechanisms underlying  Pt 
resistance have not been fully understood yet, suggesting that for a more detailed 
comprehension of this complex mechanism requires a fine analysis across the entire human 
transcriptome including known and partially or totally unknown transcripts.  
From technological point of view, the advent of NGS technology, which allows the absolute 
quantification of transcripts abundance, the identification of novel transcripts’ isoforms, or 
transcripts species has become over the last years the best high-throughput approach for a 
comprehensive fine mapping of the entire transcriptome. 
Up to now, the majority of studies published in literature have used the RNA sequencing 
technology to dissect the mechanism of Pt resistance in HGS-EOC – i.e. in cellular models 
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(150) (151), in patients-derived xenografts (PDXs) (152) and in HGS-EOC patients’ biopsies 
(153) (154)- focusing only on the absolute quantification of known transcripts, but no attention 
was directed to the identification and the investigation of the role of novel  transcripts. 
In this work of thesis, we used a high-coverage total RNA sequencing approach to achieve 
absolute quantification of known transcripts as well as to discover and to evaluate the 
expression levels of transcripts that have never been described before. 
To reinforce data obtained with total RNA sequencing, thus avoiding the problem of false 
positive data, we exploited a targeted approach on one hand to confirm the differentially 
expression of known DETs identified and on the other hand to validate both the structure and 
the expression of reconstructed transcripts. This double-step RNA sequencing approach has 
never been described in literature before and would make more reliable and robust the data that 
were obtained. In fact, it is important to note that the validation approach applied did not 
confirm the 79% -in the same cohort- and the 94% -in an independent cohort of patients- DETs 
identified in the first step of RNA sequencing analysis. 
 
In our results, considering the validated 9 known DETs identified, we found that three of these 
resulted down-regulated in Pt-r compared to Pt-s patients. Among those KIAA1324 – also 
known as EIG121-, that encodes for a transmembrane protein whose expression is induced by 
estrogen. Although its biological function is still poorly understood, the expression levels of 
KIAA1324 is reported to be correlated with good prognosis in endometrial (155), pancreatic 
(156) and ovarian cancer patients. Although we did not perform a survival analysis, in line with 
our results which indicate an overexpression of KIAA1324 in Pt-s patients, the analysis of RNA 
sequencing data derived from 373 ovarian cancer patients –TCGA dataset-, suggests that high 
expression of KIAA1324 is significantly associated with favorable prognosis (cut-off: 0.26, p-
score 0.0002) (157). Another DET that is down-regulated in Pt-r cases is the one that encodes 
for CRABP1 protein, which is a specific binding protein for a vitamin A family member and is 
thought to play an important role in retinoic acid-mediated differentiation and proliferation 
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processes. CRABP1 has been associated with poor prognosis in triple-negative breast cancer 
and it is demonstrated to inhibit the cellular growth arrest induced by retinoic-acids (158). In 
line with our results, the survival analysis performed by Miyake and colleagues (159) 
demonstrated that reduced CRABP1 expression is significantly associated with poor OS and 
PFS in both serous and clear cell ovarian carcinoma. Since CRABP1 is selectively expressed 
by mesenchymal tissues at the junction of the epithelium and the mesenchyme (160), its 
reduction in ovarian surface/Fallopian tube cells could lead to a de-differentiation of cells 
themselves and a consequent EMT process activation, that it is known to be related to Pt 
resistance (161) (92). The last known DETs that from our results emerged as down-regulated 
in Pt-r patients is HLA-A, which belongs to the HLA class I complex. Although we did not 
perform survival analysis in this part of the work, it was documented that a down-regulation of 
HLA class I factors is one of the mechanisms involved in tumour escape from the 
immunological surveillance (162) and that this down-regulation is associated with poor 
outcome in ovarian cancer patients (163). 
Among the six DETs that resulted up-regulated in Pt-r versus Pt-s HGS-EOC, to our knowledge 
no confirmed evidences regarding a possible role in Pt resistance or in HGS-EOC biology is 
reported for the proteoglycan 4 (PRG4), FLG -a filament-associated protein that aggregates 
keratin filament in mammalian epidermis- for ANXA8 (CH17-360D5.2) which encoded for a 
protein with anticoagulant activity whose overexpression is reported to be associated with poor 
prognosis in early stages of pancreatic cancer (164), and for LRRN4 –leucine rich repeat 
neuronal 4-. Another known transcript that from our analysis resulted up-regulated in Pt-r HGS-
EOC patients is IGF2. IGF2 –insulin like growth factor 2- is a member of the insulin family of 
polypeptide growth factors, which through the interaction with IGF1R –insulin growth factor 
receptor 1-, lead to the activation of oxygen-independent pathway promoting the transcription 
activity of HIF-1 (Hypoxia Inducible Factor 1). HIF-1 activated the transcription of many genes 
that encode for proteins that are involved in biological processes like angiogenesis, migration, 
cell survival and invasion, resistance to therapy in many cancer types including triple negative 
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breast cancer (165), esophageal cancer (166), osteosarcoma (167) (168). In ovarian cancer it 
has been reported significant association between high levels of IGF2 mRNA and shorter OS 
and PFS and a possible role of IGF2 in resistance to taxol treatment (169). It is important to 
note that the activation of HIF-1 promotes the transcription of several genes –including Twist-
1, Snail and ZEB1/2, that are related to EMT activation (170) and thus could be involved in Pt 
resistance (Introduction section, paragraph 1.4.3). Although its role is not clearly elucidated yet, 
the long intragenic non-coding RNA 00662 (linc00662) that we found overexpressed in Pt-r 
patients compared to Pt-s ones, has been reported to be associated with cell growth in gastric 
cancer cells (171) and with OS in lung cancer patients (172). To our knowledge no information 
regarding its possible involvement in therapy resistance is reported in literature. 
To sum up, it is evident that at the moment no data are available in literature on the role and the 
involvement of these 9-known transcripts in Pt resistance phenomenon, thus the mechanisms 
by which the expression of each of these 9 transcripts is associated with intrinsic resistance to 




5.4 Future prospectives 
 
In this work of thesis, the complex and heterogeneous phenomenon of Pt resistance in HGS-
EOC has been investigated through different genomic and transcriptomic approaches, providing 
initial insights into the changes in gene expression and alterations in HR repair system 
associated with Pt resistance. In perspective these findings may contribute to improve early 
identification of patients who would benefit from Pt-based therapy from those who would not, 
thus avoiding ineffective toxic treatment.   
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The ultimate aim of this work is to identify a reliable predictive signature applicable in the 
clinical setting. Based on the results obtained in the present thesis, it is planned to conduct 
further research aimed to: 
1. To integrate the two transcriptional signatures presented in paragraphs 4.2 and 4.4 
of the Results. At present these signatures cannot be integrated as they were 
generated by different methods. They will be tested using the same technique 
(targeted RNA sequencing) on a cohort of FFPE HGS-EOC tumour samples. 
2. To improve the in-house HRD assay (see paragraphs 4.3 of the Results) by including 
the mutational analysis of genes which are reported to be associated to Pt-resistance 
or involved in HR pathway, using the same FFPE HGS-EOC tumour samples as in 
point 1. 
3. To compare the integrated transcriptional signature obtained in point 1 with the 
implemented HRD assay developed in point 2, to identify the best approach to 
discriminate at time of diagnosis Pt-sensitive from Pt-resistant patients, allowing to 


































Table 6.1: Differentially expressed transcripts derived from total RNA sequencing 
analysis. 
 
For each DETs identified are reported the chromosome location, log Fold Change (logFC), False Discovery Rate 
(FDR), the Gff compare class code and, where possible, the nearest reference gene. 
 
chr logFC FDR class_code gene_name 
14 -8,725 4,71E-20 j DICER1-AS1 
14 -8,439 1,59E-20 k IGHG1 
1 -7,985 2,28E-17 = NRD1 
16 -7,825 3,40E-17 n PKD1P1 
4 -7,741 3,11E-16 j TAPT1-AS1 
12 -7,731 6,90E-16 j TMTC2 
17 -7,475 9,57E-16 j SPAG9 
11 -7,466 2,77E-19 n PPP6R3 
13 -7,403 6,40E-20 j TMCO3 
2 -7,317 1,45E-15 m LANCL1 
18 -7,281 3,84E-15 = LINC00908 
11 -7,252 5,24E-15 = EPS8L2 
10 -7,189 1,58E-14 j SORCS1 
15 -7,073 2,31E-14 j POLG 
12 -6,947 1,74E-10 x A2ML1-AS2 
16 -6,932 1,55E-13 n CDK10 
22 -6,871 1,32E-10 j GCAT 
10 -6,863 6,10E-19 m NRG3-AS1 
3 -6,793 1,57E-12 n ADAMTS9 
9 -6,673 9,63E-10 j ZNF782 
5 -6,438 8,99E-11 j ANKHD1-EIF4EBP3 
17 -6,386 1,21E-11 j SGSH 
14 -6,327 1,11E-16 j RP11-666E17.1 
3 -6,312 4,66E-14 j FNDC3B 
16 -6,182 4,93E-11 n MAPK8IP3 
9 -6,173 4,66E-07 k ANKRD18B 
1 -6,172 2,75E-05 = FCGR3B 
12 -6,156 1,78E-10 k CPM 
7 -6,065 8,33E-06 j POLR2J2 
2 -6,060 1,85E-10 m NR4A2 
12 -6,046 3,17E-10 = NELL2 
12 -6,030 4,62E-10 j ATXN2 
X -5,979 5,95E-05 j RAP2C-AS1 
16 -5,957 4,24E-10 = CARHSP1 
11 -5,854 9,92E-10 n PDZD3 
14 -5,772 3,72E-09 j SLC25A29 
160 
 
15 -5,767 1,56E-09 = SMAD3 
16 -5,728 1,93E-09 j RP11-505K9.4 
5 -5,721 1,80E-07 = FAM153B 
4 -5,701 1,93E-08 = RAPGEF2 
12 -5,691 4,04E-09 = PFKM 
17 -5,667 7,83E-06 n MYO15B 
1 -5,641 5,52E-09 n RP11-504P24.3 
14 -5,633 1,36E-08 m RP11-111A21.1 
8 -5,603 0,000422788 m STAR 
11 -5,602 1,78E-09 m LRP5 
15 -5,545 1,33E-08 j GOLGA8B 
20 -5,542 1,27E-07 = ABHD12 
1 -5,521 1,90E-08 j FGR 
12 -5,492 2,52E-08 = PHLDA1 
7 -5,481 1,01E-06 k ARHGEF34P 
4 -5,476 1,38E-08 = BST1 
21 -5,475 5,54E-08 j MCM3AP 
15 -5,430 5,16E-08 j RP11-661P17.1 
12 -5,405 1,08E-07 o RP11-446N19.1 
19 -5,361 2,59E-08 = FOSB 
6 -5,353 3,18E-07 = RP11-527F13.1 
16 -5,342 4,52E-08 j MYLK3 
17 -5,315 5,03E-08 j LIMD2 
19 -5,312 1,23E-07 = NFIX 
14 -5,303 5,67E-08 j NUMB 
17 -5,299 1,35E-05 = ACE 
X -5,283 0,00069139 j NHSL2 
1 -5,278 1,08E-07 = NFIA 
14 -5,271 3,84E-10 m TRAV8-3 
6 -5,264 4,59E-05 = TNFAIP3 
6 -5,251 2,26E-12 x RP1-80N2.2 
4 -5,238 1,21E-10 n SH3BP2 
6 -5,152 7,07E-06 = MCM9 
12 -5,146 3,09E-07 j LMNTD1 
17 -5,137 3,51E-10 k MYO18A 
X -5,130 0,000171588 j DMD 
3 -5,113 4,57E-07 = ZBBX 
7 -5,112 3,45E-07 n INSIG1 
11 -5,074 1,92E-10 n TTC17 
6 -5,071 7,90E-05 k RP3-329A5.8 
3 -5,070 1,46E-06 j ATXN7 
2 -5,070 4,43E-08 = LINC00570 
9 -5,060 3,76E-06 j RFX3-AS1 
2 -5,045 6,21E-07 = LIMS1 
5 -5,021 3,12E-08 j ZNF354B 
6 -5,009 2,39E-10 j PHF3 
3 -5,001 3,19E-06 = EIF4G1 
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2 -4,985 5,80E-11 j ERBB4 
1 -4,950 1,21E-10 n ABL2 
2 -4,947 8,99E-07 n PPP1R21 
17 -4,930 1,40E-06 j SKA2 
4 -4,920 1,73E-06 x RNF150 
14 -4,907 4,20E-07 = LRRC9 
22 -4,905 1,01E-06 j FAM118A 
11 -4,888 7,80E-07 j CEP164 
6 -4,884 5,11E-07 j EZR 
18 -4,872 1,46E-11 = ONECUT2 
3 -4,841 1,04E-05 = TNIK 
6 -4,838 9,77E-08 j PHF3 
5 -4,816 4,56E-06 j IQGAP2 
8 -4,808 0,005676189 = ANK1 
10 -4,801 1,92E-07 n FAM208B 
15 -4,773 2,88E-06 j EFTUD1P1 
X -4,734 4,48E-05 j RP11-761E20.1 
17 -4,723 3,44E-06 j FOXK2 
2 -4,719 2,39E-06 m CATIP 
X -4,705 0,000798941 j DDX26B 
11 -4,705 4,67E-06 j ANO1 
20 -4,670 2,80E-08 u NA 
9 -4,661 0,008344115 = C9orf3 
5 -4,617 0,000220937 = TCF7 
4 -4,616 3,26E-06 = TMEM175 
7 -4,600 6,65E-05 = RP11-448A19.1 
15 -4,600 7,49E-06 m ARRDC4 
2 -4,591 2,26E-10 j AC092159.2 
5 -4,587 1,01E-05 = TNFAIP8 
11 -4,560 4,19E-09 u NA 
3 -4,554 9,00E-06 = CFAP44 
6 -4,536 0,000311146 = GABBR1 
22 -4,513 0,000104043 j TANGO2 
2 -4,490 2,31E-07 = AC093838.4 
17 -4,489 2,60E-08 n TBX2 
22 -4,473 4,95E-09 = APOL4 
9 -4,471 0,000110707 j RP11-500B12.1 
21 -4,469 3,07E-09 = TFF3 
5 -4,463 8,33E-06 j WWC1 
4 -4,459 2,71E-05 u NA 
3 -4,441 4,00E-08 j MRPS22 
3 -4,434 4,39E-05 = TRAK1 
18 -4,428 1,96E-05 j ZBTB7C 
11 -4,423 1,81E-05 = HMBS 
6 -4,421 4,54E-05 j RNF217 
17 -4,409 2,47E-05 j NOL11 
20 -4,404 1,41E-09 j MIR646HG 
162 
 
7 -4,403 9,51E-05 x RP11-397J20.1 
14 -4,392 1,48E-07 j SPTLC2 
22 -4,390 3,72E-05 j LARGE 
4 -4,387 0,000435009 = SH3RF1 
3 -4,381 2,98E-09 j NLGN1 
17 -4,381 1,86E-09 u NA 
7 -4,376 0,000139554 x AVL9 
5 -4,369 5,34E-05 j MAST4 
13 -4,368 3,24E-05 j KIAA0226L 
2 -4,355 2,01E-05 = SCTR 
19 -4,344 3,27E-05 j NFIX 
1 -4,343 1,80E-07 k WASH7P 
17 -4,332 3,12E-05 j LIMD2 
21 -4,315 0,000289278 j ITGB2 
2 -4,310 6,22E-07 j ERBB4 
19 -4,294 4,09E-05 j OAZ1 
1 -4,292 5,66E-08 j LINC00970 
1 -4,287 1,23E-07 j GPR157 
1 -4,279 2,69E-09 n SUCO 
16 -4,268 4,18E-08 u NA 
18 -4,247 1,66E-07 o DLGAP1 
11 -4,243 3,32E-09 j FTH1 
7 -4,229 0,002223803 j RSPH10B2 
10 -4,227 8,45E-05 j C10orf107 
16 -4,198 6,27E-08 u NA 
6 -4,198 0,000153413 j PM20D2 
2 -4,197 9,36E-07 u NA 
10 -4,196 2,59E-07 j PFKP 
2 -4,165 7,90E-05 j WIPF1 
8 -4,164 0,00014098 j RBPMS-AS1 
19 -4,153 0,000330667 j FKBP8 
21 -4,151 8,04E-09 = TFF3 
12 -4,151 3,46E-08 m GCN1L1 
11 -4,150 9,04E-05 j CEP164 
7 -4,149 0,006279762 j WDR86-AS1 
11 -4,125 5,27E-06 = CCDC88B 
7 -4,109 0,000102508 = PIP 
X -4,106 3,10E-08 u NA 
16 -4,105 2,94E-08 n TP53TG3D 
5 -4,103 7,61E-05 = AFAP1L1 
7 -4,103 0,000469004 j DPY19L2P1 
1 -4,094 1,70E-07 = TMEM56 
19 -4,087 0,000377228 j LMNB2 
3 -4,077 0,000283181 x LPP 
1 -4,063 1,81E-05 u NA 
11 -4,059 1,51E-08 k RP11-428C19.5 
20 -4,059 0,000542566 = NFATC2 
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15 -4,056 2,76E-05 = ACSBG1 
20 -4,044 7,14E-06 n CTSA 
X -4,002 8,45E-06 u NA 
11 -3,977 0,000278679 = CAPRIN1 
12 -3,970 3,27E-07 u NA 
22 -3,966 0,000774632 j KIAA1671 
16 -3,963 0,000231426 j ZNF778 
5 -3,959 0,005756042 n HK3 
1 -3,951 6,21E-08 = NBPF14 
5 -3,921 0,001172578 j ADAMTS12 
15 -3,915 2,59E-07 k GOLGA8O 
12 -3,911 0,000283702 = MLXIP 
6 -3,910 1,39E-07 = PKHD1 
2 -3,903 2,67E-07 = RAPGEF4 
5 -3,890 0,002568939 = CCNO 
22 -3,887 2,99E-05 j FAM118A 
3 -3,885 9,66E-08 i RP11-441M10.1 
5 -3,881 0,001230094 = FAM153B 
15 -3,863 0,000880388 = CYP19A1 
4 -3,855 0,000520918 = CNGA1 
1 -3,840 1,74E-07 n HIVEP3 
10 -3,838 0,000677138 x ARID5B 
10 -3,821 0,000579324 j HK1 
X -3,801 0,001236153 n CXorf22 
11 -3,789 1,25E-05 j C11orf70 
12 -3,777 1,35E-05 k WASH7P 
6 -3,770 1,40E-07 = CRISP3 
19 -3,765 0,001668413 = NR1H2 
21 -3,760 5,53E-06 n MCM3AP 
2 -3,757 6,25E-05 j ERBB4 
5 -3,744 0,000911355 j GRAMD3 
22 -3,740 0,00011318 j MICAL3 
3 -3,737 0,001392882 j FOXP1 
3 -3,726 1,35E-05 n ARIH2 
21 -3,718 3,16E-06 = PRDM15 
2 -3,713 3,02E-07 j ZDBF2 
X -3,699 1,71E-05 u NA 
2 -3,688 0,000937582 j AC109826.1 
16 -3,686 0,003222421 n SMPD3 
X -3,679 3,58E-06 x RP11-305F18.1 
1 -3,660 0,002384112 = EPHA2 
12 -3,652 0,002799082 j RP11-256L6.3 
8 -3,640 0,004504678 k RP11-1081K18.1 
12 -3,633 0,000927131 n ENO2 
17 -3,631 0,001393341 j CDC6 
20 -3,628 6,73E-07 m RP5-1016A21.1 
2 -3,616 0,001810263 j DNAH7 
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1 -3,614 0,001748262 k RP11-275I14.4 
19 -3,614 3,51E-05 = CEACAM21 
20 -3,602 5,35E-07 j MIR646HG 
12 -3,582 0,002380527 n GOLGA2P5 
14 -3,574 1,57E-06 n CTD-2566J3.1 
20 -3,568 0,006189716 u NA 
8 -3,568 6,90E-06 = AP3M2 
18 -3,552 1,01E-06 = MC4R 
20 -3,552 8,11E-07 = SYCP2 
1 -3,543 1,52E-06 = YY1AP1 
11 -3,524 9,02E-07 = MMP7 
10 -3,522 0,002380527 = ACTA2 
19 -3,518 6,65E-05 = LIG1 
1 -3,511 0,000579731 = LAMC1 
1 -3,508 1,11E-06 j SRSF11 
8 -3,504 2,15E-06 j KCNB2 
21 -3,503 1,07E-06 x LINC00113 
1 -3,501 0,002056453 j TEKT2 
6 -3,498 0,005430124 n CRISP2 
11 -3,496 1,11E-06 = TMEM123 
19 -3,491 0,002214065 = ILF3 
3 -3,483 0,008085384 n TTLL3 
7 -3,481 1,60E-06 x AC005024.1 
22 -3,479 0,001324137 j TXNRD2 
7 -3,462 0,00173583 n DPY19L2P1 
2 -3,453 0,003596991 = SCN1A 
3 -3,449 3,35E-06 u NA 
5 -3,436 0,000237564 x CTD-2201E18.4 
19 -3,431 0,000261824 j PLIN5 
2 -3,423 0,002857113 j IL1R1 
21 -3,410 2,17E-06 n AL035610.2 
17 -3,409 2,62E-06 = KCNJ16 
11 -3,407 0,003097997 = SOX6 
22 -3,401 1,25E-05 j DDX17 
5 -3,399 2,55E-06 u NA 
2 -3,386 2,28E-05 n IL1R1 
1 -3,382 4,03E-05 = LGALS8 
11 -3,372 0,004344955 = CREBZF 
18 -3,371 0,001895388 = AQP4-AS1 
19 -3,371 0,000563306 = KCNC3 
15 -3,369 4,21E-06 = TPM1 
15 -3,368 0,000134098 = TMC3 
12 -3,354 0,000154823 j R3HDM2 
1 -3,347 1,04E-05 = KIAA1324 
14 -3,345 0,00010207 m FRMD6-AS2 
16 -3,339 9,79E-06 n SMG1 
10 -3,332 6,64E-05 j ACSL5 
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16 -3,328 0,000335099 = CDH16 
16 -3,324 1,42E-05 j METTL9 
11 -3,318 0,00805006 j SSSCA1 
1 -3,307 5,44E-06 x CDKN2C 
11 -3,303 0,000128135 = CD44 
12 -3,299 0,003490081 j HNF1A-AS1 
2 -3,291 0,007090746 = SCN1A 
11 -3,273 6,30E-06 k RP11-688I9.4 
10 -3,269 0,00787701 j ZFAND4 
1 -3,269 6,27E-06 u NA 
8 -3,263 2,54E-05 j TEX15 
22 -3,257 4,70E-05 j KIAA1671 
12 -3,254 0,000106964 = NCAPD2 
12 -3,252 0,001083285 = CLEC12A 
2 -3,251 0,008745081 = R3HDM1 
2 -3,229 0,000378347 u NA 
11 -3,221 8,49E-06 = RPS3 
4 -3,217 0,009484555 = FGG 
21 -3,204 0,008482345 n UMODL1 
10 -3,192 4,61E-05 = SORCS1 
17 -3,183 0,000131924 j MYO1C 
9 -3,180 6,91E-05 k CBWD5 
22 -3,178 4,16E-05 = PACSIN2 
5 -3,177 1,58E-05 u NA 
9 -3,173 1,84E-05 = GDA 
8 -3,165 1,70E-05 k AC083843.1 
X -3,165 5,49E-05 u NA 
16 -3,165 0,007485939 j STX4 
8 -3,160 1,77E-05 = NDRG1 
15 -3,159 0,009733359 = CLPX 
3 -3,156 1,86E-05 u NA 
3 -3,153 9,12E-05 = CCNL1 
6 -3,143 0,003275297 j EZR 
10 -3,141 0,006867731 j SPAG6 
11 -3,132 3,63E-05 j NADSYN1 
14 -3,125 0,001196755 j PLEKHH1 
7 -3,121 0,002012168 j MAGI2-IT1 
15 -3,104 3,86E-05 = FAM174B 
4 -3,104 0,000572021 j ARAP2 
X -3,097 0,000145564 x RP6-218J18.2 
5 -3,094 0,000198588 m COMMD10 
19 -3,093 0,000644739 n DMKN 
1 -3,085 0,001817236 u NA 
9 -3,078 0,000763698 = COL27A1 
7 -3,076 0,000137995 n RP5-1121A15.3 
10 -3,070 0,000108782 = SEMA4G 
10 -3,066 5,12E-05 m GSTO2 
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12 -3,063 0,000227714 x LRCOL1 
2 -3,055 2,83E-05 = IGKC 
6 -3,053 0,004337597 = DDR1 
16 -3,051 4,22E-05 = C16orf89 
19 -3,042 0,000105453 j PTPRS 
3 -3,042 4,03E-05 x ACTR3P3 
16 -3,039 6,45E-05 u NA 
3 -3,039 0,006448257 u NA 
14 -3,030 0,000939646 = C14orf105 
1 -3,029 0,000663109 n TMEM234 
19 -3,024 0,008526181 u NA 
3 -3,017 6,17E-05 u NA 
5 -3,015 7,64E-05 u NA 
14 -3,015 0,000118997 m NOP9 
2 -3,013 0,000355596 = IHH 
5 -3,013 0,006626795 = FLT4 
20 -3,007 0,00020816 n RP5-1016A21.1 
2 -3,006 4,01E-05 j AC078941.1 
2 -3,005 0,000171416 j AC108938.5 
16 -3,001 0,007025983 = CES4A 
1 -2,999 0,003454867 = RP4-665N4.4 
16 -2,998 9,04E-05 u NA 
10 -2,993 0,000748689 = PFKFB3 
12 -2,992 0,000542566 = LDHB 
13 -2,990 4,45E-05 k RP11-124N19.3 
5 -2,989 0,002824737 j KDM3B 
3 -2,988 0,002283552 = CAMP 
21 -2,982 0,000645481 m CH507-42P11.8 
1 -2,982 0,000146806 = KAZN 
15 -2,980 0,000414225 = RP11-326L17.1 
1 -2,971 6,04E-05 n ERICH3 
18 -2,971 0,006109993 = FHOD3 
1 -2,968 0,000593972 n RP11-421L21.3 
10 -2,967 0,001208093 j ARMC3 
4 -2,964 0,000342337 n FBXL5 
1 -2,963 0,003181097 = ECHDC2 
19 -2,960 8,01E-05 m ITPKC 
14 -2,953 0,000495463 k MMP14 
8 -2,948 0,000113404 k ZNF252P 
10 -2,944 0,001263014 j MKX 
11 -2,943 0,000305868 j C11orf49 
19 -2,938 0,000225836 = ARHGEF1 
14 -2,934 0,000311491 j PPP4R4 
2 -2,932 0,000373739 n SPOPL 
5 -2,931 0,000798941 u NA 
9 -2,926 0,001236937 n KIF27 
17 -2,923 0,000277215 k BZRAP1 
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16 -2,921 0,006867731 = TCF25 
5 -2,921 0,000631681 = TMEM167A 
1 -2,918 7,93E-05 j KIAA1324 
1 -2,916 0,006614098 m C1orf168 
19 -2,916 0,002022063 u NA 
2 -2,913 0,00290713 j HSPE1-MOB4 
1 -2,910 8,89E-05 = KIAA1324 
14 -2,907 0,00012223 n C14orf105 
14 -2,907 0,000658623 j NDRG2 
18 -2,906 0,000101457 = CHST9 
12 -2,905 0,000151798 u NA 
3 -2,903 0,001284968 = SHQ1 
1 -2,900 0,001882438 j RP1-35C21.1 
10 -2,897 0,001217027 j SORCS1 
21 -2,896 0,00219649 j TMEM50B 
16 -2,886 0,000127566 j RP11-58C22.1 
11 -2,883 0,00012882 m PHOX2A 
5 -2,879 0,002840828 j FAM153C 
1 -2,877 0,006189716 j HHAT 
18 -2,877 0,001015156 = SYT4 
11 -2,876 0,00017101 = CRACR2B 
17 -2,873 0,000292075 x TIAF1 
15 -2,868 0,001404577 j SCAND2P 
1 -2,868 0,000129933 = PKP1 
15 -2,860 0,000108584 = CRABP1 
2 -2,844 0,000126688 u NA 
19 -2,843 0,000287791 j ZNF544 
15 -2,836 0,000692798 j SIN3A 
8 -2,833 0,000130723 n NRG1 
2 -2,819 0,000203909 k AGFG1 
20 -2,816 0,000987928 = SRC 
11 -2,816 0,000440612 j UVRAG 
19 -2,816 0,00427301 = PRKD2 
21 -2,812 0,000148304 n AL035610.2 
3 -2,812 0,000210499 u NA 
11 -2,806 0,003741583 = PDZD3 
1 -2,803 0,000213056 = KIAA1324 
3 -2,798 0,000200416 = PLA1A 
1 -2,798 0,002481582 n PDE4DIP 
11 -2,797 0,000245906 n DOC2GP 
10 -2,785 0,000506344 n HECTD2 
18 -2,784 0,002390572 j DLGAP1 
3 -2,781 0,000246466 n RBM6 
X -2,778 0,000210499 = BEX1 
20 -2,767 0,000210499 x RNU6-929P 
1 -2,763 0,000433017 = PLEKHG5 
9 -2,753 0,003329736 = CBWD3 
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3 -2,750 0,000471733 y RP11-200A1.1 
18 -2,748 0,001249546 = ANKRD30B 
7 -2,747 0,000557302 = AC004540.4 
19 -2,745 0,001607357 n MBOAT7 
1 -2,742 0,00560396 j C1orf228 
2 -2,736 0,000269984 = AC079112.1 
17 -2,735 0,000726606 k RP11-219A15.1 
8 -2,731 0,000591894 = NCALD 
17 -2,718 0,0027211 = LRRC37A3 
8 -2,711 0,000297956 x RP11-21C17.1 
2 -2,710 0,000670429 j SCN1A 
2 -2,708 0,000336507 u NA 
11 -2,702 0,000336564 = MMP12 
3 -2,701 0,001230094 = DGKG 
18 -2,701 0,003293799 = SLC14A1 
17 -2,697 0,001165139 m MYBBP1A 
2 -2,695 0,001181262 j PKP4 
1 -2,694 0,000460498 x GPBP1L1 
19 -2,689 0,001748849 = ZNF497 
2 -2,688 0,000366223 m HOXD11 
3 -2,685 0,000361389 = SST 
9 -2,683 0,003222421 x RAPGEF1 
11 -2,681 0,000407612 k FZD4 
14 -2,676 0,002793367 = TTLL5 
4 -2,672 0,000430268 u NA 
4 -2,671 0,005667991 j ARHGEF38 
1 -2,669 0,000642976 n RAD54L 
18 -2,667 0,000934938 j CHST9 
10 -2,667 0,000696622 = EMX2OS 
19 -2,665 0,000856516 k CTD-2245F17.3 
10 -2,661 0,00044513 x GHITM 
6 -2,659 0,000508566 m MAP3K7 
1 -2,658 0,000435426 = KIAA1324 
12 -2,654 0,004969331 j SYT10 
14 -2,654 0,000511102 x SLC38A6 
21 -2,654 0,001682432 n C21orf58 
X -2,644 0,000546289 = SYTL5 
6 -2,641 0,003741583 = CRISP3 
11 -2,640 0,000765183 u NA 
12 -2,637 0,000663561 = NUDT4 
16 -2,636 0,001846386 m CDH16 
10 -2,636 0,000544901 u NA 
8 -2,636 0,000959409 x RNU6-442P 
1 -2,635 0,003689665 = ESRRG 
1 -2,633 0,003811725 m TXLNA 
11 -2,632 0,000624179 = LDHA 
11 -2,631 0,000541695 m RNF169 
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5 -2,631 0,002402469 = NIPBL 
6 -2,630 0,00259764 = STK19 
19 -2,625 0,000616571 k CTD-2017D11.1 
12 -2,624 0,000658623 o RP1-288H2.2 
3 -2,623 0,001061491 = FAM107A 
3 -2,614 0,000594802 j KBTBD12 
15 -2,614 0,001131558 = C2CD4B 
14 -2,613 0,006626795 j LRRC9 
10 -2,611 0,000726606 = MYO3A 
7 -2,611 0,001067455 j AC004540.4 
2 -2,609 0,000899814 = AGAP1 
2 -2,607 0,000652336 u NA 
9 -2,600 0,005969245 j TMC1 
10 -2,599 0,000625958 u NA 
14 -2,595 0,002008316 n HNRNPC 
1 -2,590 0,009074138 j RP11-413P11.1 
8 -2,585 0,000711348 o CASC8 
2 -2,582 0,000742106 j AC007389.3 
3 -2,582 0,001141302 = HMCES 
21 -2,578 0,001200198 = B3GALT5 
9 -2,578 0,002432392 u NA 
22 -2,578 0,003313376 = RBFOX2 
11 -2,572 0,002113902 k FNBP4 
19 -2,569 0,000935 j DNMT1 
2 -2,566 0,001259259 n RP11-310N16.1 
2 -2,563 0,002323196 y RP11-1223D19.1 
15 -2,563 0,001141194 j TICRR 
10 -2,562 0,001121019 u NA 
4 -2,562 0,001014323 n RBPJ 
16 -2,560 0,002269817 j ARHGAP17 
2 -2,556 0,000858812 u NA 
8 -2,553 0,001093538 x RP11-21C17.1 
16 -2,549 0,000962053 = PRSS21 
10 -2,540 0,001692414 j ADD3 
4 -2,538 0,003489677 u NA 
16 -2,537 0,002088655 j CPNE7 
2 -2,535 0,001790952 j RP11-310N16.1 
11 -2,530 0,00259764 j NUMA1 
15 -2,524 0,00099861 j GOLGA6L9 
1 -2,522 0,005130348 = PABPC4 
7 -2,519 0,001151393 n AC004540.4 
1 -2,512 0,003518642 n TMEM234 
12 -2,510 0,001266722 m IPO8 
16 -2,507 0,00565365 = USP31 
17 -2,506 0,002224882 j SPECC1 
14 -2,504 0,003271054 = MIS18BP1 
X -2,500 0,001131774 k RP5-1158E12.3 
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2 -2,499 0,002362381 j CFAP221 
2 -2,498 0,00259709 j RP11-287D1.3 
10 -2,498 0,002438918 j DDX50 
1 -2,497 0,001919648 u NA 
11 -2,494 0,007705562 m FNBP4 
15 -2,490 0,001564639 n UNC45A 
11 -2,490 0,001492832 = KLHL35 
11 -2,489 0,001404577 k RNF169 
3 -2,485 0,001229936 = IMPG2 
1 -2,485 0,002168312 = ANKRD35 
12 -2,481 0,001250638 = MYL6 
12 -2,481 0,003600438 j LINC00937 
18 -2,480 0,005211929 j OSBPL1A 
11 -2,474 0,003866961 n CRACR2B 
19 -2,461 0,003907774 j LDLR 
6 -2,461 0,001895388 = EPHA7 
8 -2,460 0,002838313 k UBXN8 
11 -2,460 0,001533886 k RNF169 
15 -2,453 0,002581434 = PRC1 
1 -2,451 0,004634286 = TRIM45 
2 -2,448 0,00163042 n AC108938.5 
2 -2,443 0,003181097 n CYP4F30P 
9 -2,442 0,006279762 j RP11-54D18.2 
19 -2,441 0,003506232 = SMIM24 
15 -2,434 0,007557152 j ADPGK 
10 -2,431 0,001846747 u NA 
16 -2,428 0,006631043 j HERPUD1 
16 -2,425 0,004506049 = PAM16 
19 -2,425 0,002529508 j CTXN1 
1 -2,423 0,002096503 = KIAA1324 
17 -2,418 0,002126498 m NOTUM 
15 -2,415 0,007483262 n PLCB2 
6 -2,415 0,006818877 = ENPP3 
14 -2,414 0,007178081 n HIF1A-AS2 
17 -2,412 0,005032545 m PTRH2 
7 -2,408 0,008005937 j DPY19L1P2 
3 -2,405 0,002137754 j C3orf58 
12 -2,405 0,003179777 = PPHLN1 
X -2,401 0,00259764 u NA 
18 -2,397 0,002134928 o ZBTB7C 
10 -2,393 0,002320126 u NA 
17 -2,391 0,004730883 = SDK2 
17 -2,389 0,005098378 = CA4 
11 -2,385 0,002688597 j ASRGL1 
21 -2,383 0,002381119 j SIM2 
1 -2,382 0,007876242 = KIAA1324 
2 -2,381 0,002705132 j STAT1 
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11 -2,377 0,002383788 = SYTL2 
2 -2,373 0,002753343 u NA 
1 -2,372 0,004576323 = KIAA1324 
22 -2,368 0,002629825 = IGLV3-1 
1 -2,366 0,002719698 u NA 
11 -2,366 0,002720987 = SYTL2 
14 -2,364 0,003659688 n PIGH 
6 -2,354 0,009488381 j CRISP2 
18 -2,354 0,003006827 = CHST9 
12 -2,353 0,003282142 x CTD-2021H9.2 
3 -2,351 0,008085384 = SPCS1 
14 -2,350 0,002954186 = IGHA2 
2 -2,346 0,009006771 j PCBP1-AS1 
15 -2,343 0,003752121 k LINS 
20 -2,342 0,004001363 = PLCB1 
3 -2,341 0,004419192 k RP11-297K7.1 
8 -2,338 0,004337597 = KB-1507C5.2 
16 -2,335 0,008408248 = DYNC1LI2 
1 -2,334 0,005481908 j GON4L 
14 -2,333 0,004157568 u NA 
14 -2,330 0,003193873 = ZFP36L1 
11 -2,330 0,003174993 j RNF169 
2 -2,330 0,003202472 u NA 
2 -2,328 0,00356238 u NA 
9 -2,327 0,003233332 = SET 
2 -2,327 0,009873733 j PSME4 
21 -2,324 0,009967151 = EVA1C 
14 -2,321 0,003557617 j CEP128 
1 -2,317 0,004890047 = SNAP47 
6 -2,315 0,008053338 = C6orf223 
2 -2,315 0,00900831 m FAM98A 
12 -2,314 0,003893659 k MPHOSPH9 
11 -2,310 0,004587262 = CTNND1 
3 -2,307 0,003720342 u NA 
14 -2,305 0,005018107 j SLC25A29 
19 -2,303 0,004248398 = RPSAP58 
1 -2,303 0,008135517 x ABCA4 
15 -2,294 0,006885159 k WDR73 
3 -2,294 0,005832481 = VEPH1 
12 -2,288 0,005289906 j MPHOSPH9 
8 -2,286 0,009158691 j NDUFAF6 
1 -2,286 0,006284452 j RP4-784A16.5 
4 -2,282 0,004626352 k CLDN22 
22 -2,282 0,004248398 j IGLL5 
22 -2,281 0,005381618 j PLA2G6 
3 -2,279 0,005222156 j KIF9-AS1 
3 -2,278 0,004480034 = VEPH1 
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17 -2,277 0,008078295 j MAP3K3 
18 -2,271 0,00839209 j DLGAP1 
3 -2,270 0,007123117 = NDUFB5 
2 -2,270 0,00437366 = IGKV4-1 
11 -2,270 0,004532548 u NA 
3 -2,269 0,005964815 = NLGN1 
12 -2,266 0,006090917 j BCL2L14 
17 -2,266 0,005285006 = PIPOX 
17 -2,265 0,007284389 j BRIP1 
3 -2,264 0,005540736 j EGFEM1P 
6 -2,263 0,004906301 = HLA-A 
20 -2,260 0,004898865 j MIR646HG 
12 -2,259 0,005318362 n KNTC1 
20 -2,258 0,005380857 = FOXA2 
15 -2,257 0,008653428 x CTD-2240J17.2 
14 -2,257 0,005983731 j SLC25A29 
5 -2,256 0,005627262 = PPP2R2B 
8 -2,253 0,005144023 j COL14A1 
12 -2,252 0,005756042 j UBC 
14 -2,252 0,007025983 o RP11-638I2.6 
3 -2,251 0,00490688 x NLGN1-AS1 
11 -2,248 0,005104998 x RNU4ATAC5P 
10 -2,247 0,009072344 j CTNNA3 
2 -2,247 0,00560396 = M1AP 
14 -2,247 0,006445841 u NA 
1 -2,247 0,005420769 k FAM96AP2 
3 -2,246 0,006774158 = VEPH1 
3 -2,243 0,009107896 = KIAA1407 
1 -2,242 0,006925131 = CPSF3L 
17 -2,240 0,006150932 = CCL13 
3 -2,240 0,0051666 = CMTM6 
1 -2,236 0,005567829 n ERICH3 
21 -2,232 0,005657829 = PCP4 
5 -2,232 0,008053338 x FBXL7 
3 -2,226 0,006454389 = PARP14 
8 -2,225 0,00907625 j KB-1507C5.2 
16 -2,225 0,007402665 = BCO1 
11 -2,224 0,006131164 = KLHL35 
3 -2,224 0,006300807 = IL17RB 
9 -2,224 0,006677393 k CLCN3P1 
2 -2,220 0,006129738 u NA 
1 -2,220 0,006614098 k MORN1 
12 -2,218 0,006222113 k AC078864.1 
11 -2,217 0,00597844 u NA 
1 -2,216 0,008768517 = ERICH3 
10 -2,215 0,007835019 = RASGEF1A 
10 -2,213 0,00906797 = ZNF33A 
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15 -2,210 0,006129738 j GOLGA6L9 
5 -2,209 0,006129738 = PIK3R1 
10 -2,198 0,008152859 j BCCIP 
12 -2,197 0,008114608 = SCNN1A 
11 -2,197 0,007417777 = NUMA1 
14 -2,195 0,007772362 u NA 
12 -2,194 0,009334505 j TPI1 
4 -2,194 0,006624778 = CXCL9 
3 -2,193 0,007832036 = SPTSSB 
7 -2,192 0,007507256 u NA 
17 -2,192 0,00787701 m SRSF1 
17 -2,189 0,008353415 = MPRIP 
1 -2,186 0,007272427 k OPN3 
19 -2,185 0,008437065 = SMIM7 
3 -2,184 0,007531375 = KBTBD12 
2 -2,183 0,008289627 m AC010883.5 
6 -2,179 0,009059136 = C6orf223 
19 -2,178 0,009388325 x GPR108 
11 -2,177 0,00734157 u NA 
2 -2,176 0,008895158 j AC007389.3 
3 -2,167 0,008482345 = GNB4 
12 -2,164 0,007931932 = PARPBP 
20 -2,161 0,008838388 j MIR646HG 
11 -2,154 0,008792841 n SNHG1 
11 -2,153 0,009016427 = TPCN2 
1 -2,149 0,009382292 j RPAP2 
6 -2,149 0,00852642 = RP11-632C17__A.1 
14 -2,147 0,00955464 = ACOT1 
2 -2,142 0,009107896 j RP11-418H16.1 
11 -2,128 0,009382292 = SCGB1D2 
3 -2,127 0,009915783 = GPR160 
6 2,116 0,009978271 j RUNX2 
11 2,119 0,009915783 = H19 
5 2,122 0,009603345 = VCAN 
19 2,125 0,009637741 = COL5A3 
6 2,127 0,00942072 = TPBG 
15 2,128 0,009388325 j LRRC28 
2 2,130 0,009334505 o AC012593.1 
10 2,132 0,009439322 = FGFR2 
1 2,133 0,009603345 x KIF26B 
1 2,135 0,009074138 = KIF26B 
10 2,135 0,009766729 n ADAMTS14 
14 2,141 0,009260116 = ZNF219 
8 2,142 0,008804961 = ZFHX4 
10 2,144 0,009563551 j CYP2E1 
5 2,146 0,009490812 n NKD2 
2 2,147 0,008890567 u NA 
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10 2,153 0,008244882 x RNLS 
12 2,153 0,008205491 = MFAP5 
8 2,154 0,008804961 = RPL7 
2 2,154 0,0083374 = SCG2 
22 2,156 0,008081401 k LRP5L 
22 2,157 0,009434768 n ZDHHC8P1 
2 2,158 0,008653428 u NA 
1 2,159 0,00924502 = PTGER3 
8 2,160 0,008016199 j LINC00534 
6 2,164 0,007892727 = COL12A1 
1 2,168 0,007835019 m RP5-1065P14.2 
1 2,171 0,007835019 j MDM4 
15 2,174 0,007537956 = ALDH1A3 
22 2,174 0,009157094 n GUSBP11 
9 2,174 0,008482345 j COL27A1 
5 2,177 0,007413863 n RP11-348J24.2 
10 2,177 0,009400258 = CFAP70 
2 2,179 0,007382158 u NA 
5 2,180 0,007133363 = LIX1 
21 2,185 0,008879785 j NCAM2 
2 2,185 0,007483262 x RPL21P32 
5 2,189 0,006770577 = ADAMTS12 
1 2,191 0,009302281 u NA 
2 2,192 0,009107896 u NA 
14 2,193 0,009325389 u NA 
11 2,195 0,006666946 = MUC5B 
11 2,196 0,007922045 j ZBTB16 
19 2,197 0,009617488 u NA 
7 2,201 0,006580809 j LRRC4 
1 2,204 0,007137502 = CSF3R 
1 2,206 0,008437065 u NA 
19 2,206 0,007090746 = CEBPA-AS1 
5 2,206 0,007056494 u NA 
10 2,207 0,006958677 n ADAMTS14 
13 2,207 0,006189716 x RP11-54H7.4 
1 2,207 0,009772272 u NA 
5 2,208 0,006614098 = LOX 
14 2,210 0,007957774 = TMEM229B 
17 2,213 0,007279347 n ARHGAP27 
2 2,215 0,006454389 k AC108938.5 
10 2,216 0,006809927 = GRID1 
17 2,217 0,005835706 k TVP23C 
2 2,219 0,008081401 x PAX3 
11 2,220 0,007828252 = PHLDB1 
7 2,223 0,007931932 j IMMP2L 
1 2,223 0,00573238 x RP11-62I21.1 
12 2,223 0,007663377 j TCP11L2 
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21 2,224 0,006312485 = RUNX1 
1 2,226 0,008806668 = PRG4 
19 2,228 0,005530158 j MUC16 
2 2,230 0,005567829 j AC007392.3 
5 2,231 0,005982119 n ZNF300 
17 2,232 0,007507256 = GAS7 
4 2,234 0,007400748 k RP11-362F19.1 
13 2,235 0,005723866 = POSTN 
19 2,236 0,006432906 j CD22 
8 2,239 0,005368693 u NA 
2 2,242 0,006507179 u NA 
17 2,244 0,006614098 j EFTUD2 
16 2,245 0,006580809 j VWA3A 
15 2,246 0,005032545 = IGF1R 
4 2,246 0,005688839 j LPHN3 
2 2,248 0,006437518 j SH3RF3 
3 2,251 0,006597454 n FAM86HP 
13 2,252 0,005022313 o MYO16-AS1 
19 2,253 0,00516743 j DPY19L3 
3 2,253 0,005329352 = ACKR4 
15 2,254 0,005059663 j GOLGA8B 
5 2,254 0,005304436 n SLC27A6 
19 2,256 0,008081401 = RHPN2 
11 2,257 0,006783376 j MRVI1 
8 2,258 0,00629969 j LPL 
11 2,260 0,005059663 n RIC3 
4 2,260 0,007232986 = COL25A1 
12 2,261 0,009637741 j PTPRQ 
10 2,261 0,006269079 m FRMPD2 
19 2,262 0,006614098 = LINC00662 
10 2,268 0,00810396 = COL17A1 
12 2,269 0,005852781 n ATN1 
11 2,273 0,004546114 x IGF2 
1 2,273 0,006752011 k MTX1 
4 2,274 0,004999397 x AP1AR 
15 2,276 0,004961547 = LRRC28 
12 2,277 0,006495154 = SCNN1A 
2 2,278 0,006444273 = DYSF 
1 2,283 0,006421887 x MYSM1 
5 2,285 0,006464293 = NKD2 
1 2,286 0,005723866 = AP006222.2 
13 2,287 0,005775408 = SUPT20H 
8 2,288 0,00937852 n AP3M2 
19 2,289 0,005574982 n NFIC 
1 2,289 0,004825919 = RP1-79C4.4 
3 2,290 0,004969331 j ROBO2 
2 2,294 0,005318362 u NA 
176 
 
16 2,296 0,005832481 = CDH11 
8 2,297 0,00437366 j RP11-30J20.1 
7 2,300 0,005285006 o TWIST1 
13 2,301 0,004344955 n N4BP2L2 
3 2,301 0,003811725 j WNT7A 
19 2,301 0,007541951 = FOSB 
1 2,302 0,003689665 n CSMD2 
10 2,305 0,005018107 = SCART1 
2 2,306 0,003623213 = AC118345.1 
1 2,308 0,003823643 k RP11-195C7.3 
4 2,308 0,009637741 n ARHGAP10 
1 2,309 0,005101297 u NA 
2 2,312 0,00492484 j PCBP1-AS1 
4 2,313 0,003873554 k GUCY1A3 
19 2,314 0,003413726 j CTC-459F4.3 
1 2,314 0,003666611 j AMY1A 
5 2,315 0,0083374 j SYNPO 
5 2,317 0,004159331 = PCDHGA6 
2 2,317 0,003356168 u NA 
12 2,318 0,006408055 = MDM1 
7 2,319 0,005654287 x CRHR2 
2 2,320 0,003662202 j PXDN 
12 2,321 0,005145781 n TPCN1 
12 2,326 0,009777021 j GOLGA3 
2 2,327 0,003262987 n AC118345.1 
3 2,328 0,003174993 k CD47 
7 2,331 0,003170749 j COL1A2 
4 2,331 0,003123776 = SFRP2 
1 2,332 0,004194356 k RP11-34P13.13 
15 2,332 0,003104853 = TTC23 
16 2,332 0,005654931 = MRPL28 
11 2,333 0,004933534 j LTBP3 
5 2,333 0,004520417 = PAM 
17 2,333 0,003527862 j TANC2 
1 2,333 0,005631822 n RP11-504P24.2 
3 2,334 0,003311926 n FBXL2 
20 2,335 0,003344275 m GMEB2 
2 2,337 0,003234251 x NAB1 
16 2,339 0,005075527 = CDH11 
12 2,340 0,005078023 j RIMBP2 
10 2,340 0,003330469 = ADAMTS14 
12 2,341 0,003961949 m RP5-944M2.3 
19 2,345 0,002902608 x CTC-459F4.7 
22 2,347 0,004401396 u NA 
10 2,348 0,003097997 = ANXA8L1 
20 2,350 0,003006827 j FAM182B 
7 2,353 0,004093388 j AC004538.3 
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22 2,354 0,003174993 k MIAT 
7 2,355 0,002954186 m COL1A2 
1 2,356 0,005644114 u NA 
11 2,358 0,002931799 = GUCY1A2 
13 2,360 0,006476248 j RP11-307N16.6 
18 2,361 0,002686481 j ALPK2 
3 2,361 0,002931799 = ALS2CL 
3 2,364 0,004753247 m PHLDB2 
19 2,364 0,00437366 j NFIX 
4 2,365 0,002817055 u NA 
17 2,365 0,003170749 j CCDC57 
3 2,366 0,003498618 j CTDSPL 
12 2,366 0,007451421 = TUBA1A 
2 2,367 0,002539536 u NA 
4 2,372 0,002658666 j RAPGEF2 
3 2,372 0,002534 j ZMAT3 
11 2,372 0,002691842 u NA 
22 2,374 0,004403761 u NA 
11 2,375 0,005212155 n TRIM22 
11 2,375 0,005414075 = TNNT3 
10 2,376 0,004010135 n FRMPD2 
10 2,378 0,002954186 = CH17-360D5.2 
11 2,378 0,005923398 = PHRF1 
9 2,379 0,005983731 = SVEP1 
12 2,389 0,002857113 m PPP1CC 
17 2,391 0,00437366 n C17orf70 
1 2,392 0,002464912 = COL16A1 
19 2,393 0,002342309 k ZNF587B 
12 2,394 0,005098378 = RP11-81H14.1 
1 2,396 0,002283552 j PRRX1 
1 2,396 0,002283552 = AMY1B 
2 2,397 0,009016427 j NDUFAF7 
20 2,400 0,003222421 m RALGAPA2 
19 2,400 0,002305872 j COL5A3 
4 2,401 0,002367247 j UBE2D3 
2 2,402 0,002271712 u NA 
12 2,403 0,006269079 = RAD52 
13 2,404 0,002065041 = POSTN 
4 2,406 0,002285147 = LPHN3 
22 2,407 0,002113902 = MMP11 
8 2,411 0,002172487 m ZFHX4 
10 2,414 0,002103511 j EMX2OS 
16 2,415 0,002495306 = RPS2 
19 2,415 0,003466232 = ILF3 
6 2,417 0,003279078 j SNX9 
9 2,417 0,002182146 n GLIS3-AS1 
22 2,420 0,003345445 u NA 
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19 2,421 0,003613532 n CIRBP 
10 2,421 0,003174993 u NA 
14 2,424 0,005618752 j LRFN5 
11 2,424 0,005381618 s RP11-819M15.2 
12 2,427 0,002323196 j PLXNC1 
20 2,427 0,003565424 j CASC20 
15 2,427 0,002269817 = LRRC28 
20 2,433 0,002305872 j ISM1 
13 2,435 0,001802322 o MYO16-AS1 
6 2,437 0,001689386 = COL12A1 
18 2,439 0,00185637 = ZNF521 
2 2,440 0,001639117 u NA 
8 2,442 0,001639117 = CLU 
20 2,443 0,002009682 n ADAM33 
1 2,443 0,00230502 = SELP 
2 2,444 0,001603922 n AC118345.1 
1 2,445 0,001776413 j CSMD2 
6 2,446 0,004848004 = SYNE1 
19 2,449 0,001540786 j MUC16 
13 2,449 0,003569232 = FAM216B 
1 2,449 0,002360543 j LYPLAL1 
20 2,450 0,001764473 = LRRN4 
7 2,451 0,002606098 = IQCE 
17 2,455 0,001836339 = PLXDC1 
11 2,456 0,008114608 m CNGA4 
9 2,458 0,001960245 j GLIS3-AS1 
3 2,458 0,008209403 = CDHR4 
1 2,459 0,005430124 n SPAG17 
4 2,460 0,001955406 n EXOC1 
20 2,460 0,009135502 n DZANK1 
2 2,462 0,003235751 n ZEB2 
8 2,463 0,003567995 k ATP6V1B2 
6 2,468 0,003811725 = PTCHD4 
4 2,468 0,003174993 = ANTXR2 
4 2,469 0,003276207 n TAPT1-AS1 
5 2,469 0,00136083 j ADAMTS12 
20 2,469 0,00139027 = PMEPA1 
1 2,470 0,001599668 = AK5 
11 2,471 0,001341185 = GUCY1A2 
20 2,475 0,003732399 x FERMT1 
2 2,477 0,001528405 n DNMT3A 
19 2,480 0,001670097 n PRKCSH 
6 2,481 0,006150932 = RNF8 
1 2,481 0,001882438 n RP11-195C7.3 
20 2,481 0,002287673 j SYS1-DBNDD2 
17 2,482 0,004093388 k SLC16A3 
1 2,482 0,001549354 j TTC39A 
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12 2,487 0,001549354 = NR2C1 
6 2,487 0,001987272 u NA 
19 2,488 0,004999397 = DOCK6 
3 2,488 0,003803537 j AGTR1 
3 2,489 0,003344275 j RP11-933H2.4 
20 2,491 0,00137945 j ISM1 
1 2,494 0,002101173 n CSF3R 
21 2,495 0,002283265 m AP000962.2 
6 2,495 0,001180901 k Y_RNA 
14 2,495 0,00363362 j NUMB 
20 2,498 0,002134144 j CASC20 
19 2,498 0,00452199 = PLEKHJ1 
3 2,499 0,004301709 = FAM198A 
10 2,499 0,006986415 = ANXA8L1 
18 2,500 0,001612219 = PIEZO2 
1 2,502 0,002151543 j MORN1 
19 2,502 0,001315595 j ANKRD27 
12 2,503 0,001099868 m LUM 
3 2,504 0,001099868 o LSAMP 
5 2,507 0,003596991 = FGF1 
2 2,508 0,00210735 x AC092162.1 
2 2,509 0,003907774 j PSD4 
16 2,512 0,002242165 n CLCN7 
17 2,516 0,003823643 k PLEKHM1P 
1 2,517 0,001284968 j CSMD2 
6 2,518 0,006664912 = CD24 
6 2,520 0,005300355 = MYLIP 
17 2,523 0,001151393 n COL1A1 
11 2,524 0,002073524 j TSKU 
13 2,526 0,001099868 = TNFRSF19 
14 2,527 0,001074363 = LTBP2 
4 2,527 0,001557028 k RP11-241F15.10 
11 2,531 0,002390572 j OSBPL5 
17 2,535 0,001202778 = DNAH9 
15 2,536 0,000941732 j TTC23 
1 2,536 0,009603934 m PTGS2 
2 2,538 0,000971947 o TWIST2 
11 2,540 0,000989783 = MRVI1 
3 2,540 0,006809927 j ROBO2 
13 2,544 0,007932377 o GPC5-AS1 
6 2,544 0,008437065 j AIM1 
19 2,545 0,003275692 j ZNF234 
3 2,546 0,003659688 x AGTR1 
1 2,547 0,00087832 = KIF26B 
20 2,548 0,00245786 m CSRP2BP 
6 2,548 0,000912898 y RP11-46B11.2 
14 2,553 0,000830719 = DUXAP10 
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4 2,553 0,0051666 j LARP1B 
11 2,556 0,000800168 = IGF2 
2 2,557 0,000930381 j ANKRD36B 
21 2,560 0,007474628 = CH507-396I9.6 
10 2,561 0,001781832 j ANXA8L1 
11 2,562 0,000830085 = IGF2 
1 2,566 0,000798941 k PTGER3 
12 2,566 0,000748333 n RAP1B 
4 2,566 0,00075205 u NA 
10 2,567 0,006653658 k CCDC186 
15 2,569 0,000824665 j TTC23 
15 2,570 0,000770302 = HSP90B2P 
5 2,572 0,004320615 = NKD2 
10 2,573 0,000939646 n MMS19 
16 2,573 0,005654931 j GPR56 
1 2,574 0,000781704 j AMY1A 
11 2,575 0,000868946 m RP11-817J15.2 
21 2,576 0,002737332 x TEKT4P2 
22 2,579 0,003626796 = MICAL3 
1 2,579 0,001438644 = CSMD2 
13 2,579 0,001338244 m LCP1 
20 2,579 0,000765183 j MIR646HG 
14 2,581 0,002044547 = TTC6 
12 2,588 0,001955406 = C12orf75 
17 2,589 0,000851548 = FAM20A 
1 2,591 0,000956787 n KIAA1614 
1 2,594 0,00805006 = CFAP74 
2 2,597 0,000692798 = INPP5D 
1 2,599 0,00516743 n LRRC71 
13 2,600 0,000748689 = DNAJC15 
11 2,600 0,000798941 m SF1 
3 2,600 0,001029491 = RASA2 
2 2,602 0,000648993 n ANKRD36B 
6 2,603 0,000660831 x RP3-495K2.3 
2 2,603 0,00224832 n TRIP12 
15 2,605 0,000673674 = LRRC28 
17 2,606 0,000993585 n HOXB3 
17 2,606 0,007993807 k USP43 
4 2,606 0,000724758 = HHIP 
19 2,607 0,000589914 n ZNF507 
5 2,607 0,000650001 j ADAMTS12 
15 2,612 0,000583094 i LRRC28 
2 2,612 0,006958677 n KIAA2012 
7 2,614 0,001121607 = WDR86 
2 2,617 0,005430124 = NFE2L2 
19 2,619 0,000678926 j AC022153.1 
6 2,619 0,000725627 m HLA-DQB1 
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10 2,621 0,002695444 n LIPN 
6 2,622 0,000748333 = CNR1 
14 2,625 0,000792634 m NOP9 
6 2,627 0,000538497 j PTCHD4 
1 2,627 0,000572021 j RP1-45C12.1 
11 2,634 0,001167172 j OSBPL5 
12 2,638 0,000546977 = CLIP1 
4 2,642 0,00493429 x ALG1L7P 
19 2,643 0,000749155 j POU2F2 
4 2,646 0,000589914 j TENM3 
2 2,646 0,000726606 j SLC30A6 
17 2,648 0,000637092 = COL1A1 
16 2,648 0,00516413 j GPR56 
6 2,652 0,0083374 j EYA4 
15 2,657 0,000639337 = FBN1 
1 2,659 0,00060453 u NA 
2 2,662 0,002754334 n CATIP 
6 2,662 0,00436419 u NA 
17 2,672 0,003649876 = WNK4 
14 2,674 0,000377228 k LINC01296 
12 2,675 0,005429332 j TXNRD1 
19 2,676 0,000506855 j NOTCH3 
10 2,677 0,000395836 j CH17-360D5.2 
20 2,678 0,000377228 = LRRN4 
4 2,679 0,001682432 j RP11-241F15.1 
2 2,680 0,000537574 = SCRN3 
15 2,681 0,001130882 j FAM189A1 
7 2,681 0,000487625 j AC093627.7 
3 2,684 0,008109836 j HHLA2 
20 2,685 0,00042269 j MIR646HG 
12 2,687 0,003111085 j NCAPD2 
7 2,688 0,004982192 u NA 
2 2,689 0,000571296 n ZEB2 
11 2,689 0,00035988 = IGF2 
7 2,692 0,001933225 j UBN2 
3 2,692 0,000851548 = MECOM 
15 2,696 0,000694993 j CCDC33 
X 2,697 0,000337851 x RP13-213K19.1 
10 2,698 0,000366223 n ADAMTS14 
11 2,698 0,001391226 n MYRF 
15 2,699 0,000384202 = TTC23 
1 2,699 0,002283151 j WDR63 
1 2,705 0,000349552 n PSMD4 
3 2,707 0,000633911 j GOLGA4 
3 2,710 0,000832165 = CLASP2 
16 2,710 0,006548823 k FBRS 
11 2,712 0,000387288 = RIC3 
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12 2,714 0,000541695 j LIMA1 
19 2,723 0,000279573 j ZNF91 
12 2,724 0,000763698 = RP11-1143G9.5 
11 2,725 0,000377228 j RP11-627G23.1 
3 2,728 0,000987325 j FAM157A 
16 2,730 0,000799816 = MAF 
3 2,733 0,000829934 n CNOT10-AS1 
2 2,736 0,000356409 = AC007392.3 
11 2,736 0,000253273 n RIC3 
2 2,737 0,000362352 n AC104809.3 
6 2,739 0,000267589 n MLLT4 
1 2,742 0,002269817 u NA 
7 2,744 0,003261542 j POLR2J4 
19 2,748 0,002691842 j EMR3 
2 2,748 0,004194491 j KANSL1L 
17 2,749 0,00189254 j DNAH9 
20 2,749 0,000339009 u NA 
12 2,751 0,000574629 = GALNT9 
5 2,751 0,000226973 m RP11-138J23.1 
20 2,756 0,00021987 x MACROD2 
18 2,757 0,000522298 n CTD-2008L17.2 
7 2,761 0,000487124 = TMEM130 
1 2,763 0,001522513 j LINC01341 
11 2,770 0,000374141 j AHNAK 
4 2,772 0,000217884 = TENM3 
19 2,775 0,005300355 j LILRB2 
4 2,777 0,00075205 j CHRNA9 
12 2,786 0,000312384 = RP11-637A17.2 
16 2,787 0,002438918 n VWA3A 
18 2,789 0,000540055 j FHOD3 
15 2,790 0,000529973 = IL16 
19 2,793 0,001725036 j GRAMD1A 
11 2,794 0,003423059 = RIN1 
12 2,796 0,000221663 = RP11-284H19.1 
19 2,798 0,000583015 j LILRA1 
2 2,804 0,001347318 n KIAA2012 
11 2,805 0,007772362 x RP11-755E23.3 
22 2,806 0,000227714 u NA 
2 2,807 0,000164763 u NA 
15 2,809 0,000332861 j SMAD6 
8 2,814 0,000182548 j RP11-30J20.1 
10 2,815 0,000148304 n CH17-360D5.2 
3 2,816 0,007402665 j SETD5 
5 2,816 0,000149591 = CXCL14 
22 2,817 0,001766925 m AC006547.14 
11 2,820 0,000639337 n RP13-726E6.2 
2 2,820 0,00014054 = COL3A1 
183 
 
2 2,827 0,000221663 m TRMT61B 
19 2,829 0,001366873 k ZNF836 
1 2,838 0,000126688 = FLG 
1 2,838 0,00046933 k WASH7P 
15 2,846 0,000121996 x LRRC28 
15 2,846 0,000171416 m PML 
10 2,851 0,000418916 j ANXA8 
1 2,851 0,005983731 n CFAP74 
11 2,851 0,000624618 j POU2AF1 
15 2,857 0,00013748 = AC022819.3 
2 2,858 0,006454389 j MAP3K19 
11 2,862 0,001637381 n ELMOD1 
16 2,863 0,00012046 u NA 
21 2,875 0,000171416 j ITSN1 
6 2,876 0,000116929 x AL590731.1 
6 2,877 0,000897939 u NA 
15 2,878 0,000126688 = RP11-35O15.2 
16 2,882 0,000100179 j LINC00922 
20 2,885 0,001170724 = SIRPB2 
16 2,886 0,000253672 n PKD1P1 
21 2,887 0,000253672 u NA 
16 2,891 0,002707177 j HAGHL 
6 2,897 0,005300355 u NA 
22 2,897 0,000446894 j FAM19A5 
17 2,899 0,000692798 j GOSR1 
16 2,899 0,001888026 j RP11-77K12.8 
15 2,900 8,94E-05 = IGF1R 
1 2,902 0,00028482 j ZBTB7B 
X 2,908 9,30E-05 u NA 
17 2,909 0,004748866 j USP43 
5 2,914 7,91E-05 = MEGF10 
10 2,916 7,77E-05 = GFRA1 
6 2,919 0,000255 x RREB1 
8 2,924 0,000504485 = FABP4 
5 2,924 7,61E-05 k MEGF10 
2 2,924 8,93E-05 = DYNC1I2 
17 2,927 0,00053665 m MINK1 
4 2,930 0,005059663 j HAND2-AS1 
13 2,930 0,005735733 u NA 
5 2,930 7,22E-05 x SLC12A7 
1 2,935 0,000908004 j HIVEP3 
16 2,938 0,000748819 j AC010547.9 
7 2,940 8,10E-05 u NA 
4 2,942 9,81E-05 j COL25A1 
1 2,946 0,000527857 u NA 
19 2,947 0,002275765 u NA 
4 2,951 0,00011593 u NA 
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X 2,952 5,80E-05 u NA 
6 2,957 7,51E-05 j PHACTR1 
13 2,958 0,007883165 u NA 
19 2,959 0,001963526 j SLC25A23 
1 2,963 6,06E-05 = CSMD2 
17 2,965 9,83E-05 = AATK 
11 2,970 0,000240688 j CPT1A 
1 2,971 9,04E-05 j CFAP45 
15 2,977 5,49E-05 o RP11-654A16.1 
10 2,979 0,000217722 = VWA2 
15 2,981 0,000406043 = WDR61 
6 2,983 0,001945584 j PCMT1 
1 2,983 6,62E-05 j CADM3 
6 2,986 0,000146635 x RP11-254A17.1 
19 2,986 0,009431948 = DNAAF3 
5 2,989 7,15E-05 = VCAN 
13 2,997 0,000219536 u NA 
21 2,999 6,56E-05 = COL6A2 
2 3,001 0,000258022 = IL1RL1 
19 3,001 8,90E-05 n ZNF780A 
10 3,002 5,75E-05 = ADAMTS14 
11 3,002 0,006688196 j ELMOD1 
11 3,005 8,67E-05 = NELL1 
11 3,005 0,000251989 = TMEM138 
11 3,021 6,43E-05 u NA 
2 3,023 0,000221556 = ANKMY1 
20 3,035 0,000118988 u NA 
20 3,042 0,000256286 u NA 
2 3,045 5,57E-05 = MAP4K4 
4 3,045 0,003262987 x RNF150 
8 3,048 2,99E-05 = PKHD1L1 
15 3,052 3,79E-05 k CHD2 
13 3,053 0,000471313 u NA 
8 3,053 0,000763698 = BLK 
12 3,055 0,000245906 x KIAA1551 
12 3,061 0,008151659 n PAN2 
7 3,062 2,75E-05 = COL1A2 
2 3,062 7,74E-05 u NA 
19 3,066 3,01E-05 j NUDT19 
22 3,067 0,000142266 k MICALL1 
1 3,068 6,25E-05 = LRP8 
3 3,068 0,000101215 m LIPH 
1 3,073 3,32E-05 j PAPPA2 
1 3,078 0,001781832 j RP11-122M14.1 
19 3,083 0,002937112 = STXBP2 
1 3,083 2,99E-05 = CHIT1 
16 3,086 4,22E-05 j RP11-256I9.3 
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17 3,087 0,00787701 j DNAI2 
10 3,088 0,001049798 j LIPN 
12 3,089 0,000347502 m GPR133 
10 3,089 2,99E-05 = ANXA8 
17 3,099 3,01E-05 j SPECC1 
7 3,105 2,00E-05 j COL1A2 
5 3,106 2,28E-05 j RP11-259O2.1 
12 3,106 0,005983731 n CCDC42B 
6 3,113 0,000234975 u NA 
12 3,119 0,000142634 j MPHOSPH9 
20 3,130 2,63E-05 u NA 
10 3,133 3,76E-05 = ANXA8L1 
7 3,137 0,000148304 j TNRC18 
17 3,139 0,000861103 = SEC14L1 
2 3,141 4,24E-05 j CFLAR 
16 3,144 6,45E-05 x GRIN2A 
4 3,145 3,75E-05 j CBR4 
1 3,146 1,50E-05 u NA 
5 3,149 2,04E-05 x SLC12A7 
12 3,150 2,17E-05 = KRT81 
1 3,154 0,002390572 = ILDR2 
20 3,155 2,55E-05 j CASC20 
12 3,156 7,10E-05 j KDM2B 
5 3,156 3,18E-05 k RP11-524L6.4 
2 3,158 1,67E-05 n LYPD6B 
1 3,161 0,005532685 = CCDC17 
20 3,162 4,90E-05 x FERMT1 
X 3,162 0,000821422 j NHSL2 
1 3,167 0,006933565 = CFAP74 
11 3,170 0,000269984 j TNNT3 
15 3,174 1,29E-05 j TTC23 
12 3,187 1,10E-05 = CCT2 
10 3,192 0,000103969 = ANXA8 
19 3,194 5,31E-05 x MUC16 
6 3,195 1,09E-05 x RP3-495K2.3 
4 3,195 0,007402665 j FAM47E 
7 3,198 2,61E-05 u NA 
4 3,198 2,39E-05 n RP11-696N14.1 
12 3,198 0,000645481 n DAZAP2 
21 3,198 5,49E-05 j AGPAT3 
1 3,201 0,007553616 j BAI2 
21 3,203 0,00014098 j COL6A2 
20 3,204 0,007772362 u NA 
6 3,206 0,003596991 n MLLT4 
17 3,207 6,63E-05 = SERPINF2 
21 3,207 0,000440612 = KCNE1 
20 3,209 0,006917054 j PLCB1 
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19 3,209 4,45E-05 = TTYH1 
22 3,213 1,35E-05 n MMP11 
4 3,220 0,001506648 n TRIM2 
1 3,222 8,50E-06 = AMY1A 
7 3,224 0,000322145 = IQUB 
4 3,230 4,18E-05 j BMPR1B 
2 3,231 1,14E-05 u NA 
19 3,234 0,000172451 = HDGFRP2 
19 3,236 0,001388527 = CACNG6 
4 3,236 0,007835019 = SPATA18 
20 3,236 0,004329704 m DDRGK1 
17 3,241 0,001338244 y FLJ45079 
15 3,242 1,85E-05 k LRRK1 
2 3,247 9,94E-06 x ST6GAL2 
4 3,250 1,77E-05 n HHIP 
2 3,252 1,94E-05 u NA 
2 3,257 1,35E-05 u NA 
10 3,262 8,67E-05 k CH17-360D5.2 
13 3,265 0,003525695 m UGGT2 
2 3,265 0,006783376 = CYP4F62P 
1 3,266 0,002754334 n CSF3R 
7 3,268 0,001321172 j ZNF398 
14 3,272 0,000485447 = SLC24A4 
3 3,272 5,06E-05 j CADM2 
8 3,275 0,00131082 = CSMD3 
4 3,277 0,000857587 = DTHD1 
4 3,282 2,28E-05 k CFAP97 
17 3,282 7,49E-06 k HOXB3 
1 3,284 6,94E-06 u NA 
13 3,294 5,99E-06 n ARHGEF7 
15 3,297 2,21E-05 = ZNF106 
2 3,298 0,004602809 j LIMS1 
14 3,300 0,000110823 = G2E3 
16 3,304 8,22E-06 n ITGAX 
12 3,310 4,51E-06 = CPSF6 
4 3,320 0,004806208 j TET2 
15 3,322 4,51E-06 = TTC23 
21 3,326 5,66E-05 j SETD4 
20 3,331 1,11E-05 u NA 
15 3,332 4,56E-06 o RP11-35O15.1 
10 3,336 5,38E-06 j CH17-360D5.2 
2 3,336 2,28E-05 u NA 
1 3,336 2,19E-05 n CSF3R 
5 3,345 5,71E-06 j NKD2 
11 3,349 0,001092756 j ELMOD1 
17 3,351 0,002767772 = RP11-334C17.5 
2 3,351 0,000726311 = TUBA4B 
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12 3,352 4,41E-05 j CCDC62 
1 3,352 0,000523661 j PTPRC 
11 3,355 2,78E-05 = C11orf88 
22 3,359 7,81E-06 n A4GALT 
15 3,364 3,44E-06 x RP11-294C11.4 
14 3,367 0,003585423 u NA 
16 3,370 1,69E-05 j GAS8 
16 3,376 0,005688839 j IL4R 
14 3,387 2,55E-06 k LINC01296 
19 3,392 0,001011737 j CRLF1 
4 3,395 0,000446894 j MAPK10 
19 3,395 5,59E-06 n PTPRS 
4 3,400 4,51E-06 j SH3D19 
21 3,401 3,29E-06 j BAGE2 
3 3,402 2,49E-06 k WNT7A 
20 3,411 3,44E-06 u NA 
2 3,416 6,11E-06 j SFXN5 
2 3,417 3,13E-06 j AC159540.1 
3 3,421 2,24E-06 = LSAMP 
2 3,429 0,004228577 x ST6GAL2 
6 3,431 3,64E-06 u NA 
2 3,439 7,68E-06 = DYSF 
15 3,439 0,004248398 j CSPG4 
20 3,444 2,99E-06 u NA 
21 3,456 0,002371435 = CH507-396I9.6 
14 3,458 7,25E-05 n SYNE3 
3 3,458 5,22E-05 m CDHR4 
14 3,459 0,000387789 o RP11-356O9.2 
1 3,466 0,004969331 k C1orf87 
16 3,467 0,002712237 = MEFV 
12 3,468 0,007474628 j KLRC1 
3 3,471 0,00028482 = PRKRIRP2 
19 3,475 7,28E-05 j CD22 
16 3,477 0,002600373 o RP11-459F6.3 
4 3,478 2,49E-06 n FRAS1 
4 3,484 3,07E-06 = HHIP 
15 3,488 1,29E-06 o RP11-20G13.1 
10 3,488 2,49E-06 = CUBN 
19 3,489 0,002606098 n ZNF414 
10 3,492 0,00231028 j KNDC1 
10 3,497 2,27E-05 = ANXA8 
4 3,498 9,02E-05 = EPGN 
22 3,498 1,21E-06 = EIF3D 
17 3,498 0,000312761 x AKAP10 
1 3,499 1,02E-05 j DAB1 
14 3,502 0,000296877 x MIPOL1 
1 3,503 0,000110357 y RP11-543E8.1 
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17 3,504 3,85E-06 k BZRAP1 
4 3,507 3,57E-05 u NA 
15 3,507 1,59E-05 j LINC00923 
3 3,512 1,87E-06 n COL6A6 
20 3,518 1,04E-05 u NA 
5 3,519 0,00414397 = SNCAIP 
12 3,520 9,23E-05 j CEP83 
4 3,528 9,55E-05 = SORBS2 
19 3,531 0,002683587 j PCAT19 
1 3,539 5,45E-06 o C1orf132 
13 3,545 6,98E-05 = ANKRD10 
2 3,546 0,002113163 j UBXN4 
2 3,551 0,000151096 j FBXO11 
15 3,558 1,21E-06 = IGF1R 
20 3,561 5,94E-06 u NA 
16 3,562 4,70E-05 j AC010547.9 
2 3,562 1,67E-06 j ADD2 
4 3,563 0,000420131 u NA 
3 3,566 5,94E-06 u NA 
5 3,567 7,08E-07 = VCAN 
2 3,572 2,24E-06 u NA 
14 3,572 0,001637381 j TC2N 
6 3,573 0,004180041 j MYCT1 
12 3,574 0,000935 = PZP 
22 3,577 0,000568929 j XXbac-B444P24.8 
3 3,580 6,60E-06 = ZBTB20 
1 3,581 6,73E-07 = CLIC4 
17 3,582 6,84E-06 j ST6GALNAC2 
20 3,583 0,001068699 m RBCK1 
1 3,584 8,42E-07 y RP11-543E8.1 
11 3,589 5,42E-07 u NA 
12 3,593 0,008353415 j LMNTD1 
16 3,598 0,000889801 n FAM92B 
15 3,600 0,001212074 m CORO2B 
1 3,601 0,000994495 = CCDC17 
21 3,602 0,001822675 n RSPH1 
2 3,602 0,001078967 n SLC11A1 
14 3,607 0,000146972 o RP11-7F17.4 
10 3,608 3,50E-06 j FRMPD2 
6 3,610 0,000153413 u NA 
15 3,612 6,83E-06 = MAP1A 
1 3,614 1,66E-05 u NA 
21 3,615 6,38E-07 n AL078471.5 
11 3,623 2,04E-05 j NARS2 
12 3,627 4,03E-07 = MDM2 
15 3,627 5,37E-07 = TTC23 
15 3,629 0,002212564 = ABHD17C 
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2 3,634 8,93E-06 = GLS 
11 3,636 0,000234975 j SBF2 
6 3,638 0,00354439 u NA 
14 3,639 0,001315595 j LRFN5 
6 3,651 0,000798941 x RP1-6P5.2 
2 3,651 3,70E-06 m NR4A2 
7 3,659 0,002080827 = RSPH10B2 
19 3,661 3,13E-05 = CLEC17A 
15 3,662 1,62E-06 m NOX5 
3 3,675 2,74E-05 = GRAMD1C 
15 3,684 2,85E-07 j TTC23 
3 3,692 0,001088463 j MYH15 
2 3,713 1,81E-06 j CYP26B1 
1 3,715 1,22E-06 n TMEM234 
5 3,721 0,001032819 j TTC23L 
20 3,734 5,36E-07 j LRRN4 
19 3,738 1,42E-06 = TTYH1 
7 3,749 0,00382441 = PNPLA8 
22 3,750 9,21E-07 u NA 
17 3,755 0,001067455 u NA 
16 3,755 2,21E-07 m VWA3A 
1 3,759 2,30E-06 = SORT1 
15 3,760 7,47E-07 k CTD-2311M21.2 
17 3,766 6,22E-06 j GLOD4 
14 3,768 0,000456952 = STON2 
3 3,769 2,52E-07 j COL6A6 
4 3,773 3,45E-06 u NA 
3 3,773 9,92E-07 = ST6GAL1 
15 3,776 1,23E-07 = IGF1R 
9 3,777 1,23E-07 u NA 
19 3,778 0,00060977 n GRIN3B 
13 3,795 0,000872422 k ATP11A 
22 3,796 2,15E-05 j KIAA1671 
8 3,798 4,27E-07 = FABP4 
10 3,805 4,17E-07 j KCNMA1 
11 3,811 0,000104782 j TMEM9B-AS1 
19 3,817 0,001196755 n CAPN12 
1 3,823 3,19E-05 j TAL1 
1 3,823 2,50E-05 x C1orf140 
18 3,835 2,49E-06 = B4GALT6 
6 3,846 8,07E-08 n PTCHD4 
11 3,846 8,02E-06 n BEST1 
2 3,847 1,36E-07 n PKP4 
4 3,852 0,00937852 = C4orf22 
12 3,859 9,12E-08 n RP11-71J4.2 
14 3,866 9,11E-05 j AKAP6 
3 3,871 1,10E-06 = CADM2 
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1 3,880 0,000502005 j CFAP57 
21 3,884 0,000282078 n C21orf58 
15 3,890 5,05E-08 j IGF1R 
3 3,890 0,009594259 = IQSEC1 
20 3,894 1,15E-07 x FERMT1 
19 3,896 2,98E-06 = FFAR1 
14 3,899 4,52E-05 = MAP3K9 
15 3,907 6,67E-08 k RP11-6O2.2 
16 3,909 1,15E-07 j SMG1P1 
2 3,913 0,001391846 = BIRC6 
11 3,913 3,72E-06 n FLI1 
20 3,927 5,52E-06 j PTPRT 
20 3,928 1,66E-07 u NA 
18 3,936 0,000309541 j ATP9B 
10 3,937 4,52E-08 n RP11-144G6.12 
2 3,939 1,01E-07 k COMMD1 
11 3,945 0,000378347 = RELA 
8 3,951 0,000832165 = UNC5D 
19 3,955 1,19E-07 j RGL3 
16 3,960 5,91E-07 u NA 
17 3,963 0,000250098 = LINC00854 
7 3,974 0,001637381 = RSPH10B 
1 3,985 0,000179354 = NBPF15 
3 3,985 0,00043408 j GOLIM4 
1 3,998 0,000171416 j CFAP57 
2 4,000 1,19E-06 j CATIP 
1 4,006 3,04E-08 x RP11-63B19.1 
1 4,007 9,58E-05 m SYTL1 
6 4,010 0,001417651 = ZNF451 
7 4,013 3,44E-06 u NA 
2 4,014 4,69E-05 j AC104809.3 
5 4,014 0,0003661 j RP11-1415C14.4 
19 4,015 0,000349552 = PPP1R13L 
17 4,047 0,000176146 n CRLF3 
13 4,065 0,000129933 k MRPS31 
6 4,067 5,68E-08 u NA 
14 4,084 0,00011592 = NPAS3 
3 4,089 1,28E-05 u NA 
19 4,091 7,82E-07 n TLE2 
2 4,098 0,000366223 = IL1R2 
1 4,098 0,00014098 j AMY1C 
2 4,102 1,02E-08 j LINC01473 
12 4,139 6,66E-09 j CPSF6 
3 4,141 8,75E-09 m COL6A6 
7 4,143 7,07E-06 n SMURF1 
19 4,148 0,000448552 j RAVER1 
2 4,151 0,000150952 = SLC4A10 
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1 4,164 7,51E-05 = DENND4B 
2 4,167 5,36E-05 = CCDC108 
17 4,169 0,000105453 n DBF4B 
7 4,179 3,72E-08 j NAMPT 
2 4,183 3,31E-05 = KIAA2012 
9 4,197 0,002580172 j IFT74 
2 4,203 4,15E-05 = TNS1 
20 4,211 1,66E-08 u NA 
12 4,220 1,34E-08 = TSPAN9 
3 4,223 7,89E-09 j COL6A6 
2 4,226 2,46E-06 j KIAA2012 
4 4,226 6,16E-09 = RP11-362F19.1 
6 4,227 0,000126688 = ECT2L 
4 4,246 3,24E-05 = MAN2B2 
19 4,250 5,71E-06 = ZFP36 
19 4,252 6,32E-05 = ICAM4 
15 4,252 2,86E-09 j RP11-20G13.1 
7 4,254 0,00054332 x RP11-397J20.1 
19 4,262 4,75E-05 j CTD-2207O23.3 
13 4,271 5,79E-09 k GAS6-AS1 
11 4,280 4,24E-05 j LMO2 
14 4,292 5,07E-05 j ACIN1 
18 4,304 3,71E-05 n GATA6 
20 4,305 8,45E-05 = NNAT 
20 4,307 2,14E-06 = BTBD3 
17 4,324 2,94E-05 = MYL4 
19 4,327 2,71E-05 j GIPR 
1 4,330 1,76E-06 = ANGPTL7 
1 4,340 2,71E-05 = FHAD1 
12 4,343 1,30E-09 n RAP1B 
7 4,352 0,005342271 k STAG3L5P-PVRIG2P-PILRB 
11 4,377 3,36E-05 = MS4A1 
17 4,379 2,70E-05 k ZNF652 
1 4,384 1,20E-08 j TRIM11 
5 4,389 2,62E-05 = ICE1 
3 4,398 4,43E-09 m NISCH 
1 4,403 2,85E-09 j PAPPA2 
4 4,421 1,53E-09 = ADH1B 
1 4,427 9,00E-10 u NA 
16 4,435 3,06E-05 m ZFPM1 
5 4,449 4,45E-05 n CTD-2544H17.1 
2 4,454 1,93E-05 j MGAT5 
3 4,483 1,40E-05 n RBM6 
11 4,489 1,16E-05 = CFL1 
16 4,490 0,008085384 = ZNF598 
12 4,495 8,66E-05 j GALNT9 
2 4,499 1,51E-05 x PLCL1 
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2 4,512 3,51E-05 = ATG4B 
16 4,521 1,08E-07 x ZNF263 
4 4,522 6,67E-10 = RP11-362F19.1 
2 4,524 1,15E-05 = WIPF1 
12 4,527 1,11E-05 u NA 
6 4,528 3,43E-05 n FAM46A 
6 4,548 2,33E-10 o PTCHD4 
11 4,549 8,45E-06 m BCL9L 
3 4,563 1,24E-05 = LINC00969 
17 4,571 5,34E-06 = ALOX15 
12 4,574 8,77E-10 j WNK1 
9 4,578 5,66E-08 u NA 
3 4,579 1,37E-09 n COL6A6 
17 4,583 0,00573238 = MYL4 
2 4,589 2,36E-07 = UBE2F 
3 4,594 5,87E-06 n LINC01267 
12 4,598 8,23E-06 j LTA4H 
1 4,600 6,23E-06 j SSBP3 
16 4,621 5,48E-06 k EIF3C 
16 4,632 7,80E-06 m STUB1 
1 4,656 1,91E-09 = ESRRG 
10 4,686 2,67E-07 = FRMPD2 
1 4,691 4,34E-06 j SELP 
5 4,699 4,43E-08 = TCOF1 
3 4,704 2,15E-06 m AC024560.3 
15 4,706 8,99E-11 k OR4N3P 
20 4,717 9,62E-09 u NA 
11 4,745 2,07E-05 o RP11-755E23.3 
1 4,769 2,07E-06 j ZMYM4 
3 4,773 3,72E-06 = ANKUB1 
7 4,784 0,001217027 n STAG3L5P-PVRIG2P-PILRB 
16 4,785 1,87E-06 j QPRT 
10 4,791 5,30E-10 = SCART1 
18 4,793 4,25E-06 k MBD1 
19 4,795 2,40E-06 j NFIC 
16 4,801 0,001168283 = ZNF23 
19 4,802 1,18E-05 n CAPN12 
11 4,813 1,37E-09 = SCGB1A1 
3 4,828 2,98E-11 u NA 
12 4,830 1,83E-06 = AACS 
4 4,891 2,78E-11 u NA 
19 4,919 2,79E-05 j PPP6R1 
21 4,922 5,45E-07 n C21orf58 
6 4,927 4,17E-06 n FAM120B 
8 4,931 1,13E-05 n LONRF1 
3 4,931 1,13E-11 = COL6A6 
3 4,948 2,76E-11 j COL6A6 
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9 4,948 0,005574982 j GLIS3 
12 4,951 1,53E-05 j GPR133 
16 4,965 1,09E-06 m PLK1 
5 4,995 1,35E-05 k FAM153C 
19 4,998 4,20E-07 j CSNK1G2 
2 5,022 2,45E-08 n TUBA4B 
14 5,033 3,53E-07 j WDR20 
1 5,068 1,70E-05 u NA 
19 5,072 1,17E-07 n CAPN12 
16 5,089 3,01E-12 u NA 
16 5,109 1,41E-07 n FAM92B 
15 5,111 4,12E-12 = SPINT1 
4 5,128 3,26E-06 j NUDT6 
7 5,139 7,28E-05 = RSPH10B2 
6 5,145 1,88E-12 m PTCHD4 
9 5,169 0,007876242 = GLIS3 
11 5,172 2,32E-07 u NA 
7 5,180 4,78E-06 j CREB5 
6 5,181 1,86E-12 u NA 
3 5,181 2,93E-12 j COL6A6 
19 5,192 1,52E-07 m HMG20B 
6 5,211 8,56E-13 u NA 
2 5,231 4,00E-07 = NEU4 
19 5,234 1,08E-07 j GLTSCR2 
22 5,239 7,43E-08 = PITPNB 
3 5,249 7,82E-08 j ABHD6 
20 5,265 8,83E-10 = SOGA1 
12 5,265 5,03E-08 j ENO2 
16 5,297 5,32E-08 j NFATC3 
3 5,299 1,44E-06 = MUC4 
2 5,300 7,21E-08 o AC074011.2 
5 5,301 6,17E-12 n MTRR 
1 5,304 1,11E-09 j LEPR 
14 5,304 1,40E-07 k DDHD1 
22 5,373 0,00805006 = P2RX6 
21 5,387 4,72E-08 j KCNJ15 
6 5,403 1,55E-13 x RP11-254A17.1 
15 5,420 0,000332162 = NOX5 
1 5,425 8,19E-11 = ZBTB8B 
1 5,426 1,94E-08 j CDK11B 
22 5,438 2,40E-06 n XXbac-B444P24.8 
17 5,442 1,04E-08 n DNAH2 
3 5,443 3,85E-08 n GRAMD1C 
7 5,445 1,88E-06 n SUN1 
2 5,446 7,61E-09 n AC093838.4 
3 5,455 2,20E-08 y RP11-451B8.1 
19 5,467 1,33E-08 = HNRNPM 
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1 5,487 1,96E-10 j HSPG2 
13 5,489 2,87E-08 j UPF3A 
4 5,536 2,03E-08 = NDNF 
2 5,543 2,78E-12 x ST6GAL2 
12 5,547 2,15E-12 u NA 
6 5,575 4,20E-07 m KLHL31 
19 5,587 7,43E-09 j WTIP 
11 5,589 4,82E-09 j USP2 
7 5,592 4,23E-07 = CAV2 
7 5,593 1,40E-07 k STAG3L4 
2 5,609 5,42E-09 j CFLAR 
X 5,632 0,000242605 j USP9X 
3 5,642 3,93E-09 n RP5-966M1.6 
12 5,647 4,18E-08 = CLEC1B 
4 5,657 4,29E-09 = FGF5 
14 5,658 5,29E-09 = KCNH5 
6 5,681 1,90E-08 n NFYA 
10 5,701 1,60E-08 = ANXA8 
15 5,712 9,08E-09 = PAK6 
2 5,713 1,97E-09 = RABL2A 
5 5,726 2,55E-09 n SPEF2 
7 5,739 6,88E-15 m RP11-328J2.1 
13 5,769 4,52E-09 u NA 
17 5,774 1,06E-12 j HOXB3 
16 5,775 1,35E-09 k FUS 
10 5,787 2,85E-09 j CPEB3 
6 5,789 5,66E-15 x RP11-254A17.1 
3 5,802 5,54E-08 u NA 
7 5,831 3,43E-05 o RP11-449P15.2 
3 5,841 6,01E-10 = MKRN2 
2 5,842 9,00E-09 x ALPPL2 
16 5,865 9,21E-12 j TERF2 
12 5,909 2,96E-14 j KCNA1 
2 5,926 3,53E-10 j GREB1 
1 5,961 3,99E-09 = GPBP1L1 
8 5,978 6,61E-07 j PRKDC 
6 5,982 2,28E-09 = KIF13A 
3 5,983 5,09E-13 j BCL6 
14 5,988 1,63E-15 = CHGA 
11 5,992 6,16E-10 = MAML2 
7 5,996 6,14E-05 = RBM33 
2 6,001 1,02E-12 m NR4A2 
15 6,004 5,27E-10 = SYNM 
1 6,008 8,02E-16 = AMY1B 
12 6,025 1,06E-14 = KCNA1 
2 6,028 1,85E-10 = ARMC9 
19 6,031 2,29E-10 j ZNF701 
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22 6,125 9,74E-14 = DEPDC5 
14 6,133 6,61E-11 = ZFP36L1 
16 6,139 1,20E-11 = BAIAP3 
20 6,144 2,52E-10 j ITCH 
21 6,149 1,32E-10 j C2CD2 
12 6,224 1,30E-12 u NA 
19 6,230 2,09E-11 = R3HDM4 
15 6,231 8,41E-11 j MGA 
3 6,293 7,23E-11 n TNIK 
14 6,312 3,97E-11 j KTN1-AS1 
22 6,384 1,92E-11 u NA 
2 6,481 1,03E-17 n TEX41 
3 6,487 1,36E-17 j RP11-615J4.3 
4 6,504 4,17E-12 n FRYL 
6 6,505 2,46E-10 j MDN1 
10 6,540 4,83E-12 j MXI1 
2 6,570 2,19E-12 n IFT172 
10 6,652 9,06E-13 k SFXN2 
8 6,670 2,46E-09 x RPS3AP34 
3 6,684 2,34E-12 k ZBTB20 
16 6,784 3,90E-13 n DDX19A 
22 6,784 3,17E-13 j PPARA 
8 6,789 6,63E-19 n RALYL 
2 6,791 5,09E-13 j EPAS1 
21 6,798 2,12E-13 j PCNT 
20 6,808 1,66E-13 = PSMF1 
17 6,832 9,83E-15 = BCAS3 
17 6,998 3,46E-14 = GAS7 
20 7,057 2,69E-14 j RALY 
12 7,171 1,18E-14 = ANKRD13A 
10 7,182 1,99E-14 j GFRA1 
7 7,272 1,62E-10 j CTTNBP2 
6 7,317 2,49E-14 m CD83 
15 7,424 3,19E-21 x LRRC28 
14 7,462 2,61E-15 j CDKL1 
20 7,519 8,91E-16 = GZF1 
11 7,524 7,79E-16 m NXF1 
14 7,634 2,61E-15 k SOS2 
12 7,698 1,56E-16 j ERC1 
2 7,759 1,63E-15 m NR4A2 
1 7,987 1,18E-17 = PLEKHO1 
16 8,183 1,23E-18 k FUS 
3 8,449 3,04E-19 n RPUSD3 
4 8,568 6,96E-19 j CBR4 
9 8,570 3,41E-12 j XPA 
3 8,691 1,07E-25 j RP11-615J4.3 
8 9,611 5,97E-18 = ZBTB10 
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20 9,697 2,56E-23 u NA 
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